
<html lang="en"     class="pb-page"  data-request-id="d8a2bc56-6097-43e1-95ed-1a539afeee06"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-17;article:article:10.1021/acs.jmedchem.0c00705;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity" /></meta><meta name="dc.Creator" content="Michael G.  Thomas" /></meta><meta name="dc.Creator" content="Manu  De Rycker" /></meta><meta name="dc.Creator" content="Richard J.  Wall" /></meta><meta name="dc.Creator" content="Daniel  Spinks" /></meta><meta name="dc.Creator" content="Ola  Epemolu" /></meta><meta name="dc.Creator" content="Sujatha  Manthri" /></meta><meta name="dc.Creator" content="Suzanne  Norval" /></meta><meta name="dc.Creator" content="Maria  Osuna-Cabello" /></meta><meta name="dc.Creator" content="Stephen  Patterson" /></meta><meta name="dc.Creator" content="Jennifer  Riley" /></meta><meta name="dc.Creator" content="Frederick R. C.  Simeons" /></meta><meta name="dc.Creator" content="Laste  Stojanovski" /></meta><meta name="dc.Creator" content="John  Thomas" /></meta><meta name="dc.Creator" content="Stephen  Thompson" /></meta><meta name="dc.Creator" content="Claire  Naylor" /></meta><meta name="dc.Creator" content="Jose M.  Fiandor" /></meta><meta name="dc.Creator" content="Paul G.  Wyatt" /></meta><meta name="dc.Creator" content="Maria  Marco" /></meta><meta name="dc.Creator" content="Susan  Wyllie" /></meta><meta name="dc.Creator" content="Kevin D.  Read" /></meta><meta name="dc.Creator" content="Timothy J.  Miles" /></meta><meta name="dc.Creator" content="Ian H.  Gilbert" /></meta><meta name="dc.Description" content="Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26 000–65 000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy..." /></meta><meta name="Description" content="Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26 000–65 000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 14, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00705" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00705" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00705" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00705" /></link>
        
    
    

<title>Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00705" /></meta><meta property="og:title" content="Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0015.jpeg" /></meta><meta property="og:description" content="Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26 000–65 000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable dosing options. The need for new treatments is urgent and led to a collaboration between the Drugs for Neglected Diseases initiative (DNDi), GlaxoSmithKline (GSK), and the University of Dundee. An 8-hydroxynaphthyridine was identified as a start point, and an early compound demonstrated weak efficacy in a mouse model of VL but was hampered by glucuronidation. Efforts to address this led to the development of compounds with improved in vitro profiles, but these were poorly tolerated in vivo. Investigation of the mode of action (MoA) demonstrated that activity was driven by sequestration of divalent metal cations, a mechanism which was likely to drive the poor tolerability. This highlights the importance of investigating MoA and pharmacokinetics at an early stage for phenotypically active series." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00705"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00705">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00705&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00705&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00705&amp;href=/doi/10.1021/acs.jmedchem.0c00705" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 9523-9539</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00689" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00734" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent <i>In Vitro</i> Antileishmanial Activity: Initial SAR and Assessment of <i>In Vivo</i> Activity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Michael G. Thomas</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael G. Thomas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#367b186c18625e595b57457652435852535318575518435d"><span class="__cf_email__" data-cfemail="703d5e2a5e24181f1d11033014051e1415155e11135e051b">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+G.++Thomas">Michael G. Thomas</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0377-0281" title="Orcid link">http://orcid.org/0000-0003-0377-0281</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manu De Rycker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manu De Rycker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manu++De+Rycker">Manu De Rycker</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3171-3519" title="Orcid link">http://orcid.org/0000-0002-3171-3519</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard J. Wall</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard J. Wall</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+J.++Wall">Richard J. Wall</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Spinks</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Spinks</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Spinks">Daniel Spinks</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ola Epemolu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ola Epemolu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ola++Epemolu">Ola Epemolu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sujatha Manthri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sujatha Manthri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sujatha++Manthri">Sujatha Manthri</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Suzanne Norval</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Suzanne Norval</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Suzanne++Norval">Suzanne Norval</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Osuna-Cabello</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Osuna-Cabello</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Osuna-Cabello">Maria Osuna-Cabello</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Patterson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Patterson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Patterson">Stephen Patterson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer Riley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer Riley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Riley">Jennifer Riley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Frederick R. C. Simeons</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Frederick R. C. Simeons</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Frederick+R.+C.++Simeons">Frederick R. C. Simeons</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laste Stojanovski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laste Stojanovski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laste++Stojanovski">Laste Stojanovski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Thomas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Thomas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Thomas">John Thomas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Thompson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Thompson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Thompson">Stephen Thompson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claire Naylor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claire Naylor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claire++Naylor">Claire Naylor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jose M. Fiandor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jose M. Fiandor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Health R&D, GlaxoSmithKline, Tres Cantos 28760, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jose+M.++Fiandor">Jose M. Fiandor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul G. Wyatt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul G. Wyatt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+G.++Wyatt">Paul G. Wyatt</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0397-245X" title="Orcid link">http://orcid.org/0000-0002-0397-245X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Marco</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Marco</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Health R&D, GlaxoSmithKline, Tres Cantos 28760, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Marco">Maria Marco</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2442-0021" title="Orcid link">http://orcid.org/0000-0002-2442-0021</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan Wyllie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan Wyllie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Wyllie">Susan Wyllie</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8810-5605" title="Orcid link">http://orcid.org/0000-0001-8810-5605</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin D. Read</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin D. Read</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+D.++Read">Kevin D. Read</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8536-0130" title="Orcid link">http://orcid.org/0000-0002-8536-0130</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy J. Miles</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy J. Miles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Health R&D, GlaxoSmithKline, Tres Cantos 28760, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a5f1ccc88bef8be8ccc9c0d6e5c2d6ce8bc6cac8"><span class="__cf_email__" data-cfemail="e7b38e8ac9adc9aa8e8b8294a780948cc984888a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+J.++Miles">Timothy J. Miles</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7407-7404" title="Orcid link">http://orcid.org/0000-0001-7407-7404</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ian H. Gilbert</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ian H. Gilbert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#147d3a7c3a737d78767166605470617a7071713a75773a617f"><span class="__cf_email__" data-cfemail="d3bafdbbfdb4babfb1b6a1a793b7a6bdb7b6b6fdb2b0fda6b8">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ian+H.++Gilbert">Ian H. Gilbert</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5238-1314" title="Orcid link">http://orcid.org/0000-0002-5238-1314</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00705&amp;href=/doi/10.1021%2Facs.jmedchem.0c00705" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 9523–9539</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 14, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 April 2020</li><li><span class="item_label"><b>Published</b> online</span>14 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00705" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00705</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00705"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1362</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00705" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;G. Thomas&quot;},{&quot;first_name&quot;:&quot;Manu&quot;,&quot;last_name&quot;:&quot;De Rycker&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;J. Wall&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Spinks&quot;},{&quot;first_name&quot;:&quot;Ola&quot;,&quot;last_name&quot;:&quot;Epemolu&quot;},{&quot;first_name&quot;:&quot;Sujatha&quot;,&quot;last_name&quot;:&quot;Manthri&quot;},{&quot;first_name&quot;:&quot;Suzanne&quot;,&quot;last_name&quot;:&quot;Norval&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Osuna-Cabello&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Patterson&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Riley&quot;},{&quot;first_name&quot;:&quot;Frederick&quot;,&quot;last_name&quot;:&quot;R. C. Simeons&quot;},{&quot;first_name&quot;:&quot;Laste&quot;,&quot;last_name&quot;:&quot;Stojanovski&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Thomas&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Thompson&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;Naylor&quot;},{&quot;first_name&quot;:&quot;Jose&quot;,&quot;last_name&quot;:&quot;M. Fiandor&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;G. Wyatt&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Marco&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Wyllie&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;D. Read&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;J. Miles&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;H. Gilbert&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;9523-9539&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00705&quot;},&quot;abstract&quot;:&quot;Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26 000–65 000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable dosing options. The need for new treatments is urgent and led to a collaboration between the Drugs for Neglected Diseases initiative (DNDi), GlaxoSmithKline (GSK), and the University of Dundee. An 8-hydroxynaphthyridine was identified as a start point, and an early compound demonstrated weak efficacy in a mouse model of VL but was hampered by glucuronidation. Efforts to address this led to the development of compounds with improved in vitro profiles, but these were poorly tolerated in vivo. Investigation of the mode of action (MoA) demonstrated that activity was driven by sequestration of divalent metal cations, a mechanism which was likely to drive the poor tolerability. This highlights the importance of investigating MoA and pharmacokinetics at an early stage for phenotypically active series.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00705&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00705" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00705&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00705" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00705&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00705" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00705&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00705&amp;href=/doi/10.1021/acs.jmedchem.0c00705" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00705" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00705" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00705%26sid%3Dliteratum%253Aachs%26pmid%3D32663005%26genre%3Darticle%26aulast%3DThomas%26date%3D2020%26atitle%3DIdentification%2Band%2BOptimization%2Bof%2Ba%2BSeries%2Bof%2B8-Hydroxy%2BNaphthyridines%2Bwith%2BPotent%2BIn%2BVitro%2BAntileishmanial%2BActivity%253A%2BInitial%2BSAR%2Band%2BAssessment%2Bof%2BIn%2BVivo%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D17%26spage%3D9523%26epage%3D9539%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/jmcmar.2020.63.issue-17/20200910/jmcmar.2020.63.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Visceral leishmaniasis (VL) is a parasitic infection that results in approximately 26 000–65 000 deaths annually. The available treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable dosing options. The need for new treatments is urgent and led to a collaboration between the Drugs for Neglected Diseases <i>initiative</i> (DND<i>i</i>), GlaxoSmithKline (GSK), and the University of Dundee. An 8-hydroxynaphthyridine was identified as a start point, and an early compound demonstrated weak efficacy in a mouse model of VL but was hampered by glucuronidation. Efforts to address this led to the development of compounds with improved <i>in vitro</i> profiles, but these were poorly tolerated <i>in vivo</i>. Investigation of the mode of action (MoA) demonstrated that activity was driven by sequestration of divalent metal cations, a mechanism which was likely to drive the poor tolerability. This highlights the importance of investigating MoA and pharmacokinetics at an early stage for phenotypically active series.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">According to the World Health Organization (WHO), neglected tropical diseases (NTDs) affect in excess of 1 billion people, the majority being in the most impoverished areas of the world.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Of these NTDs, visceral leishmaniasis (VL) remains one of the most challenging to treat. VL is caused by infection with the protozoan parasites <i>Leishmania donovani</i> and <i>Leishmania infantum</i>, which are transmitted through the bite of female phlebotomine sand flies.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Following infection, parasites reside predominantly in the liver, spleen, and bone marrow, and if left untreated, the disease is invariably fatal. Although it is challenging to precisely determine the number of people affected by VL, WHO estimates suggest that 50 000–90 000 new infections result in an annual death toll of between 26 000 and 65 000, with the vast majority of cases occurring in India, Bangladesh, Sudan, Ethiopia, and Brazil.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Although there are a number of available treatments, all suffer from major issues that limit their use. Miltefosine, the only orally available treatment, is teratogenic so can only be prescribed to women of childbearing age alongside contraception, and also shows other side effects, as well as variable efficacy.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Liposomal amphotericin B (Ambisome) is widely effective in Asia, but its use is limited by the need for intravenous (iv) administration which requires hospitalization, and it also requires a cold-chain for storage. An alternative aminoglycoside antibiotic paromomycin is much less expensive but demonstrates variable efficacy and requires a long course of painful intramuscular injections.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Finally, pentavalent antimonials, such as sodium stibogluconate, have been widely used since the 1940s, but they are cardiotoxic, require parenteral administration, and are largely ineffective in large areas of India due to high levels of drug resistance. Although new compounds have recently entered the development pipeline,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> including two preclinical candidates developed within this collaboration (DDD853651/GSK3186899 and DDD1305143/GSK3494245) as well as the Novartis compound GNF6702, which have been disclosed in recent publications,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> there is still an urgent need for new treatments with improved safety profiles, more straightforward administration, lower costs, and also with alternate modes of action.</div><div class="NLM_p">One of the major challenges for drug discovery for VL is the lack of robustly validated drug targets in <i>Leishmania</i> spp. For this reason, to identify suitable start points for drug discovery, compound libraries are screened directly against parasites <i>in vitro</i>, leading to phenotypically active compounds with unknown mechanisms of action. An additional confounding factor in attempts to identify chemical start points is the fact that in the human host, parasites are found within macrophages, where they reside within a parasitophorous vacuole. Therefore, relevant high-content screens, suitable for high-throughput screening (HTS), require culture of parasites in macrophages, typically differentiated THP-1 cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> For any compounds to be identified as hits in these screens, they would be required to have suitable physicochemical properties to cross a number of cell membranes, across various pH gradients, as well as having antiparasitic activity. As a result, hit rates are extremely low in these assays, typically below 0.1%.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Nevertheless, compound series that are active in this assay and can be developed to give suitable properties for <i>in vivo</i> dosing have a high likelihood of success in rodent models of VL.</div><div class="NLM_p">Using this intramacrophage assay, an HTS screen of a GlaxoSmithKline (GSK) collection of 1.8 M compounds was performed against <i>L. donovani</i>.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The hits identified were screened in secondary antiparasitic assays, assessed for nonspecific cytotoxicity in HepG2 cells, clustered, and filtered based on favorable physicochemical properties, resulting in the identification of 33 chemical series and 75 singletons. One of the identified series was exemplified by <b>1</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), an 8-hydroxynaphthyridine, which was shown to have potency against the parasite (pEC<sub>50</sub> = 6.5) with ∼100-fold selectivity over the human THP-1 cell line (pEC<sub>50</sub> = 4.5). This compared favorably to the current treatments, amphotericin (pEC<sub>50</sub> = 6.7) and miltefosine (pEC<sub>50</sub> = 5.4). Upon further profiling, <b>1</b> was shown to have reasonable aqueous (aq) solubility (219 μM) but low stability in mouse liver microsomes (Cl<sub>i</sub> = 18 mL/min/g). On the basis of this, <b>1</b> was selected as a suitable start point for a hit-to-lead program.</div><div class="NLM_table-wrap" id="tbl1">Table 1<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0007.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Ld InMac is the intramacrophage assay carried out in THP-1 cells with <i>L. donovani</i> amastigotes. Data are the result of at least four independent replicates, and standard deviations are ≤0.4.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Cl<sub>i</sub> is mouse liver microsomal intrinsic clearance.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Aq solubility is kinetic aqueous solubility.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">ND means not determined.</p></div></div><div></div></div><div class="NLM_p last">The principal aim of this work was to identify analogues of <b>1</b> with a suitable profile for dosing in a mouse efficacy model of VL as rapidly as possible, to demonstrate that the series had the potential to progress into lead-optimization. Therefore, the initial chemistry program focused on understanding the structure–activity relationship (SAR) of the series, with an aim of identifying compounds with improved solubility and metabolic stability, as well as suitable potency for <i>in vivo</i> studies. Our targets were to achieve pEC<sub>50</sub> > 5.8, aqueous solubility >200 μM, and mouse liver microsomal clearance of <5.0 mL/min/g, as these criteria had been used previously to identify chemical series likely to have <i>in vivo</i> efficacy.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lack of knowledge regarding the molecular target of compound <b>1</b> made optimization challenging, with no guide as to the potential pharmacophore, or which vectors were most likely to positively influence activity. We therefore focused on utilizing tractable chemistry that would facilitate a rapid exploration of SAR. Also, to maintain good solubility and hopefully improve metabolic stability, we aimed to reduce, or at least maintain, the Log <i>D</i> of the initial analogues. This led us to focus on the triazole substituent, as well as the 5-position of the naphthyridine as initial points for exploration.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> SAR of 7-Triazolyl Analogues</h3><div class="NLM_p">Variations to the benzyl substituent of the triazole (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), including substitutions on the phenyl position (exemplified by <b>2</b>), or on the methylene (exemplified by <b>3</b>), led to a ∼10-fold loss in potency compared to <b>1</b>, although <b>3</b> did show an improvement in metabolic stability. A truncated analogue <b>4</b> was inactive, but we were encouraged by its improved solubility and metabolic stability. We thus replaced the 4-chlorophenyl group of <b>1</b> with more polar substituents, with the aim of regaining <i>in vitro</i> potency while maintaining a favorable absorption, distribution, metabolism, and excretion (ADME) profile. Morpholine-substituted <b>5</b> and pyrrolidinone-substituted <b>6</b> were synthesized and indeed proved to be both soluble and metabolically stable, although both compounds were essentially inactive. Switching to an amide as an isosteric replacement for the triazole was also investigated, and the matched pairs (<b>7</b><i>vs</i><b>1</b>) showed similar levels of potency, although the amide did not appear to show any clear advantage over the triazole as its mouse liver microsomal clearance was still not below the targeted 5 mL/min/g.</div><div class="NLM_table-wrap" id="tbl2">Table 2<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0008.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0009.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Ld InMac is the intramacrophage assay carried out in THP-1 cells with <i>L. donovani</i> amastigotes. Data are the result of at least three independent replicates, and standard deviations are ≤0.4.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Cl<sub>i</sub> is mouse liver microsomal intrinsic clearance.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Aq solubility is kinetic aqueous solubility.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">ND means not determined.</p></div></div><div></div></div><div class="NLM_p last">We next switched attention to the naphthyridyl 5-position. Initially, nitrogen-linked analogues were investigated. While both methylamine <b>8</b> and dimethylamine <b>9</b> were essentially inactive, larger amines such as <i>p</i>-chlorobenzylamine <b>10</b> and morpholine <b>11</b> both had pEC<sub>50</sub> values above 5, with good solubility and low clearance. Cyclic amides, such as <b>12</b>, proved to be inactive, as did sultam <b>13</b>, presumably due to the reduced electron density in the aromatic ring. Compound <b>13</b> was of particular interest as 5-sultam-substituted naphthyridines had been previously reported in a series of integrase inhibitors and were shown to impart very good pharmacokinetics (PK) properties.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Indeed, the lead compound from this series progressed as far as phase II clinical trials (compound <b>30</b>; <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Further exploration of N-linked analogues failed to deliver compounds with the necessary potency for progression to <i>in vivo</i> studies, so we switched our focus to carbon-linked analogues. Interestingly, the unsubstituted phenyl analogue <b>14</b> showed reasonable potency (pEC<sub>50</sub> = 5.9), and further analogues showed ortho-substitution to be beneficial, with the <i>o</i>-trifluoromethyl analogue <b>15</b> giving a significant increase in antiparasitic activity (pEC<sub>50</sub> = 7.0), possibly driven by the increased lipophilicity, and the <i>o</i>-methoxy analogue <b>16</b> showing a good balance of potency, stability, and solubility (pEC<sub>50</sub> = 6.2, Cl<sub>i</sub> = 1.4 mL/min/g and aqueous solubility >250 μM). Replacement of phenyl by aromatic heterocycles (such as pyridyl or pyrazolyl) was also explored, as was substitution on the other side of the naphthyridine (2-, 3-, and 4-positions), but these changes led to only weakly active compounds (data not shown).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Profiling of Compound <b>16</b></h3><div class="NLM_p">Compounds <b>15</b> and <b>16</b> both showed a promising balance of potency, solubility, and metabolic stability. Because of having higher metabolic stability (in mouse liver microsomes) and lower Chrom Log <i>D</i>, compound <b>16</b> was progressed into a VL <i>in vivo</i> efficacy study, carried out in our previously described VL mouse model.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Mice were dosed orally with the standard antileishmanial drug miltefosine, or with <b>16</b> dosed intraperitoneal (ip) two times daily for 5 days post infection (although <b>16</b> had a suitable profile for oral dosing, we elected to dose ip to maximize exposure and increase our chances of demonstrating <i>in vivo</i> proof of concept for the series). Parasite load was determined in the livers of animals 3 days after cessation of treatment, and parasite burden was expressed in Leishman Donovan units (LDUs, the mean number of amastigotes per liver cell × mg weight of liver). The blood exposure of compound <b>16</b> was also determined in dosed animals on days 1 and 5 to better understand the PK/pharmacodynamics (PD) relationship of the series. According to our project criteria, a compound needs to reduce parasite burden by >70% before being considered suitable for progression to lead-optimization, while a reduction of >95% would be considered suitable for a preclinical development candidate.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">In the study, miltefosine behaved as expected, reducing parasite levels by >99% at 30 mg/kg qd. After twice daily ip dosing at 50 mg/kg, compound <b>16</b> reduced parasite burden in mouse liver by 46%. This provided an early proof of concept for this series but fell short of our target of >70% parasite reduction. Upon examining the blood samples taken on days 1 and 5, it was clear that <b>16</b> was rapidly cleared from blood, with unbound concentrations of compound exceeding EC<sub>99</sub> only during the first hour post-dose (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Further examination of the samples revealed the presence of glucuronidated adducts of <b>16</b>, suggesting secondary metabolism as the key driver of the low exposure.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Blood Levels of <b>16</b>, Measured on Days 1 and 5 of a Mouse Efficacy Study, Dosing ip at 50 mg/kg b.i.d.</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">AUC<sub>(0–t)</sub> (μM min)</th><th class="rowsep1 colsep0" colspan="2" align="center"><i>C</i><sub>max</sub> (μM)</th><th class="rowsep1 colsep0" colspan="2" align="center"><i>T</i><sub>max</sub> (h)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">day 1</th><th class="colsep0 rowsep0" align="center">day 5</th><th class="colsep0 rowsep0" align="center">day 1</th><th class="colsep0 rowsep0" align="center">day 5</th><th class="colsep0 rowsep0" align="center">day 1</th><th class="colsep0 rowsep0" align="center">day 5</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1236</td><td class="colsep0 rowsep0" align="left">606</td><td class="colsep0 rowsep0" align="left">25.2</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td></tr></tbody></table></div></div><div class="NLM_p">Glucuronidation is a means of increasing water solubility of small molecules, facilitating their elimination from the body in urine. It involves transfer of the glucuronic acid component of uridine diphosphate glucuronic acid to a suitable substrate, catalyzed by UDP-glucuronosyltransferase (UGT), and occurs mainly in the liver.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Glucuronidation occurs at nucleophilic sites such as R–OH, R–NH<sub>2</sub>, or R–COOH, which can be present in the small molecule, or generated <i>via</i> phase I metabolism. Due to the low rates of microsomal clearance of <b>16</b>, alongside our <i>in vivo</i> data, we surmised that glucuronidation was occurring on the parent compound, most likely at the phenolic OH or the triazole N–H. Also, the observed reduction of parasite load, despite the high <i>in vivo</i> clearance, suggested that reducing glucuronidation to increase the duration of exposure above EC<sub>99</sub> would be a key strategy to progress the series toward lead-optimization.</div><div class="NLM_p">As a means of measuring glucuronidation <i>in vitro</i>, <b>16</b> was assessed in a mouse liver hepatocyte assay. Unfortunately, <b>16</b> showed similar stability to that seen in mouse liver microsomes (0.9 mL/min/g in microsomes <i>vs</i> 1.4 mL/min/g in hepatocytes) with negligible amounts of the glucuronide adduct being observed. This suggested that there was little involvement of the hepatic UDP-glucuronosyltransferase in the <i>in vivo</i> phase II metabolism. This result made series progression challenging, as there was no way to determine the potential impact of glucuronidation without running an <i>in vivo</i> study, limiting our understanding of the SAR surrounding the observed secondary metabolism.</div><div class="NLM_p">One possible strategy to identify compounds with improved metabolic stability would be to reduce lipophilicity. This had been shown previously to be a potential strategy for reducing glucuronidation;<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> however, as shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, this was very challenging within this compound series. Looking at measured log <i>D</i> (Chrom Log <i>D</i><sub>7.4</sub>),<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> analogues with Chrom Log <i>D</i><sub>7.4</sub> values below 3 were generally only weakly active, with pEC<sub>50</sub>’s above 5.8 only being achieved where Chrom Log <i>D</i><sub>7.4</sub> was greater than 3. In our experience, this is a common problem when trying to optimize series phenotypically, where increasing potency without increasing lipophilicity is very challenging; this highlights a key advantage of running structure-enabled programs. Because of this, alternative approaches to improving metabolic stability were required.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chrom Log <i>D</i><sub>7.4</sub><i>vs</i> intramacrophage potency (Ld InMac pEC<sub>50</sub>) for all compounds presented. The green line represents Chrom Log <i>D</i><sub>7.4</sub> = 3; the black line represents Ld InMac pEC<sub>50</sub> = 5.8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> SAR of the Naphthyridine Core</h3><div class="NLM_p">Our initial approach to reduce potential phase II metabolism within the series was therefore to investigate the SAR around the phenolic hydroxyl group and the triazole. Understanding which of these features was important for antiparasitic activity might enable us to synthesize potent analogues with lower potential for glucuronidation. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, removal or methylation of the naphthyridine 8-hydroxyl group led to a loss of antiparasitic activity compared to <b>16</b> (<b>17</b> and <b>18</b>, respectively), although <b>18</b> was close to the targeted pEC<sub>50</sub> of 5.8. Also, replacement of triazole with oxadiazole to remove the nucleophilic N–H led to a loss of activity (<b>19</b>). Synthesis of other analogues to explore the naphthyridine SAR proved extremely challenging within the triazole subseries, so to more rapidly address this, we switched attention to the bioisosteric replacement of triazole with amide; this change had previously been seen to have limited effect on potency (<i>e.g</i>., <b>1</b><i>vs</i><b>7</b>) and allowed much more straightforward synthesis of the analogues of interest. Thus, deletion of the naphthyridine N-6 of <b>7</b> led to a compound that was toxic to the host THP-1 cells, and deletion of naphthyridine N-1 led to loss of antiparasitic activity (<b>20</b> and <b>21</b>, respectively). Moving to a scaffold that trapped the phenolic OH as a carbonyl removed all antiparasitic activity despite the parent amides having pEC<sub>50</sub> values >6.0 (comparing <b>22</b> to <b>28</b> and <b>23</b> to <b>27</b>). Finally, we examined Raltegravir (<b>24</b>), an inhibitor of human immunodeficiency virus (HIV) integrase marketed as a treatment for HIV.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <b>24</b> contains the key acceptor–donor–acceptor binding motif identified within the naphthyridine series. Although <b>24</b> was inactive in our in vitro <i>Leishmania</i> assays, we surmised that transferring the known SAR of the naphthyridine core onto the Raltegravir scaffold could be a viable strategy to regain activity. Unfortunately, as exemplified by <b>25</b>, none of the analogues based on this scaffold were active. From this round of synthesis, we concluded that we were unlikely to identify active compounds without the acceptor–donor–acceptor binding motif of the 7-substituted-1,6-naphthyridin-8-ol core.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Highlighting the acceptor–donor–acceptor motifs of triazole analogue <b>1</b>, amide analogue <b>7</b>, and Raltegravir <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4">Table 4<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Ld InMac is the intramacrophage assay carried out in THP-1 cells with <i>L. donovani</i> amastigotes. Data are the result of at least three independent replicates, and standard deviations are ≤0.4.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Cl<sub>i</sub> is mouse liver microsomal intrinsic clearance.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Aq solubility is kinetic aqueous solubility.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">ND means not determined.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> SAR of 7-Carboxamide Analogues</h3><div class="NLM_p">Previous SAR demonstrated that replacing the triazole with an amide led to compounds such as <b>7</b> that retained antiparasitic activity. Since <b>7</b> itself was metabolically unstable (Cl<sub>i</sub> = 10 mg/mL/g), we became interested in transferring the SAR from the triazole subseries (<i>e.g</i>., <b>16</b>) to investigate its impact on metabolic stability, with a particular focus on glucuronidation. To this end, we synthesized <b>26</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) as a direct analogue of triazole <b>16</b>. Although it did not show sufficient potency for progression into efficacy studies, it had reasonable aqueous solubility (219 μM) and good metabolic stability (Cl<sub>i</sub> = 0.9 mL/min/g) and was therefore progressed into a mouse PK study to assess the extent of <i>in vivo</i> glucuronidation. After dosing (50 mg/kg ip) and analyzing the metabolites generated (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), there was little evidence of glucuronidation, with the major metabolism observed being hydroxylation. As significant quantities of parent were still present 8 h post-dose, this supported a strategy of switching to the amide series to reduce phase II metabolism and improve <i>in vivo</i> exposure.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PK profile of <b>26</b>, showing levels of parent, glucuronide adduct, major hydroxylated metabolite, and other minor metabolites. Data are based on two replicates, with error bars representing the range of the data from the two runs. Blood/water (30 μL, 1:2) were collected following 50 mg/kg ip administration to Balb C mice at prescribed time points; 90 μL of acetonitrile (ACN) was then added to each sample and the samples were centrifuged for 5 min at 7000 rpm; 90 μL of supernatant was removed and added to 50 μL of Milli-Q water before ultrahigh-performance liquid chromatography–quadrupole time-of-flight (UPLC Q-TOF) analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5">Table 5<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Ld InMac is the intramacrophage assay carried out in THP-1 cells with <i>L. donovani</i> amastigotes. Data are the result of at least three independent replicates, and standard deviations are ≤0.4.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Cl<sub>i</sub> is mouse liver microsomal intrinsic clearance.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Aq solubility is kinetic aqueous solubility.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">ND means not determined.</p></div></div><div></div></div><div class="NLM_p">With this in mind, we further explored the SAR of the amide subseries, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. We synthesized a set of benzyl amides, where 4-methoxy analogue <b>27</b> and α-methyl-4-fluoro analogue <b>28</b> both gave very encouraging profiles, meeting progression criteria in terms of potency, metabolic stability, and clearance. Alternatively, nonaromatic amides were explored, and although none were identified with suitable profiles for progression, cyclopropylmethyl analogue <b>29</b> did demonstrate reasonable potency. Due to its impressive <i>in vitro</i> potency, we selected <b>28</b> for progression into an <i>in vivo</i> PK study. However, upon dosing (50 mg/kg ip), the compound proved to be toxic, rapidly giving symptoms (within 3.5 h) requiring termination of the experiment.</div><div class="NLM_p last">We noted that a related compound from Merck, L-870,810 (<b>30</b>),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> was reported as a clinical candidate targeting HIV integrase, which progressed as far as phase II clinical trials. Compound <b>30</b> was inactive in our <i>in vitro</i> efficacy assays, but the report, alongside the <i>in vivo</i> data for <b>26</b>, suggested that compounds with substitutions in the naphthyridine 5-position could have suitable profiles for <i>in vivo</i> studies. Also, introducing substituents into the 5-naphthyridyl position had been a successful strategy for improving metabolic stability and potency in the triazole subseries. We therefore investigated a range of 5-substituted naphthyridyl analogues (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). THP-amine <b>31</b> and morpholine <b>32</b> lost potency compared to parent compound <b>7</b>, so we switched attention back to 5-phenylnaphthyridines. Previously identified groups were combined (the 4-methoxyphenyl of <b>16</b> and the cyclopropylmethyl amide of <b>29</b>), leading to <b>33</b>, which unfortunately did not deliver the expected increase in potency. Further combinations of nonaromatic amides with differently substituted 5-phenylnaphthyridines were synthesized, and while changing the phenyl substituent gave flat SAR and no advantage over previous compounds, exploration of the amide led to <b>34</b> with a <i>trans</i>-4-methoxycyclopropylamide. Compound <b>34</b> gave a good balance of potency, solubility, and microsomal stability and was therefore selected for a mouse PK study. Disappointingly, when dosed at 50 mg/kg ip, the mice again displayed the similar symptoms as with compound <b>28</b>, and the study was terminated after 60 min.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Profiling of <b>16</b>, <b>28</b>, and <b>34</b></h3><div class="NLM_p">Due to the encouraging results within the series (<b>16</b> showing low-level efficacy and <b>26</b> giving a good PK profile), we were keen to understand the origins of the observed toxicity of <b>28</b> and <b>34</b>. As previously mentioned, compound <b>30</b> progressed as far as phase II clinical trials as an HIV integrase inhibitor, and although it was inactive against VL, we were keen to assess whether there was scope to progress our related series further. To this end, two studies were conducted in parallel; a screen against receptors with known links to toxicity and investigation of mode of action (MoA).</div><div class="NLM_p">First, the compounds which were poorly tolerated in mice, <b>28</b> and <b>34</b>, were screened against a panel of >30 receptors with known links to <i>in vivo</i> toxicity (GSK-enhanced cross-screen panel (eXP)).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Compound <b>28</b> gave a pIC<sub>50</sub> value of 5.4 against monoamine oxidase A, highlighting a slight risk of drug–drug interactions and possible side effects, and a pIC<sub>50</sub> value of 4.9 in a phenotypic cell health assay, suggesting possible effects on mitochondrial integrity that could lead to an increased risk of hepatotoxicity. Compound <b>34</b> also showed potency in the cell health assay, alongside activity in a bile salt export pump (BSEP) assay (pIC<sub>50</sub> value of 4.8, hepatotoxicity risk) and a phospholipidosis assay. From this, it was not clear whether the effects seen in the receptor screen were related to the observed <i>in vivo</i> toxicity.</div><div class="NLM_p last">Alongside these screens, mode-of-action studies were initiated focusing on <b>10</b>, <b>16</b>, and <b>28</b>, as representatives of both the triazole and amide subseries. We were particularly interested in confirming that the compounds inhibited a shared target, identifying off-target effects, and understanding the source of the observed toxicity. The results of these studies have been reported previously and demonstrated that the compounds act as nonspecific chelators of divalent metal cations, in particular Zn<sup>2+</sup>, Fe<sup>2+</sup>, and Cu<sup>2+</sup>, and that this property is likely responsible for their antiparasitic activity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Indeed, the propensity of these compounds to nonspecifically chelate divalent cations may well explain the observed <i>in vivo</i> toxicity associated with this series.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Chemistry</h3><div class="NLM_p">To access the required analogues, a number of different approaches were needed, as illustrated in <a class="ref internalNav" href="#sch1" aria-label="scheme 1">scheme 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Compounds <b>1</b> and <b>2</b> were previously reported,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and synthesis of the remaining 7-triazolyl-8-hydroxy naphthyridines started from 7-cyanonaphthyridine <b>35</b><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), where cyclization with substituted hydrazides under acidic conditions led to compounds <b>3</b>–<b>6</b>. To access 5-substituted analogues, <b>35</b> could be brominated with <i>N</i>-bromosuccinimide (NBS) to give <b>36</b> and subsequently cyclized to give <b>37</b>, which was treated with a suitable amine to give <b>8</b>–<b>11</b>. For <b>12</b> and <b>13</b>, protection of the phenol proved to be necessary. Hence, <b>36</b> could be tosyl-protected to give <b>38</b>, followed by either Buchwald–Hartwig coupling to introduce the pryrrolidinone (<b>12</b>) or copper coupling with 1,2-thiazinane 1,1-dioxide to introduce the sultam (<b>13</b>). Alternatively, <b>36</b> could be directly coupled with phenylboronic acid to give <b>14</b>, or benzyl-protected to give <b>39</b>, which could be coupled to give <b>15</b> and <b>16</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,4-dioxane/acetic acid, 140–200 °C, 22–38%; (b) NBS, dichloromethane (DCM), 2 h, 84%; (c) acetohydrazide, 1,4-dioxane/acetic acid, 200 °C, 30 min, 45%; (d) relevant amine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), <i>N</i>-methyl-2-pyrrolidone (NMP), 180 °C, 1–18 h, 25–50%; (e) TsCl, NEt<sub>3</sub>, DCM, 40 °C, 3 h, 83%; (f) i. for <b>12</b>: pyrrolidin-2-one, Cs<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, Xantphos, 1,4-dioxane, 65 °C. For <b>13</b>: 1,2-thiazinane 1,1-dioxide, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, 1,4-dioxane, 65 °C. ii. NaOMe, dimethylformamide (DMF), 50 °C. iii. Acetohydrazide, 1,4-dioxane/acetic acid, 180 °C, 2 h, 7–16% over three steps; (g) BnBr, PPH<sub>3</sub>, diisopropyl azodicarboxylate (DIAD), tetrahydrofuran (THF), 0 °C, 18 h, 15%; (h) phenylboronic acid, K<sub>3</sub>PO<sub>4</sub>, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, DMF/water, 130 °C, then acetohydrazide, 1,4-dioxane/acetic acid, 200 °C, 45 min, 3% over two steps (<b>14</b>); (i) i. relevant boronic acid, K<sub>3</sub>PO<sub>4</sub>, tetrakis, 1,4-dioxane/water, 120 °C, 1.5 h. ii. Acetohydrazide, 1,4-dioxane/acetic acid, 180 °C, 18 h, 22% (<b>15</b>)/24% (<b>16</b>) over two steps.</p></p></figure><div class="NLM_p">To fully explore the SAR around the naphthyridine ring, and also to introduce alternative heterocycles to replace the triazole, a number of analogues required bespoke synthesis. Analogues <b>17</b>, <b>18</b>, <b>20</b>, and <b>21</b> were synthesized according to established procedures and are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_001.pdf" class="ext-link">Supporting Information</a>, with the synthesis of <b>19</b>, <b>22</b>, <b>23</b>, and <b>25</b> highlighted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Thus, 5-bromo-8-methoxy-1,6-naphthyridine-7-carboxylic acid <b>40</b> was cyclized with acetylhydrazide to give <b>41</b>, followed by Suzuki coupling and deprotection of the 8-methoxy group to give oxadiazole <b>19</b>. Compound <b>22</b> was synthesized from 3-chloropicolinic acid <i>via</i> conversion to the acid chloride, condensation with ethyl 3-(dimethylamino)acrylate, cyclization with methylamine, and ester hydrolysis to give <b>42</b>. This was then coupled with 4-fluoro-α-(<i>R</i>)-methylbenzylamine to give <b>22</b>. To access <b>23</b>, methyl 3-fluoropicolinate was condensed with <i>tert</i>-butyl acetate to give <b>43</b>, which was treated with 4-acetamidobenzenesulfonyl azide (ABSA), PBu<sub>3</sub>, then 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)/iodomethane to give cyclized <b>44</b>, which was subsequently hydrolyzed and coupled with 4-methoxybenzylamine to give <b>23</b>. Finally, <b>25</b> was synthesized according to a previously published route such that 2-cyanoanisole was treated with <i>N</i>-methylhydroxylamine and cyclized to <b>45</b>. Thermal rearrangement gave <b>46</b>, which was treated with 4-fluoro-α-(<i>R</i>)-methylbenzylamine to give <b>25</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) i. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), DIPEA, hydroxybenzotriazole (HOBt), acethydrazide, DCM, 0 °C, 18 h. ii. PPh<sub>3</sub>, CCl<sub>4</sub>, NEt<sub>3</sub>, MeCN, 60 °C, 2 h, 53%. (b) i. Phenylboronic acid, Na<sub>2</sub>CO<sub>3</sub>, tetrakis, 1,4-dioxane/water, 120 °C, 18 h. ii. Trimethylchlorosilane, NaI, MeCN, reflux, 18 h, 44% over two steps; (c) i. oxalyl chloride, DCM, RT then 3-ethoxy-3-oxo-propanoic acid, BuLi, −78 °C, 1 h. ii. DMF·dimethylacetamide (DMA), DMF, 100 °C, 1 h. iii. MeNH<sub>2</sub>, ether/EtOH, RT, 1 h. iv. 1 M NaOH, MeOH, RT, 2 h, 69% over four steps; (d) DIPEA, T3P, DMF, 2 h, 8%; (e) lithium diisopropylamide (LDA), <i>tert</i>-butyl acetate, THF, −78 °C, 2 h, quant. (f) i. ABSA, NEt<sub>3</sub>, MeCN, 0 °C, 18 h. ii. PBu<sub>3</sub>, THF, RT, 15 min. iii. DBU, MeI, MeCN, RT, 18 h, 32% over three steps. (g) i. Trifluoroacetyl (TFA), DCM, RT, 18 h. ii. EDCI, HOBt, DIPEA, DCM, 16 h, 88% over two steps. (h) i. MeNH–OH, Na<sub>2</sub>CO<sub>3</sub>, water/EtOH, 28 h, 80 °C. ii. Diethyl acetylenedicarboxylate, EtOH, RT, 1 h, 61% over two steps. (i) <i>p</i>-Xylene, reflux, 2 days, 41%; (j) toluene, reflux, 18 h, 46%.</p></p></figure><div class="NLM_p">7-Carboxamide analogues were synthesized from the corresponding ester <b>47</b> according to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Amides <b>7</b> and <b>27</b>–<b>29</b> were synthesized directly from the ester by treating with the relevant amine at high temperature. To access the desired 6-functionalized analogues, <b>47</b> was brominated with NBS to give <b>48</b>, tosyl-protected to give <b>49</b>, and converted to sultam <b>30</b>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Alternatively, <b>48</b> could be treated with 4-chlorobenzylamine to give <b>51a</b>, then coupled with another amine to give <b>31</b> and <b>32</b>. Compound <b>49</b> could also be coupled with 2-methoxyphenylboronic acid and hydrolyzed to give <b>50</b>, which was coupled with <i>trans-</i>4-methoxycyclohexylamine to give <b>34</b>. Alternatively, <b>48</b> could be treated directly with a relevant amine to give <b>51b</b> and <b>51c</b>, with subsequent Suzuki coupling with 2-methoxyphenylboronic acid giving <b>26</b> and <b>33</b>.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) i. EtOH, reflux, 18 h, 65%; (b) NBS, DCM, room temperature (RT), 2 h, 93%; (c) TsCl, NEt<sub>3</sub>, DCM, 40 °C, 2 days, 49%; (d) i. 1,2-thiazinane 1,1-dioxide, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, 1,4-dioxane, 65 °C, 24 h. ii. NaOMe, DMF, 50 °C, 24 h. iii. 4-Fluorobenzylamine, T3P, DIPEA, DMF, RT, 18 h, 11% over three steps; (e) relevant amine, EtOH, 100 °C, 18 h, 45–86%; (f) (2-methoxyphenyl)boronic acid, K<sub>3</sub>PO<sub>4</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, 1,4-dioxane/water, 140 °C, 1 h, 30% (<b>26</b>)/38% (<b>33</b>); (g) relevant amine, DIPEA, NMP, 150–180 °C, 5 h, 17% (<b>31</b>)/33% (<b>32</b>); (h) i. (2-methoxyphenyl)boronic acid, tetrakis, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/water, 60 °C, 18 h. ii. NaOMe, MeOH, 50 °C, 15 min. iii. LiOH, water, 60 °C, 18 h, 58% over three steps; (i) trans-4-methoxycyclohexanamine, DIPEA, T3P, 50 °C, 18 h, 56%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">To identify new compound series with the potential to be developed as new therapeutics for VL, a collection of 1.8 M compounds from the GSK corporate collection was screened against <i>L. donovani</i><i>in vitro</i>. One hit series identified from this, exemplified by <b>1</b>, was selected for a hit-to-lead program. <i>In vivo</i> studies of an early compound, <b>16</b>, demonstrated that the series had the potential to reduce parasite burden, but that glucuronidation was a potential barrier to series progression. Scaffold hopping from the core triazole to an amide was a key strategy for progressing the series, leading to <b>28</b> with a very good <i>in vitro</i> profile. Dosing of <b>28</b> identified an issue with toxicity for the series and further chemistry failed to identify compounds that did not carry this liability. MoA studies suggested that the antiparasitic activity, and the toxicity, was likely driven by chelation of divalent metal cations. Based on these findings, we concluded that attempting to develop compounds within this series that would separate antiparasitic activity from inherent toxicity would be extremely challenging and unlikely to succeed. With this in mind, work on the series was halted. This demonstrates the importance of understanding the mode of action from a very early stage in the drug discovery process, when working to progress phenotypically active hit compounds.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p last">Chemicals and solvents were purchased from Aldrich Chemical Company, Fluka, ABCR, VWR, Acros Organics, Fluorochem, and Alfa Aesar and were used as received. Air- and moisture-sensitive reactions were carried out under an inert atmosphere of argon in oven-dried glassware. Analytical thin-layer chromatography (TLC) was performed on precoated TLC plates (layer 0.20 mm silica gel 60 with fluorescent indicator UV254, from Merck). Developed plates were air-dried and analyzed under a UV lamp (UV254/365 nm). Flash column chromatography was performed using prepacked silica gel cartridges (230–400 mesh, 40–63 μm, from SiliCycle) using a Teledyne ISCO CombiFlash Companion, or CombiFlash Retrieve. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance DPX 500 spectrometer (<sup>1</sup>H at 500.1 MHz, <sup>13</sup>C at 125.8 MHz). Chemical shifts (δ) are expressed in parts per million (ppm) recorded using the residual solvent as the internal reference in all cases. Signal splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), broad (b), or a combination thereof. Coupling constants (<i>J</i>) are quoted to the nearest 0.1 Hz. Liquid chromatography–mass spectrometry (LC–MS) analyses were performed with either an Agilent HPLC 1100 series connected to a Bruker Daltonics MicrOTOF or an Agilent Technologies 1200 series HPLC connected to an Agilent Technologies 6130 quadrupole LC/MS, where both instruments were connected to an Agilent diode array detector. Mobile phase was water/acetonitrile + 0.1% HCOOH, or water/acetonitrile + 0.1% NH<sub>3</sub>; linear gradient, 80:20–5:95 over 3.5 min and then held for 1.5 min; flow rate, 0.5 mL/min. All intermediates had a measured purity ≥90%, and all assay compounds had a measured purity of ≥95%, as determined using this analytical LC–MS system (total ion current (TIC) and UV). High-resolution electrospray measurements were performed on a Bruker Daltonics MicrOTOF mass spectrometer. Microwave-assisted chemistry was performed using a Biotage Initiator Microwave Synthesizer.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> 7-(3-(Hydroxy(phenyl)methyl)-1<i>H</i>-1,2,4-triazol-5-yl)-1,6-naphthyridin-8-ol (<b>3</b>)</h3><div class="NLM_p last"><b>35</b> (100 mg, 0.58 mmol) and 2-hydroxy-2-phenylacetohydrazide (288 mg, 1.74 mmol) in 1,4-dioxane (1.5 mL)/acetic acid (0.5 mL) were heated in microwave at 140 °C for 2 h. The mixture was cooled to RT, and the resulting solid was collected, washed with 1,4-dioxane, and dried under vacuum to give <b>3</b> (43 mg, 0.13 mmol, 22%). <sup>1</sup>H NMR (dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub>): δ 14.90 (s, 1H), 12.29 (bs, 1H), 9.15 (s, 1H), 9.02 (s, 1H), 8.63–8.56 (m, 1H), 7.82–7.74 (m, 1H), 7.56–7.50 (m, 2H), 7.42–7.24 (m, 3H), 6.23 (bs, 1H), 5.91 (bs, 1H); <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>14</sub>N<sub>5</sub>O<sub>2</sub>, 320.1147; found, 320.1146.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 7-(3-Methyl-1<i>H</i>-1,2,4-triazol-5-yl)-1,6-naphthyridin-8-ol (<b>4</b>)</h3><div class="NLM_p last"><b>35</b> (30 mg, 0.16 mmol) and acetylhydrazide (58.4 mg, 0.79 mmol) in 1,4-dioxane (2 mL)/acetic acid (0.2 mL) were heated in microwave at 200 °C for 15 min. The mixture was cooled, solvent-evaporated, and the crude material was purified by mass-directed prep. HPLC to give <b>4</b> (10 mg, 0.04 mmol, 27%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.74 (s, 1H), 12.45 (s, 1H), 9.18–9.15 (m, 1H), 9.04 (s, 1H), 8.63–8.58 (m, 1H), 7.83–7.76 (m, 1H), 2.45 (s, 3H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 158.8, 158.5, 154.5, 149.5, 143.9, 141.9, 136.7, 125.6, 124.8, 12.8; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>10</sub>N<sub>5</sub>O, 228.0885; found, 228.0886.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 7-(3-(Morpholinomethyl)-1<i>H</i>-1,2,4-triazol-5-yl)-1,6-naphthyridin-8-ol (<b>5</b>)</h3><div class="NLM_p last"><b>35</b> (150 mg, 0.88 mmol) and 2-(4-morpholinyl)acetohydrazide (419 mg, 2.63 mmol) in 1,4-dioxane (3 mL)/acetic acid (0.3 mL) were heated in microwave at 180 °C for 2 h. The resulting solution was evaporated, cyclohexane (3 × 10 mL) was added, and evaporated. Acetone (15 mL) was added, and the resulting solid was collected by filtration, washed with MeOH, and dried to give <b>5</b> (105 mg, 0.34 mmol, 38%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.83 (s, 1H), 9.18–9.16 (m, 1H), 9.04 (s, 1H), 8.63–8.60 (m, 1H), 8.15 (s, 1H), 7.82–7.78 (m, 1H), 3.73 (s, 2H), 3.63–3.58 (m, 4H), 2.60–2.54 (m, 4H, under solvent peak); <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub>O<sub>2</sub>, 313.1413; found, 313.1411.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 1-((5-(8-Hydroxy-1,6-naphthyridin-7-yl)-1<i>H</i>-1,2,4-triazol-3-yl)methyl)pyrrolidin-2-one (<b>6</b>)</h3><div class="NLM_p last"><b>6</b> was synthesized by an analogous method to <b>3</b>, from <b>35</b> (100 mg, 0.58 mmol) and 2-(2-oxopyrrolidin-1-yl)acetylhydrazide (273 mg, 1.74 mmol). The crude material was purified by mass-directed prep. HPLC to give <b>6</b> (70 mg, 0.15 mmol, 26%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.20–9.17 (m, 1H), 9.06 (s, 1H), 8.65–8.61 (m, 1H), 7.83–7.80 (m, 1H), 4.61 (s, 2H), 3.47–3.44 (m, 2H), 2.34–2.29 (m, 2H), 2.04–1.95 (m, 2H); <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>15</sub>N<sub>6</sub>O<sub>2</sub>, 311.1256; found, 311.1260.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>N</i>-(4-Chlorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide (<b>7</b>)</h3><div class="NLM_p last">A mixture of <b>47</b> (51 mg, 0.25 mmol) and 4-chlorobenzylamine (701 mg, 0.5 mmol) in EtOH (4 mL) was stirred at 80 °C for 18 h. The hot reaction mixture was poured into a solution of acetic acid (0.5 mL) in water (4 mL). After stirring for 10 min, cold water (15 mL) was added and stirred at RT for 40 min. The resulting solid was collected, washed with water, and dried to give <b>7</b> (42 mg, 0.13 mmol, 53%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.67 (s, 1H), 9.18–9.16 (m, 1H), 8.93 (bs, 1H), 8.61 (d, <i>J</i> = 7.7 Hz, 1H), 7.86–7.82 (m, 1H), 7.44–7.39 (m, 4H), 4.55 (d, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 170.1, 154.6, 142.6, 138.4, 136.5, 132.0, 129.9, 128.8, 127.0, 126.0, 125.4, 42.1; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>Cl, 314.0696; found, 314.0695.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 7-(3-Methyl-1<i>H</i>-1,2,4-triazol-5-yl)-5-(methylamino)-1,6-naphthyridin-8-ol (<b>8</b>)</h3><div class="NLM_p last">A mixture of <b>37</b> (100 mg, 0.33 mmol), methylamine (327 μL, 0.653 mmol, 2 N in THF), and DIPEA (0.171 mL, 0.980 mmol) in NMP (2 mL) was stirred at 180 °C for 18 h in a sealed tube. Further, methylamine (327 μL, 0.653 mmol, 2 N in THF) was added and stirring was continued for further 18 h. The solvent was evaporated, DCM (3 mL) was added, and the resulting solid was collected and purified by mass-directed prep. HPLC to give <b>8</b> (21 mg, 0.82 mmol, 25%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.06 (s, 1H), 10.97 (s, 1H), 8.94–8.91 (m, 1H), 8.54 (d, <i>J</i> = 7.9 Hz, 1H), 7.57–7.51 (m, 1H), 7.29 (bs, 1H), 2.97 (d, <i>J</i> = 3.8 Hz, 3H), 2.33 (s, 3H); <i>m</i>/<i>z</i> 257.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 5-(Dimethylamino)-7-(3-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-1,6-naphthyridin-8-ol (<b>9</b>)</h3><div class="NLM_p last">A mixture of <b>37</b> (100 mg, 0.33 mmol), dimethylamine (0.327 mL, 0.653 mmol, 2 M in THF), and DIPEA (171 μL, 0.98 mmol) in NMP (2 mL) was stirred at 180 °C for 18 h in a sealed tube. Further dimethylamine (0.327 mL, 0.653 mmol, 2 M in THF) was added and stirring was continued for a further 18 h. The solvent was evaporated, and the crude residue was purified by flash chromatography (0–50% EtOAC/EtOH (3:1)/cyclohexanes) to give <b>9</b> (34 mg, 0.13 mmol, 38%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.20 (s, 1H), 11.47 (bs, 1H), 8.99–8.96 (m, 1H), 8.46 (d, <i>J</i> = 8.2 Hz, 1H), 7.61–7.56 (m, 1H), 2.93 (s, 6H), 2.35 (s, 3H); <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>13</sub>H<sub>15</sub>N<sub>6</sub>O, 271.1307; found, 271.1309.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 5-((4-Chlorobenzyl)amino)-7-(3-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-1,6-naphthyridin-8-ol (<b>10</b>)</h3><div class="NLM_p last"><b>10</b> was synthesized by an analogous method to <b>8</b> from <b>37</b> (50 mg, 0.15 mmol), 4-chlorobenzylamine (42 mg, 0.29 mmol), and DIPEA (57 mg, 0.44 mmol) to give <b>10</b> (30 mg, 0.074 mmol, 50%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.18 (bs, 1H), 11.12 (bs, 1H), 9.04–9.01 (m, 1H), 8.75–8.72 (m, 1H), 7.90–7.85 (m, 1H), 7.67–7.62 (m, 1H), 7.54–7.50 (m, 2H), 7.37–7.33 (m, 2H), 4.89 (s, 2H), 2.43 (s, 3H); <sup>13</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 158.8, 154.9, 153.5, 149.3, 144.5, 141.2, 140.6, 132.4, 131.4, 130.1, 128.4, 122.7, 121.2, 116.1, 43.4, 14.0; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>6</sub>OCl, 367.1074; found, 367.1088.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 7-(3-Methyl-1<i>H</i>-1,2,4-triazol-5-yl)-5-morpholino-1,6-naphthyridin-8-ol (<b>11</b>)</h3><div class="NLM_p last">A mixture of <b>37</b> (50 mg, 0.16 mmol), DIPEA (90 μL, 0.49 mmol), and morpholine (28 μL, 0.32 mmol) in NMP (0.5 mL) was heated in microwave to 200 °C for 1 h. After cooling, the crude mixture was purified by prep. HPLC to give <b>11</b> (31 mg, 0.073 mmol, 46%) as the TFA salt. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.13 (dd, <i>J</i> = 1.6, 4.2 Hz, 1H), 8.59 (dd, <i>J</i> = 1.6, 8.5 Hz, 1H), 7.77–7.73 (m, 1H), 3.90–3.85 (m, 4H), 3.34–3.30 (m, 4H), 2.52 (s, 3H, under DMSO signal); <i>m</i>/<i>z</i> 313.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 1-(8-Hydroxy-7-(3-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-1,6-naphthyridin-5-yl)pyrrolidin-2-one (12)</h3><div class="NLM_p last">To a solution of pyrrolidin-2-one (0.068 mL, 0.89 mmol) in 1,4-dioxane (7 mL) was added <b>38</b> (300 mg, 0.74 mmol), caesium carbonate (484 mg, 1.48 mmol), palladium acetate (3 mg, 0.015 mmol), and Xantphos (17 mg, 0.03 mmol), and the mixture was heated at 65 °C for 18 h. Water (50 mL)/HCl (2 M, two drops) was added, extracted with DCM (2 × 50 mL), and the combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and solvent-evaporated. The crude residue (120 mg, 0.30 mmol) in DMF (0.3 mL) was added to a solution of sodium methoxide (1.5 mL, 0.74 mmol, 0.5 M in MeOH) and heated to 50 °C for 5 min, cooled to room temperature, and stirred for 15 min. Acetic acid (0.033 mL, 0.59 mmol) and water (3 mL) were added dropwise, and the resulting suspension was stirred for 2 h, poured into water (20 mL), and the pH adjusted to approximately 5 by addition of HCl (1 M, 0.1 mL). DCM (20 mL) was added, and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford crude 8-hydroxy-5-(2-oxopyrrolidin-1-yl)-1,6-naphthyridine-7-carbonitrile (57 mg, 0.22 mmol, 25% over two steps). To this crude intermediate in a mixture of acetic acid (0.1 mL) and 1,4-dioxane (1 mL) was added acetic hydrazide (50 mg, 0.67 mmol), and the mixture was heated in microwave to 180 °C for 2 h. Further, acetic hydrazide (50 mg, 0.67 mmol) was added and heated in microwave to 180 °C for 2 h. The solvent was evaporated, and the crude material was purified by prep. HPLC to give <b>12</b> (5 mg, 0.016 mmol, 7%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.48 (bs, 1H), 12.25 (bs, 1H), 9.18–9.15 (m, 1H), 8.39–8.35 (m, 1H), 7.78–7.73 (m, 1H), 4.15–4.08 (m, 2H), 2.66–2.60 (m, 2H), 2.49 (s, 3H, under solvent peak), 2.32–2.23 (m, 2H); <i>m</i>/<i>z</i> 311.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2-(8-Hydroxy-7-(3-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-1,6-naphthyridin-5-yl)-1,2-thiazinane 1,1-dioxide (<b>13</b>)</h3><div class="NLM_p last">To a solution of <b>38</b> (300 mg, 0.74 mmol) in 1,4-dioxane (7 mL) were added 1,2-thiazinane 1,1-dioxide (120 mg, 0.89 mmol), caesium carbonate (484 mg, 1.48 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (13 mg, 0.015 mmol), and Xantphos (17 mg, 0.03 mmol), and the resulting mixture was stirred at 65 °C for 1 h. The mixture was poured into water (50 mL)/HCl (2 M, two drops) and extracted with DCM (2 × 50 mL). The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and solvent-evaporated. The crude mixture in DMF (0.6 mL) was added to a solution of sodium methoxide (2.7 mL, 1.36 mmol, 0.5 M in MeOH), and the resulting solution heated to 50 °C for 5 min, cooled to room temperature, and stirred 15 min. An acetic acid (0.06 mL, 1.09 mmol)/water (5.5 mL) mixture was added dropwise, and the resulting suspension was stirred for 2 h, poured into water (20 mL), and the pH was adjusted to approximately 5 by addition of HCl (1 M, 0.1 mL). DCM (20 mL) was added, and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford crude 5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-hydroxy-1,6-naphthyridine-7-carbonitrile (190 mg, 0.53 mmol, 71% over two steps). To this crude material in a mixture of acetic acid (0.1 mL) and 1,4-dioxane (1 mL) was added acetic hydrazide (139 mg, 1.83 mmol), and the mixture was stirred in microwave at 180 °C for 2 h, concentrated to dryness, and purified by mass-directed prep. HPLC to give <b>13</b> (35 mg, 0.1 mmol, 16%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.45 (bs, 1H), 12.41 (bs, 1H), 9.09–9.06 (m, 1H), 8.51–8.45 (m, 1H), 7.78–7.70 (m, 1H), 4.02–3.97 (m, 1H), 3.89–3.81 (m, 1H), 3.70–3.61 (m, 2H), 3.38–3.31 (m, 2H), 3.09–3.06 (m, 1H), 2.23 (s, 3H), 1.57–1.48 (m, 1H); <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub>O<sub>3</sub>S, 361.1083; found, 361.1079.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 7-(3-Methyl-1<i>H</i>-1,2,4-triazol-5-yl)-5-phenyl-1,6-naphthyridin-8-ol (<b>14</b>)</h3><div class="NLM_p last"><b>36</b> (75 mg, 0.39 mmol), 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane (122 mg, 0.60 mmol), potassium phosphate tribasic (191 mg, 0.90 mmol), and Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (12 mg, 0.015 mmol) in DMF (1.5 mL)/water (0.5 mL) were heated in microwave at 130 °C for 1 h. EtOAc (10 mL) and 20% aqueous NaCl (10 mL) were added, and the organic layer was separated, washed with brine, and solvent-evaporated to give crude intermediate. To this crude material in 1,4-dioxane (2 mL)/acetic acid (0.2 mL) was added acetylhydrazide (667 mg, 0.90 mmol) and heated in microwave to 200 °C for 45 min. The resulting mixture was filtered to remove solid, solvent-evaporated, and purified by mass-directed prep. HPLC to give <b>14</b> (3 mg, 0.009 mmol, 3%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.50 (bs, 1H), 9.15 (s, 1H), 8.37 (d, <i>J</i> = 8.3 Hz, 1H), 7.76–7.66 (m, 3H), 7.63–7.52 (m, 4H), 2.48 (s, 3H, under DMSO signal); <i>m</i>/<i>z</i> 304.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 7-(3-Methyl-1<i>H</i>-1,2,4-triazol-5-yl)-5-(2-(trifluoromethyl)phenyl)-1,6-naphthyridin-8-ol (<b>15</b>)</h3><div class="NLM_p last">A mixture of <b>39</b> (250 mg, 0.74 mmol), 2-(trifluoromethyl)benzeneboronic acid (279 mg, 1.47 mmol), sodium carbonate (234 mg, 2.21 mmol), and tetrakis(triphenylphosphine)palladium(0) (42 mg, 0.037 mmol) in water (3 mL)/1,4-dioxane (9 mL), was heated in microwave at 120 °C for 1 h. The mixture was partitioned between DCM (15 mL) and sat. NH<sub>4</sub>Cl (30 mL), the phases were separated, and the aqueous layer was further extracted with DCM (3 × 10 mL). The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated, and the resulting solid was triturated with ether to give a mixture of 8-(benzyloxy)-5-(2-(trifluoromethyl)phenyl)-1,6-naphthyridine-7-carbonitrile and 8-hydroxy-5-(2-(trifluoromethyl)phenyl)-1,6-naphthyridine-7-carbonitrile (0.150 g). The crude mixture was taken up in acetic acid (0.1 mL)/1,4-dioxane (1 mL), acetic hydrazide (46 mg, 0.62 mmol) was added, and heated in microwave at 180 °C for 8 h. Further, acetic hydrazide (0.031 g, 0.416 mmol) was added and heating was continued for 17 h. The solvent was evaporated, and the crude mixture was dissolved in 5% MeOH/DCM (20 mL), washed with water (1 × 50 mL), and the aqueous phase was extracted with further DCM (1 × 30 mL). The combined organics were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a brown oil, which was precipitated with a mixture of ether and acetone. The resulting solid was further triturated with ether to give a brown pale solid, which was dried under vacuum to give <b>15</b> (60 mg, 0.16 mmol, 22% over two steps). <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 9.23–9.20 (m, 1H), 7.96–7.89 (m, 2H), 7.77–7.69 (m, 2H), 7.57–7.47 (m, 2H), 2.59 (s, 3H); <i>m</i>/<i>z</i> 372.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 5-(2-Methoxyphenyl)-7-(3-methyl-1<i>H</i>-1,2,4-triazol-5-yl)-1,6-naphthyridin-8-ol (<b>16</b>)</h3><div class="NLM_p last">A mixture of <b>39</b> (700 mg, 2.06 mmol), 2-methoxyphenylboronic acid (626 mg, 4.12 mmol), sodium carbonate (655 mg, 6.18 mmol), and tetrakis(triphenylphosphine)palladium(0) (120 mg, 0.103 mmol) in 1,4-dioxane (9 mL)/water (3 mL) was heated at 120 °C in microwave for 1.5 h, poured into water (15 mL)/brine (5 mL), and extracted with EtOAc (20 mL). The organics were dried over MgSO4, filtered, and concentrated. The crude was dissolved in acetic acid (0.5 mL)/1,4-dioxane (5 mL), acetic hydrazide (0.23 g, 3.10 mmol) was added, and stirred at 180 °C in microwave for 2 h. Further, acetic hydrazide (0.23 g, 3.10 mmol) was added and the mixture was heated in microwave at 180 °C for 6 h. The resulting solution was concentrated and taken up in 9:1 DCM/MeOH (15 mL), washed with water (10 mL), brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting solid was triturated with ether (10 mL) and acetonitrile (10 mL) to give <b>16</b> (165 mg, 0.50 mmol, 24%). <sup>1</sup>H NMR (MeOD): δ 9.09–9.05 (m, 1H), 8.09–8.05 (m, 1H), 7.68–7.63 (m, 1H), 7.58–7.53 (m, 1H), 7.50–7.46 (m, 1H), 7.22–7.13 (m, 2H), 3.71 (s, 3H), 3.32 (s, 3H); <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>O<sub>2</sub>, 334.1304; found, 334.1294.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 5-(2-Methoxyphenyl)-7-(5-methyl-1,3,4-oxadiazol-2-yl)-1,6-naphthyridin-8-ol (<b>19</b>)</h3><div class="NLM_p last"><b>41</b> (80 mg, 0.25 mmol), 2-methoxyphenylboronic acid (76 mg, 0.50 mmol), sodium carbonate (79 mg, 0.747 mmol), and tetrakis(triphenylphosphine)palladium(0) (14 mg, 0.012 mmol) in a mixture of water (1 mL)/1,4-dioxane (3 mL) were stirred at 120 °C overnight. The reaction mixture was concentrated to dryness, and the crude residue was purified by flash chromatography (0–70% EtOH/EtOAc (1:3)/cyclohexane) to give 2-(8-methoxy-5-(2-methoxyphenyl)-1,6-naphthyridin-7-yl)-5-methyl-1,3,4-oxadiazole (86 mg, 0.25 mmol). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.16–9.14 (m, 1H), 7.95–7.92 (m, 1H), 7.69–7.65 (m, 1H), 7.51–7.46 (m, 1H), 7.32–7.29 (m, 1H), 7.18–7.15 (m, 1H), 7.08–7.04 (m, 1H), 4.19 (s, 3H), 3.58 (s, 3H), 2.53 (s, 3H). To a solution of 2-(8-methoxy-5-(2-methoxyphenyl)-1,6-naphthyridin-7-yl)-5-methyl-1,3,4-oxadiazole (68 mg, 0.195 mmol) in CH<sub>3</sub>CN (2 mL) were added trimethylchlorosilane (37 μL, 0.293 mmol) and sodium iodide (44 mg, 0.293 mmol) and heated to reflux overnight. The crude residue was poured into water (30 mL) and extracted with DCM (50 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude residue was triturated with MeOH (5 mL), and the resulting solid was collected by filtration to give <b>19</b> (29 mg, 0.087 mmol, 44%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.19 (dd, <i>J</i> = 1.5, 4.0 Hz, 1H), 7.99 (dd, <i>J</i> = 1.5, 8.6 Hz, 1H), 7.77 (dd, <i>J</i> = 4.2, 8.5 Hz, 1H), 7.58–7.53 (m, 1H), 7.40–7.37 (m, 1H), 7.23 (d, <i>J</i> = 8.1 Hz, 1H), 7.15 (dd, <i>J</i> = 7.3, 7.3 Hz, 1H), 3.66 (s, 3H), 2.62 (s, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 164.1, 163.6, 157.2, 153.9, 150.1, 149.6, 141.9, 136.7, 131.7, 131.1, 126.9, 125.1, 124.5, 122.9, 121.2, 111.9, 55.8, 11.1; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>15</sub>N<sub>4</sub>O<sub>3</sub>, 335.1144; found, 335.1155.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>R</i>)-<i>N</i>-(1-(4-Fluorophenyl)ethyl)-1-methyl-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxamide (<b>22</b>)</h3><div class="NLM_p last">To <b>42</b> (100 mg, 0.47 mmol) in DMF (2 mL) were added 4-fluoro-α-(<i>R</i>)-methylbenzylamine (71 mg, 0.51 mmol) and DIPEA (180 mg, 1.40 mmol). Propylphosphonic anhydride (444 mg, 1.4 mmol, 50% solution in EtOAc) was added dropwise, and the mixture was stirred for 2 h, poured into sat NaHCO<sub>3</sub> (10 mL), and extracted into EtOAc (3 × 10 mL). The combined organics were washed with brine, dried, evaporated, and the crude material was purified by column chromatography (0–20% MeOH/DCM) to give <b>22</b> (13 mg, 0.38 mmol, 8%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.49 (d, <i>J</i> = 7.8 Hz, 1H), 8.88–8.85 (m, 2H), 8.35–8.31 (m, 1H), 7.89–8.85 (m, 1H), 7.46–7.40 (m, 2H), 7.21–7.15 (m, 2H), 5.24–5.15 (m, 1H), 4.02 (s, 3H), 1.51 (d, <i>J</i> = 6.9 Hz, 3H); <i>m</i>/<i>z</i> 326.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(4-Methoxybenzyl)-1-methyl-4-oxo-1,4-dihydropyrido[3,2-<i>c</i>]pyridazine-3-carboxamide (<b>23</b>)</h3><div class="NLM_p">To crude <b>43</b> (8 g, 33.4 mmol) in MeCN (130 mL) at 0 °C were added triethylamine (6 g, 60 mmol) and 4-acetamidobenzenesulfonyl azide (8.8 g, 36.8 mmol), allowed to warm to RT, and stirred for 18 h. The crude mixture was filtered to remove solid, and the filtrate was concentrated and purified by column chromatography (pet. ether/EtOAc, 3:1) to give <i>tert</i>-butyl 2-diazo-3-(3-fluoropyridin-2-yl)-3-oxopropanoate (8.1 g, 30.5 mmol, 91%). This material was dissolved in THF (80 mL), tributylphosphine (6.854 g, 33.6 mmol) was added, stirred for 15 min, and quenched by addition of water (5.5 mL). The solvent was evaporated, and the residue was purified by flash chromatography (pet. ether/EtOAc 3:1) to give <i>tert</i>-butyl-3-(3-fluoropyridin-2-yl)-2-hydrazono-3-oxopropanoate (9 g, quant.). This material was dissolved in MeCN (180 mL), and DBU (10.7 g, 10.7 mmol) and methyl iodide (5 g, 35.3 mmol) were added and stirred at RT for 18 h. The mixture was quenched with sat. aq NH<sub>4</sub>Cl, extracted into DCM, and the organics were concentrated and purified by flash chromatography (1% MeOH in DCM) to give crude <b>44</b>, which was used without further purification (2.8 g, 10.7 mmol, 32%); <i>m</i>/<i>z</i> 206.0 [M + H <i>– t</i>Bu]<sup>+</sup>. To a solution of <b>44</b> (2.8 g, 10.7 mmol) in DCM (100 mL) was added TFA (15.7 g, 139 mmol) and stirred for 18 h. Ether was added and evaporated and further ether added. The resulting solid was collected and dried to give crude 1-methyl-4-oxo-1,4-dihydropyrido[3,2-<i>c</i>]pyridazine-3-carboxylic acid (1.6 g, 73%), which was used without purification.</div><div class="NLM_p last">A mixture of the crude material (300 mg, 1.46 mmol), HOBt (237 mg, 1.75 mmol), EDCI (420 mg, 2.19 mmol), and DIPEA (378 mg, 2.92 mmol) in DCM (12 mL) was stirred for 30 min, a solution of (4-methoxyphenyl)methanamine (241 mg, 1.75 mmol) in DCM (12 mL) added, and stirred for 16 h. The mixture was concentrated and purified by prep. HPLC to give <b>23</b> (419 mg, 1.29 mmol, 88%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.87–9.84 (m, 1H), 8.93 (d, <i>J</i> = 4.2 Hz, 1H), 8.43 (d, <i>J</i> = 8.8 Hz, 1H), 7.96–7.94 (m, 1H), 7.31 (d, <i>J</i> = 8.1 Hz, 2H), 6.91 (d, <i>J</i> = 8.2 Hz, 2H), 4.50 (d, <i>J</i> = 5.8 Hz, 2H), 4.24 (s, 3H), 3.75 (s, 3H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 169.3, 162.0, 158.8, 150.1, 141.3, 140.3, 139.0, 131.4, 129.2, 128.9, 127.0, 114.3, 55.5, 44.9, 42.3; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>17</sub>N<sub>4</sub>O<sub>3</sub>, 325.1295; found, 325.1305.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>R</i>)-<i>N</i>-(Fluoro(4-methoxyphenyl)methyl)-5-hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide (<b>25</b>)</h3><div class="NLM_p last">To a suspension of <b>46</b> (240 mg, 0.79 mmol) in toluene (5 mL), (<i>R</i>)-4-fluoro-α-methylbenzylamine (549 mg, 3.94 mmol) was added. The resulting solution was heated to reflux overnight. The solvent was evaporated, and the residue was purified by prep. HPLC to give <b>25</b> (145 mg, 46% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 12.55–12.48 (m, 1H), 9.07–9.02 (m, 1H), 7.56–7.50 (m, 1H), 7.47–7.40 (m, 3H), 7.20–7.09 (m, 4H), 5.17 (dd, <i>J</i> = 8.0, 15.3 Hz, 1H), 3.81 (d, <i>J</i> = 7.3 Hz, 3H), 3.17 (d, <i>J</i> = 3.0 Hz, 3H), 1.50 (dd, <i>J</i> = 2.7, 6.9 Hz, 3H); <i>m</i>/<i>z</i> 398.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 8-Hydroxy-5-(2-methoxyphenyl)-<i>N</i>-methyl-1,6-naphthyridine-7-carboxamide (<b>26</b>)</h3><div class="NLM_p last">To a mixture of <b>51a</b> (72 mg, 0.25 mmol), (2-methoxyphenyl)boronic acid (77 mg, 0.51 mmol), and potassium phosphate tribasic (162 mg, 0.77 mmol) in 1,4-dioxane (2 mL) was added Pd(dppf)Cl<sub>2</sub>.DCM (12 mg, 0.015 mmol) in water (0.5 mL) and heated in microwave at 140 °C for 1 h. After cooling, EtOAc (9 mL) and 20% aqueous NaCl (10 mL) were added and the organics were separated, dried over MgSO<sub>4</sub>, evaporated, and the crude material was purified by column chromatography (0–8% MeOH/DCM) to give <b>26</b> (25 mg, 0.077 mmol, 30%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.17–9.15 (m, 1H), 9.02–8.98 (m, 1H), 7.95–7.92 (m, 1H), 7.75–7.72 (m, 1H), 7.58–7.54 (m, 1H), 7.44–7.42 (m, 1H), 7.25–7.22 (m, 1H), 7.18–7.15 (m, 1H), 3.68 (s, 3H), 2.91 (d, <i>J</i> = 4.9 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 170.3, 157.2, 154.1, 148.6, 142.5, 136.4, 132.0, 131.0, 127.1, 125.9, 125.1, 121.2, 111.8, 55.8, 26.3; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub>, 310.1192; found, 310.1196.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 8-Hydroxy-<i>N</i>-(4-methoxybenzyl)-1,6-naphthyridine-7-carboxamide (<b>27</b>)</h3><div class="NLM_p last">A mixture of <b>47</b> (100 mg, 0.50 mmol) and 4-methoxybenzylamine (134 mg, 0.98 mmol) in EtOH (20 mL) was heated to reflux overnight. To the hot mixture was added water (30 mL) and acetic acid (2 mL), cooled to RT, solvent-evaporated, and the crude material was purified by mass-directed prep. HPLC to give <b>27</b> (84 mg, 0.27 mmol, 54%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.69 (bs, 1H), 9.83 (bs, 1H), 9.19–9.14 (m, 1H), 8.93–8.85 (m, 1H), 8.60 (d, <i>J</i> = 8.3 Hz, 1H), 7.83–7.79 (m, 1H), 7.35–7.32 (m, 2H), 6.92–6.89 (m, 2H), 4.49 (d, <i>J</i> = 6.4 Hz, 2H), 3.75 (s, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 169.8, 158.8, 154.9, 154.4, 142.5, 136.5, 131.3, 129.5, 127.0, 126.1, 125.4, 114.2, 55.5, 42.1; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub>, 310.1192; found, 310.1192.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(1-(4-Fluorophenyl)ethyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide (<b>28</b>)</h3><div class="NLM_p last">A mixture of <b>47</b> (300 mg, 1.4 mmol) and 4-fluoro-α-methylbenzylamine (383 mg, 2.7 mmol) in EtOH (12 mL) was heated in microwave at 120 °C for 2 h. After cooling to 50 °C, water (10 mL) and acetic acid (1 mL) were added and the mixture was cooled to RT. Further, water (10 mL) and acetic acid (1 mL) were added, the mixture was stirred for 40 min, and the resulting solid was collected, washed with water, and dried to give <b>28</b> (280 mg, 0.89 mmol, 65%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.69 (s, 1H), 9.66–9.60 (m, 1H), 9.18–9.15 (m, 1H), 8.93 (s, 1H), 8.64–8.61 (m, 1H), 7.85–7.81 (m, 1H), 7.57–7.51 (m, 2H), 7.20–7.15 (m, 2H), 5.31–5.24 (m, 1H), 1.59 (d, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 169.2, 161.6 (d, <i>J</i> = 242 Hz), 154.9, 154.6, 142.4, 140.5, 136.5, 128.9, (d, <i>J</i> = 8.1 Hz), 127.0. 125.9, 125.4, 115.5 (d, <i>J</i> = 21.3 Hz), 48.2, 22.1; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>F, 312.1148; found, 312.1139.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(Cyclopropylmethyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide (<b>29</b>)</h3><div class="NLM_p last"><b>29</b> was synthesized by an analogous method to <b>28</b> from <b>47</b> (100 mg, 0.50 mmol) and aminomethylcyclopropane (70 mg, 0.98 mmol) to give <b>29</b> (23 mg, 0.09 mmol, 19%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.92 (bs, 1H), 9.38 (bs, 1H), 9.18–9.16 (m, 1H), 8.92 (s, 1H), 8.64–8.60 (m, 1H), 7.86–7.81 (m, 1H), 3.26 (t, <i>J</i> = 6.6 Hz, 2H), 1.19–1.11 (m, 1H), 0.49–0.45 (m, 2H), 0.34–0.29 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 169.8, 154.8, 154.5, 142.5, 142.3, 136.4, 126.9, 126.2, 125.2, 43.6, 11.3, 3.8; <i>m</i>/<i>z</i> 244.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(4-Fluorobenzyl)-5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-hydroxy-1,6-naphthyridine-7-carboxamide (<b>30</b>)</h3><div class="NLM_p last">To a solution of <b>49</b> (365 mg, 0.835 mmol) in 1,4-dioxane (8.4 mL), 1,2-thiazinane 1,1-dioxide (135 mg, 1.00 mmol), caesium carbonate (544 mg, 1.67 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (15 mg, 0.017 mmol), and Xantphos (19 mg, 0.033 mmol) were added, and the resulting mixture was stirred at 65 °C for 2.5 h. The reaction was partitioned between DCM (25 mL) and sat. NH<sub>4</sub>Cl (50 mL), the phases were separated, and the aqueous phase was extracted with further DCM (1 × 25 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a crude material, which was dissolved in dichloromethane and purified by flash chromatography (0–30% ethyl acetate/ethanol (3:1)/cyclohexane) to give methyl 5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-(tosyloxy)-1,6-naphthyridine-7-carboxylate, which was used without further purification. To a suspension of the crude material (0.070 g, 0.142 mmol) in isopropanol (1.4 mL), a solution of lithium hydroxide (20 mg, 0.47 mmol) in water was added, and the resulting suspension was heated at 60 °C overnight and then stirred at room temperature overnight. 2 M HCl was added to adjust the pH to approximately 2, and the mixture was concentrated to give crude 5-(1,1-dioxido-1,2-thiazinan-2-yl)-8-hydroxy-1,6-naphthyridine-7-carboxylic acid. To a suspension of the crude material (108 mg, 0.33 mmol) in DMF (3.3 mL), 4-fluorobenzylamine (0.045 mL, 0.40 mmol), HOBt (61 mg, 0.40 mmol), and DIPEA (0.088 mL, 0.50 mmol) were added, and the resulting solution was purged with nitrogen and cooled to 0 °C. EDCI (96 mg, 0.50 mmol) was added, and the solution was stirred at room temperature for 8 h and then at 50 °C overnight. Further, HOBt (61 mg, 0.40 mmol), EDCI (96 mg, 0.50 mmol), and 4-fluorobenzylamine (0.046 mL, 0.40 mmol) were added, and the resulting solution was stirred at 50 °C overnight. After cooling, the reaction was partitioned between EtOAc (20 mL) and sat. NH<sub>4</sub>Cl (50 mL), the layers were separated, and the aqueous phase was extracted with further EtOAc (1 × 20 mL). The combined organics were dried over Na<sub>2</sub>SO4, filtered, and concentrated to give a crude oil, which was purified by preparative HPLC to give <b>30</b> (11 mg, 0.025 mmol, 7% over three steps). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.15 (bs, 1H), 8.61–8.59 (m, 1H), 7.84–7.80 (m, 1H), 7.49–7.43 (m, 2H), 7.37–7.25 (m, 1H), 7.18–7.12 (m, 2H), 7.11–7.03 (m, 1H), 4.66 (d, <i>J</i> = 6.0 Hz, 2H), 3.89–3.86 (m, 2H), 3.49–3.45 (m, 2H), 2.36–2.28 (m, 3H), 2.02–1.99 (m, 1H); <i>m</i>/<i>z</i> 431.0 [M + H]<sup>+</sup>; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>SF, 431.1189; found, 431.1192.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-(4-Chlorobenzyl)-8-hydroxy-5-((tetrahydro-2<i>H</i>-pyran-4-yl)amino)-1,6-naphthyridine-7-carboxamide (<b>31</b>)</h3><div class="NLM_p last">To a solution of DIPEA (747 μL, 0.428 mmol) in NMP (1.43 mL) were added 4-aminotetrahydropyran (103 μL, 0.998 mmol) and <b>51c</b> (56 mg, 0.143 mmol), and the resulting solution was heated in microwave at 180 °C for 5 h. The reaction was partitioned between EtOAc (15 mL) and a saturated solution of NaHCO<sub>3</sub> (60 mL). The layers were separated, and the aqueous phase was extracted with EtOAc (3 × 30 mL). The organic phases were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and the crude material was purified by preparative HPLC to afford <b>31</b> (10 mg, 17%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 12.43 (s, 1H), 9.07–9.02 (m, 2H), 8.78 (dd, <i>J</i> = 1.5, 8.6 Hz, 1H), 7.69 (dd, <i>J</i> = 4.3, 8.3 Hz, 1H), 7.43–7.35 (m, 4H), 7.00 (d, <i>J</i> = 7.6 Hz, 1H), 4.58 (d, <i>J</i> = 6.3 Hz, 2H), 4.47–4.39 (m, 1H), 3.92–3.88 (m, 2H), 3.55–3.47 (m, 2H), 1.97–1.90 (m, 2H), 1.62–1.50 (m, 2H); <i>m</i>/<i>z</i> 413.17 [M + H]<sup>+</sup>.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(4-Chlorobenzyl)-8-hydroxy-5-morpholino-1,6-naphthyridine-7-carboxamide (<b>32</b>)</h3><div class="NLM_p last">A mixture of <b>51c</b> (30 mg, 0.07 mmol) and morpholine (312 mg, 0. 36 mmol) in NMP (0.5 mL) was heated in microwave at 150 °C for 1 h. The crude solution was purified by mass-directed prep. HPLC to give <b>32</b> (10 mg, 0.024 mmol, 33%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.14 (bs, 1H), 9.45–9.32 (m, 1H), 9.16–9.07 (m, 1H), 8.62–8.53 (m, 1H), 7.81–7.70 (m, 1H), 7.45–7.38 (m, 4H), 4.62–5.53 (m, 2H), 3.92–3.81 (m, 4H), 3.30–3.23 (m, 4H, under water signal); <i>m</i>/<i>z</i> 399.1, 401.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(Cyclopropylmethyl)-8-hydroxy-5-(2-methoxyphenyl)-1,6-naphthyridine-7-carboxamide (<b>33</b>)</h3><div class="NLM_p last"><b>33</b> was synthesized by an analogous method to <b>26</b> from <b>51b</b> (40 mg, 0.14 mmol) and 2-methoxyphenylboronic acid (43 mg, 0.28 mmol) to give <b>33</b> (20 mg, 0.05 mmol, 38%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.51 (s, 1H), 9.17–9.15 (m, 1H), 8.28–8.23 (m, 1H), 8.00–7.96 (m, 1H), 7.58–7.44 (m, 3H), 7.21–7.17 (m, 1H), 7.12–7.09 (m, 1H), 3.74 (s, 3H), 3.40–3.35 (m, 2H), 1.16–1.08 (m, 1H), 0.61–0.56 (m, 2H), 0.36–0.311 (m, 2H); <i>m</i>/<i>z</i> 350.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 8-Hydroxy-<i>N</i>-(<i>trans</i>-4-methoxycyclohexyl)-5-(2-methoxyphenyl)-1,6-naphthyridine-7-carboxamide (<b>34</b>)</h3><div class="NLM_p last">To a solution of <b>50</b> (750 mg, 2.53 mmol) in DMF (17 mL) were added <i>trans</i>-4-methoxycyclohexanamine (491 mg, 3.80 mmol), DIPEA (1.33 mL, 7.59 mmol), and propylphosphonic anhydride solution (T3P) (4.83 g, 7.59 mmol) and stirred at RT for 2 h and then at 50 °C for 18 h. After cooling, the reaction mixture was partitioned between water (70 mL) and EtOAc (30 mL), the layers were separated, and the pH of the aqueous layer was adjusted to approximately 5 with 1 M NaOH. The aqueous layer was extracted with EtOAc (2 × 30 mL), and the combined organics were washed with sat. NH<sub>4</sub>Cl (1 × 40 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting solid was triturated with ether (3 × 5 mL) and dried to give <b>34</b> (580 mg, 1.42 mmol, 56% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.88 (s, 1H), 9.14–9.12 (m, 1H), 8.67–8.64 (m, 1H), 7.90–7.88 (m, 1H), 7.72–7.70 (m, 1H), 7.57–7.52 (m, 1H), 7.32–7.40 (m, 1H), 7.22–7.13 (m, 2H), 3.92–3.84 (m, 1H), 3.64 (s, 3H), 3.23 (s, 3H), 3.11–3.05 (m, 1H), 2.05–1.99 (m, 2H), 1.85–1.83 (m, 2H), 1.63–1.54 (m, 2H), 1.27–1.17 (m, 2H); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 169.2, 157.2, 154.3, 154.1, 148.6, 142.4, 136.4, 131.9, 131.1, 127.0, 125.9, 121.2, 111.8, 78.1, 55.8, 55.6, 48.1, 30.8, 29.8; <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub>, 408.1923; found, 408.1913.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 5-Bromo-8-hydroxy-1,6-naphthyridine-7-carbonitrile (<b>36</b>)</h3><div class="NLM_p last">To a solution of <b>35</b> (1.10 g, 6.43 mmol) in DCM (64 mL), NBS (1.37 g, 7.71 mmol) was added and stirred for 2 h. Water (100 mL) was added, the phases were separated, and the aqueous layer was extracted with 5% MeOH/DCM (3 × 40 mL). The combined organics were washed with water (4 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>36</b> as a yellow solid (1.35 g, 5.42 mmol, 84%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 9.30–9.28 (m, 1H), 8.64–8.61 (m, 1H), 8.06–8.02 (m, 1H); δ <i>m</i>/<i>z</i> 250.0, 252.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 5-Bromo-7-(5-methyl-4<i>H</i>-1,2,4-triazol-3-yl)-1,6-naphthyridin-8-ol (<b>37</b>)</h3><div class="NLM_p last">To <b>36</b> (750 mg, 2.85 mmol) in 1,4-dioxane (6 mL)/acetic acid (2 mL) was added acetohydrazide (666 mg, 9.0 mmol) and heated in microwave at 200 °C for 0.5 h. Upon cooling, the resulting solid was collected, washed with 1,4-dioxane, and dissolved in water. 1 M HCl was added to adjust the pH to approximately 4–5, and the resulting solid was collected, washed with water, and dried in vacuo to give <b>37</b> (460 mg, 1.35 mmol, 45%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.14 (bs, 1H), 8.83–8.82 (m, 1H), 8.27–8.24 (m, 1H), 7.63–7.60 (m, 1H), 2.31 (s, 3H); <i>m</i>/<i>z</i> 305.9, 307.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 5-Bromo-7-cyano-1,6-naphthyridin-8-yl 4-methylbenzenesulfonate (<b>38</b>)</h3><div class="NLM_p last">To a suspension of <b>36</b> (500 mg, 2.0 mmol) in DCM (15 mL) were added triethylamine (418 μL, 3.00 mmol) and tosyl chloride (457 mg, 2.4 mmol) and heated in a sealed tube at 40 °C for 3 h. After cooling, sat. NaHCO<sub>3</sub> (25 mL) was added, the layers were separated, and the aqueous layer was extracted with DCM (30 mL). The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by flash chromatography (0–80% EtOAc/cyclohexane) to give <b>38</b> (867 g, 1.66 mmol, 83%); <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.01–9.00 (m, 1H), 8.62–8.60 (m, 1H), 7.92–7.89 (m, 1H), 7.77 (d, <i>J</i> = 8.4 Hz, 2H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 2.36 (s, 3H); <i>m</i>/<i>z</i> 406.0. 408.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 8-(Benzyloxy)-5-bromo-1,6-naphthyridine-7-carbonitrile (<b>39</b>)</h3><div class="NLM_p last">To a solution of <b>38</b> (2.47 g, 9.9 mmol) in THF (60 mL) at 0 °C was added triphenylphosphine (3.89 g, 14.8 mmol) and benzyl alcohol (1.12 mL, 10.9 mmol), stirred for 15 min, and diisopropyl azodicarboxylate (2.91 mL, 14.82 mmol) was added dropwise. The resulting solution was stirred at 0 °C for 2 h, allowed to warm to room temperature, and stirred overnight. The solution was poured into water (150 mL) and extracted with EtOAc (150 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified using column chromatography (0–25% EtOAc/cyclohexane) to give a white solid, which was triturated with a mixture of Et<sub>2</sub>O and cyclohexane (1:1, 20 mL) to give <b>39</b> (0.5 g, 1.47 mmol, 15%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.40–9.37 (m, 1H), 8.72–8.68 (m, 1H), 8.08–8.04 (m, 1H), 7.53–7.48 (m, 2H), 7.43–7.35 (m, 3H), 5.86 (s, 2H); <i>m</i>/<i>z</i> 338.1, 340.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 2-(5-Bromo-8-methoxy-1,6-naphthyridin-7-yl)-5-methyl-1,3,4-oxadiazole (<b>41</b>)</h3><div class="NLM_p last">To a solution of EDCI (335 mg, 1.75 mmol) in DCM (15 mL) at 0 °C were added DIPEA (0.509 mL, 2.91 mmol) and HOBt (268 mg, 1.75 mmol) and stirred at 0 °C for 10 min. Acethydrazide (130 mg, 1.75 mmol) and <b>40</b> (330 mg, 1.17 mmol) were added, and the solution was stirred for 18 h. Water (25 mL) and DCM (25 mL) were added, and the aqueous layer was extracted with DCM (2 × 15 mL). The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give crude <i>N</i>′-acetyl-5-bromo-8-methoxy-1,6-naphthyridine-7-carbohydrazide (170 mg, 43%) which was used without purification. Triphenylphosphine (247 mg, 0.944 mmol), carbon tetrachloride (0.182 mL, 1.89 mmol), and triethylamine (0.132 mL, 0.944 mmol) were added to a mixture of the crude material (160 mg, 0.472 mmol) in CH<sub>3</sub>CN (4 mL) and stirred at 60 °C for 2 h. After cooling, the reaction mixture was concentrated and purified by flash chromatography (0–70% EtOH/EtOAc 1:3/cyclohexane) to give <b>41</b> (0.08 g, 53% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.34–9.33 (m, 1H), 8.76–8.73 (m, 1H), 8.00–7.97 (m, 1H), 4.25 (s, 3H), 2.66 (s, 3H); <i>m</i>/<i>z</i> 321.0, 323.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 1-Methyl-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylic Acid (<b>42</b>)</h3><div class="NLM_p last">To 3-chloropyridine-2-carboxylic acid (1 g, 6.3 mmol) in DCM (40 mL) was added oxalyl chloride (1.6 g, 12.7 mmol) and DMF (one drop) and stirred for 2 h. The solvent was evaporated, and THF (20 mL) was added. In parallel, to 3-ethoxy-3-oxo-propanoic acid (1.31 g, 10.2 mmol) in THF (20 mL) at −78 °C was added BuLi (4.3 mL, 2.5 M in hexanes, 10.8 mmol) dropwise over 10 min. To this was added the acid chloride solution dropwise, and the mixture was stirred at −78 °C for 30 min, warmed to −30 °C, and stirred again for 30 min, and then quenched by pouring into a mix of ice/1 M HCl. The aqueous layer was extracted with EtOAc (3 × 20 mL), and the combined organics were washed with sat NaHCO<sub>3</sub>, 1 M HCl, and brine, dried, and evaporated. The crude material (480 mg, 1.9 mmol) and DMF·DMA (2.49 g, 2.1 mmol) in DMF (2 mL) were heated in microwave at 100 °C for 1 h and solvent-evaporated. Water (5 mL) was added and washed with EtOAc (2 × 5 mL). The combined organics were washed with brine, dried, and solvent-evaporated. Ether (4 mL)/EtOH (1 mL) and methylamine (33% in EtOH, 60 mg, 1.9 mmol) were added and stirred for 1 h, and the resulting solid was collected, taken up in DMF (4 mL), potassium carbonate (424 mg, 3.0 mmol) was added, and the mixture was stirred in a sealed tube at 100 °C overnight. The solvent was evaporated, 1 M NaOH (1 mL)/MeOH (1 mL) was added, and the mixture was stirred for 2 h. The resulting solid was collected, suspended in water (5 mL), and acidified with acetic acid. The resulting solid was collected, washed with water, and dried under vacuum to give <b>42</b> (151 mg, 0.70 mmol, 69% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 15.32 (bs, 1H), 9.11 (bs, 1H), 8.98–8.96 (m, 1H), 8.48–8.44 (m, 1H), 8.00–7.97 (m, 1H), 4.11 (s, 3H); <i>m</i>/<i>z</i> 205.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>tert</i>-Butyl 3-(3-Fluoropyridin-2-yl)-3-oxopropanoate (<b>43</b>)</h3><div class="NLM_p last">To LDA (33 mL, 65.8 mmol, 2 M in THF) at −78 °C was added <i>tert</i>-butyl acetate (9.5 g, 82.2 mmol), stirred for 45 min, and methyl 3-fluoropicolinate (5.1 g, 32.9 mmol) in THF (30 mL) was added dropwise. The reaction mixture was stirred for 2 h, quenched at −78 °C by addition of pet. ether and water, and warmed to RT. The layers were separated, and the aqueous phase was extracted with pet. ether. The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give crude <b>43</b>, which was used in the synthesis of <b>23</b> without purification (8 g, quant.); <i>m</i>/<i>z</i> 205.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Ethyl 5-(2-Ethoxy-2-oxoethyl)-3-(2-methoxyphenyl)-2-methyl-2,5-dihydro-1,2,4-oxadiazole-5-carboxylate (<b>45</b>)</h3><div class="NLM_p last">To a mixture of 2-methoxybenzonitrile (500 mg, 3.76 mmol) and <i>N</i>-methylhydroxylamine hydrochloride (627 mg, 7.51 mmol) in water (3.8 mL)/EtOH (1.9 mL) was added sodium carbonate (438 mg, 4.13 mmol), and the mixture was stirred at 80 °C for 28 h. The solvent was evaporated, DCM was added, stirred for 18 h, and the mixture was filtered. The solid was discarded, and the filtrate was evaporated to give crude <i>N</i>-hydroxy-2-methoxy-<i>N</i>-methylbenzimidamide (742 mg, 4.12 mmol), which was used in the next step without purification. To this crude material in EtOH (10 mL) was added diethyl acetylenedicarboxylate (771 mg, 4.53 mmol), stirred for 1 h, and the solvent was evaporated. The crude material was purified by flash chromatography (0–80% EtOAc/cyclohexane) to give <b>45</b> (880 mg, 2.5 mmol, 61%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.57–7.53 (m, 1H), 7.49–7.46 (m, 1H), 7.18–7.16 (m, 1H), 7.07–7.03 (m, 1H), 4.20–4.16 (m, 2H), 4.08 (q, <i>J</i> = 7.0 Hz, 2H), 3.83 (s, 3H), 3.27–3.23 (m, 1H), 2.97–2.93 (m, 1H), 2.91 (s, 3H), 1.24–1.16 (m, 6H); <i>m</i>/<i>z</i> 351.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Ethyl 5-Hydroxy-2-(2-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate (<b>46</b>)</h3><div class="NLM_p last">A solution of <b>45</b> (880 mg, 2.51 mmol) in <i>p</i>-xylene (5.38 mL) was heated to reflux for 2 days. Hexane (5 mL) was added, the resulting mixture was sonicated, and the resulting suspension was stored at 0 °C for 3 days. The solid was collected, washed with cyclohexane, and dried to give <b>46</b> (540 mg, 1.78 mmol, 41%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.45 (s, 1H), 7.56–7.51 (m, 1H), 7.37–7.34 (m, 1H), 7.19–7.17 (m, 1H), 7.11–7.07 (m, 1H), 4.28 (q, <i>J</i> = 6.9 Hz, 2H), 3.82 (s, 3H), 3.20 (s, 3H), 1.27 (t, <i>J</i> = 7.0 Hz, 3H); <i>m</i>/<i>z</i> 305.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Methyl 5-Bromo-8-hydroxy-1,6-naphthyridine-7-carboxylate (<b>48</b>)</h3><div class="NLM_p last">To <b>47</b> (800 mg, 3.9 mmol) in DCM (20 mL) was added NBS (837 mg, 4.7 mmol) and stirred for 2 h. The resulting solid was collected, washed with DCM, and dried under vacuum to give <b>46</b> (1.09 g, 3.65 mmol, 93% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 11.54 (bs, 1H), 9.27–9.25 (m, 1H), 8.60–8.57 (m, 1H), 8.01–7.99 (m, 1H), 3.95 (s, 3H); <i>m</i>/<i>z</i> 283.0. 285.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Methyl 5-Bromo-8-(tosyloxy)-1,6-naphthyridine-7-carboxylate (<b>49</b>)</h3><div class="NLM_p last">To a suspension of <b>48</b> (1.3 g, 4.59 mmol) in DCM (31 mL), triethylamine (0.96 mL, 6.89 mmol) and tosyl chloride (1.05 g, 5.51 mmol) were added, and the suspension was heated at 40 °C for 2 days. A saturated solution of NaHCO<sub>3</sub> (50 mL) was added, and the layers were separated. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and purified by flash chromatography (0–80% EtOAc/cyclohexane) to give <b>49</b> (0.98 g, 2.3 mmol, 49%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.95–8.92 (m, 1H), 8.55–8.53 (m, 1H), 7.84–7.81 (m, 1H), 7.61 (d, <i>J</i> = 8.4 Hz, 2H), 7.31 (d, <i>J</i> = 8.3 Hz, 2H), 3.67 (s, 3H), 2.32 (s, 3H); <i>m</i>/<i>z</i> 437.0, 439.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 8-Hydroxy-5-(2-methoxyphenyl)-1,6-naphthyridine-7-carboxylic Acid (<b>50</b>)</h3><div class="NLM_p last">To a suspension of <b>49</b> (19.75 g, 45.2 mmol) in 1,4-dioxane (339 mL) were added (2-methoxyphenyl)boronic acid (13.73 g, 90 mmol), aqueous sodium carbonate (14.36 g, 136 mmol, 113 mL of water), and tetrakis(triphenylphosphine)palladium(0) (2.61 g, 2.26 mmol), purged with N<sub>2</sub>, and stirred at 60 °C for 18 h. After cooling, the mixture was partitioned between DCM (200 mL) and water (1.2 L), and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude intermediate was purified by flash chromatography (0–100% EtOAc/ethanol (5:1)/cyclohexane) to give methyl 5-(2-methoxyphenyl)-8-(tosyloxy)-1,6-naphthyridine-7-carboxylate (16 g, 34.5 mmol), which was used without further purification. To a solution of the crude material (16 g, 34.5 mmol) in DMF (34.4 mL) was added sodium methoxide in MeOH (172 mL, 86 mmol, 0.5 N), stirred at 50 °C for 5 min, cooled to RT, and stirred for a further 15 min. Acetic acid (3.94 mL, 68.9 mmol)/water (130 mL) was added, stirred for 30 min, and the resulting solid was collected and washed with 1:1 MeOH/H<sub>2</sub>O (2 × 50 mL). The crude solid was taken up in THF (193 mL)/MeOH (97 mL), a solution of lithium hydroxide monohydrate (2.43 g, 58.0 mmol) in water (50 mL) was added, and the resulting suspension was stirred at 60 °C overnight. After cooling, pH was adjusted to approximately 4–5 by addition of 2 M HCl, and the resulting solid was collected, washed with 1:1 MTBE/cyclohexane, and dried to give <b>50</b> (7.65 g, 26 mmol, 89%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.99–8.97 (m, 1H), 7.79–7.76 (m, 1H), 7.57–7.54 (m, 1H), 7.52–7.47 (m, 1H), 7.34–7.32 (m, 1H), 7.18–7.15 (m, 1H), 7.13–7.08 (m, 1H), 3.64 (s, 3H).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 5-Bromo-<i>N</i>-(4-chlorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide (<b>51a</b>)</h3><div class="NLM_p last"><b>51a</b> was synthesized by an analogous method to <b>51b</b> from <b>48</b> (120 mg, 0.40 mmol) and 4-chlorobenzylamine (57 mg, 9.40 mmol) to give <b>51a</b> (75 mg, 0.18 mmol, 45%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.70 (bs, 1H), 9.75 (bs, 1H), 9.24–9.21 (m, 1H), 8.59–8.57 (m, 1H), 7.97–7.94 (m, 1H), 7.42–7.41 (m, 4H), 4.56 (d, <i>J</i> = 6.4 Hz, 2H); <i>m</i>/<i>z</i> 391.8, 393.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 5-Bromo-8-hydroxy-<i>N</i>-methyl-1,6-naphthyridine-7-carboxamide (<b>51b</b>)</h3><div class="NLM_p last">To <b>48</b> (1.3 g, 4.6 mmol) in EtOH (25 mL) was added methylamine (33% in EtOH, 2.2 mL, 23 mmol) and stirred at 100 °C overnight. The hot mixture was poured into water (40 mL)/acetic acid (10 mL), allowed to cool to RT, stirred for 1 h, and the resulting solid was collected, washed with water, and dried under vacuum to give <b>51b</b> (1.18 g, 3.96 mmol, 86% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.98 (bs, 1H), 9.24–9.06 (m, 2H), 8.59–8.55 (m, 1H), 7.96–7.92 (m, 1H), 2.90 (d, <i>J</i> = 2.9 Hz, 3H); <i>m</i>/<i>z</i> 282.0, 284.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 5-Bromo-<i>N</i>-(cyclopropylmethyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide (<b>51c</b>)</h3><div class="NLM_p last"><b>51c</b> was synthesized by an analogous method to <b>51b</b> from <b>48</b> (400 mg, 1.4 mmol) and cyclopropylmethanamine (150 mg, 2.1 mmol) to give <b>51c</b> (392 mg, 1.16 mmol, 82%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 14.00 (bs, 1H), 9.28–9.22 (m, 2H), 8.62–8.58 (m, 1H), 8.00–7.95 (m, 1H), 3.26–3.23 (m, 2H), 1.18–1.12 (m, 1H), 0.51–0.45 (m, 2H), 0.34–0.30 (m, 2H); <i>m</i>/<i>z</i> 322.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Intramacrophage <i>L. donovani</i> Assay</h3><div class="NLM_p last">This assay was conducted as previously described,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> except for compound exposure time, which was 96 h instead of 72 h.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Kinetic Aqueous Solubility Assessment and Intrinsic Clearance Experiments</h3><div class="NLM_p last">These assays were conducted as previously described.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Chrom Log <i>D</i><sub>pH7.4</sub></h3><div class="NLM_p last">This assay was conducted as previously described.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>In vivo</i> Mouse Efficacy Studies</h3><div class="NLM_p last"><i>In vivo</i> studies were carried out as previously described.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Ethical Statements</h3><div id="sec4_48_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Mouse and Rat Pharmacokinetics</h4><div class="NLM_p last">All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK/Dundee University Policy on the Care, Welfare, and Treatment of Animals.</div></div><div id="sec4_48_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>In Vivo</i> Efficacy</h4><div class="NLM_p last">All regulated procedures, at the University of Dundee, on living animals were carried out under the authority of a project license issued by the Home Office under the Animals (Scientific Procedures) Act 1986, as amended in 2012 (and in compliance with EU Directive EU/2010/63). License applications will have been approved by the University’s Ethical Review Committee (ERC) before submission to the Home Office. The ERC has a general remit to develop and oversee policy on all aspects of the use of animals on University premises and is a subcommittee of the University Court, its highest governing body.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00705" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35616" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35616" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00705?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00705</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental details and HPLC traces for key target compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_002.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_001.pdf">jm0c00705_si_001.pdf (1.52 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_002.xlsx">jm0c00705_si_002.xlsx (11.64 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00705" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael G. Thomas</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0377-0281" title="Orcid link">http://orcid.org/0000-0003-0377-0281</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4e036014601a2621232f3d0e2a3b202a2b2b602f2d603b25"><span class="__cf_email__" data-cfemail="eca1c2b6c2b88483818d9fac889982888989c28d8fc29987">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy J. Miles</span> - <span class="hlFld-Affiliation affiliation">Global
Health R&D, GlaxoSmithKline, Tres Cantos 28760, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7407-7404" title="Orcid link">http://orcid.org/0000-0001-7407-7404</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84d0ede9aaceaac9ede8e1f7c4e3f7efaae7ebe9"><span class="__cf_email__" data-cfemail="ca9ea3a7e480e487a3a6afb98aadb9a1e4a9a5a7">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian H. Gilbert</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5238-1314" title="Orcid link">http://orcid.org/0000-0002-5238-1314</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#731a5d1b5d141a1f111601073317061d1716165d12105d0618"><span class="__cf_email__" data-cfemail="147d3a7c3a737d78767166605470617a7071713a75773a617f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manu De Rycker</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3171-3519" title="Orcid link">http://orcid.org/0000-0002-3171-3519</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard J. Wall</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Spinks</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ola Epemolu</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sujatha Manthri</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suzanne Norval</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Osuna-Cabello</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Patterson</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Riley</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frederick R. C. Simeons</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laste Stojanovski</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Thomas</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Thompson</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire Naylor</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jose M. Fiandor</span> - <span class="hlFld-Affiliation affiliation">Global
Health R&D, GlaxoSmithKline, Tres Cantos 28760, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul G. Wyatt</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0397-245X" title="Orcid link">http://orcid.org/0000-0002-0397-245X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Marco</span> - <span class="hlFld-Affiliation affiliation">Global
Health R&D, GlaxoSmithKline, Tres Cantos 28760, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2442-0021" title="Orcid link">http://orcid.org/0000-0002-2442-0021</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Wyllie</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8810-5605" title="Orcid link">http://orcid.org/0000-0001-8810-5605</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin D. Read</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division
of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8536-0130" title="Orcid link">http://orcid.org/0000-0002-8536-0130</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The following authors have shares in GlaxoSmithKline: J.M.F., P.G.W., M.M., K.D.R., and T.J.M. The other authors declare no competing interests.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3976-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Funding for this work was provided by Wellcome (nos. 092340 and 100476). The authors thank DND<i>i</i> and their team for their support and scientific discussions. They also thank Gina MacKay, Darren Edwards, and Dan Fletcher for performing HRMS and for assistance with performing other NMR and MS analyses; Raul Fernandez Velasco and the Galchimia chemistry team for synthesizing key compounds; and Alastair Pate, Francesco Gastaldello, and James Burkinshaw for data management.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">VL</td><td class="NLM_def"><p class="first last">visceral leishmaniasis</p></td></tr><tr><td class="NLM_term">DND<i>i</i></td><td class="NLM_def"><p class="first last">Drugs for Neglected Diseases <i>initiative</i></p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">GlaxoSmithKline</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr><tr><td class="NLM_term">NTD</td><td class="NLM_def"><p class="first last">neglected tropical disease</p></td></tr><tr><td class="NLM_term">THP-1</td><td class="NLM_def"><p class="first last">human monocytic cell line derived from an acute monocytic leukemia patient</p></td></tr><tr><td class="NLM_term">Ld InMac</td><td class="NLM_def"><p class="first last">intramacrophage assay carried out in THP-1 cells with <i>L. donovani</i> amastigotes</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00745" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00745" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 23 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>World
Health Organization (WHO) List of Neglected Tropical Diseases</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>. <a href="http://www.who.int/neglected_diseases/diseases/en/" class="extLink">http://www.who.int/neglected_diseases/diseases/en/</a> (accessed April 23, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+World%0AHealth+Organization+%28WHO%29+List+of+Neglected+Tropical+Diseases%3B+World+Health+Organization%3A+Geneva%2C+2018.+http%3A%2F%2Fwww.who.int%2Fneglected_diseases%2Fdiseases%2Fen%2F+%28accessed+April+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWorld%250AHealth%2520Organization%2520%2528WHO%2529%2520List%2520of%2520Neglected%2520Tropical%2520Diseases%26pub%3DWorld%2520Health%2520Organization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrie, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Anti-trypanosomatid Drug Discovery: an Ongoing Challenge and a Continuing Need</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/nrmicro.2016.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fnrmicro.2016.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=28239154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=217-231&author=M.+C.+Fieldauthor=D.+Hornauthor=A.+H.+Fairlambauthor=M.+A.+J.+Fergusonauthor=D.+W.+Grayauthor=K.+D.+Readauthor=M.+De+Ryckerauthor=L.+S.+Torrieauthor=P.+G.+Wyattauthor=S.+Wyllieauthor=I.+H.+Gilbert&title=Anti-trypanosomatid+Drug+Discovery%3A+an+Ongoing+Challenge+and+a+Continuing+Need&doi=10.1038%2Fnrmicro.2016.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need</span></div><div class="casAuthors">Field, Mark C.; Horn, David; Fairlamb, Alan H.; Ferguson, Michael A. J.; Gray, David W.; Read, Kevin D.; De Rycker, Manu; Torrie, Leah S.; Wyatt, Paul G.; Wyllie, Susan; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-231</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases.  These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal.  Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them.  In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled.  In addn., we consider the important challenges to drug discovery strategies and the new technologies that can address them.  The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIBpRGL7YaP7Vg90H21EOLACvtfcHk0lirGZnep1VbUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D&md5=1585d954d6eb695196a6c8921a84e300</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro.2016.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro.2016.193%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BC.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DTorrie%26aufirst%3DL.%2BS.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DAnti-trypanosomatid%2520Drug%2520Discovery%253A%2520an%2520Ongoing%2520Challenge%2520and%2520a%2520Continuing%2520Need%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2017%26volume%3D15%26spage%3D217%26epage%3D231%26doi%3D10.1038%2Fnrmicro.2016.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span> <i>World
Health Organization (WHO) Leishmaniasis Fact Sheet</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>. <a href="https://www.who.int/news-room/fact-sheets/detail/leishmaniasis" class="extLink">https://www.who.int/news-room/fact-sheets/detail/leishmaniasis</a> (accessed April 23, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+World%0AHealth+Organization+%28WHO%29+Leishmaniasis+Fact+Sheet%3B+World+Health+Organization%3A+Geneva%2C+2019.+https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fleishmaniasis+%28accessed+April+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWorld%250AHealth%2520Organization%2520%2528WHO%2529%2520Leishmaniasis%2520Fact%2520Sheet%26pub%3DWorld%2520Health%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olliaro, P. L.</span></span> <span> </span><span class="NLM_article-title">Miltefosine in the treatment of leishmaniasis: Clinical Evidence for Informed Clinical Risk Management</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">740</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=18472998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGrtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=733-740&author=S.+Sundarauthor=P.+L.+Olliaro&title=Miltefosine+in+the+treatment+of+leishmaniasis%3A+Clinical+Evidence+for+Informed+Clinical+Risk+Management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management</span></div><div class="casAuthors">Sundar, Shyam; Olliaro, Piero L.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">733-740</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Visceral leishmaniasis (VL) is a life-threatening disease.  Traditional treatment with pentavalent antimony injections has become ineffective in the area with the world's highest prevalence of disease (North Bihar, India) and is becoming less effective elsewhere as well.  A replacement is needed, best if it can be given to more patients outside the hospital.  Miltefosine is the first oral drug registered for VL.  Given daily under medical supervision for 4 wk, it cures 94% of patients (both children and adults) and is reasonably safe.  Miltefosine has great potential for improving access to treatment and overall control of VL and will be crit. in the VL elimination campaign in the Indian subcontinent, but must be safeguarded or will be lost if misused.  Its main limitations are adherence (and hence potential for selection of drug resistant parasites) and teratogenicity (pregnancy must be avoided during treatment and the following two months).  This calls for responsible deployment, setting in place mechanisms to protect female patients in child-bearing age, monitoring effects and optimizing adherence in real-life conditions through directly obsd. therapy.  One option to protect the useful life-span of miltefosine consists in shortening treatment duration by combining it with another drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPDC_6xNNyc7Vg90H21EOLACvtfcHk0lh8YjJGvrMTiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGrtLzK&md5=9a845dabc6ff85abb881cbb77e7aaa0d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSundar%26aufirst%3DS.%26aulast%3DOlliaro%26aufirst%3DP.%2BL.%26atitle%3DMiltefosine%2520in%2520the%2520treatment%2520of%2520leishmaniasis%253A%2520Clinical%2520Evidence%2520for%2520Informed%2520Clinical%2520Risk%2520Management%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2007%26volume%3D3%26spage%3D733%26epage%3D740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span> <span> </span><span class="NLM_article-title">Injectable Paromomycin for Visceral Leishmaniasis in India</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">2571</span>– <span class="NLM_lpage">2581</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa066536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1056%2FNEJMoa066536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=17582067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmslKjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2571-2581&author=S.+Sundarauthor=T.+K.+Jhaauthor=C.+P.+Thakurauthor=P.+K.+Sinhaauthor=S.+K.+Bhattacharya&title=Injectable+Paromomycin+for+Visceral+Leishmaniasis+in+India&doi=10.1056%2FNEJMoa066536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Injectable paromomycin for visceral leishmaniasis in India</span></div><div class="casAuthors">Sundar, Shyam; Jha, T. K.; Thakur, Chandreshwar P.; Sinha, Prabhat K.; Bhattacharya, Sujit K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2571-2581</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in South Asia, Africa, and Brazil.  Safe, effective, and affordable new therapies are needed.  We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present std. of care in Bihar, India.  In 4 treatment centers for visceral leishmaniasis, 667 patients between 5 and 55 years of age who were neg. for the human immunodeficiency virus and had parasitol. confirmed visceral leishmaniasis were randomly assigned in a 3:1 ratio to receive paromomycin (502 patients) at a dose of 11 mg per kg of body wt. i.m. daily for 21 days or amphotericin B (165 patients) at a dose of 1 mg per kg i.v. every other day for 30 days.  Final cure was assessed 6 mo after the end of treatment; safety assessments included daily clin. evaluations and weekly lab. and audiometric evaluations.  Noninferiority testing was used to compare 6-mo cure rates, with a chosen margin of noninferiority of 10 percentage points.  Paromomycin was shown to be noninferior to amphotericin B (final cure rate, 94.6% vs. 98.8%; difference, 4.2 percentage points; upper bound of the 97.5% confidence interval, 6.9).  Mortality rates in the 2 groups were < 1%.  Adverse events, which were more common among patients receiving paromomycin than among those receiving amphotericin B (6% vs. 2%), included transient elevation of aspartate aminotransferase levels (>3 times the upper limit of the normal range); transient reversible ototoxicity (2% vs. 0); and injection-site pain (55% vs. 0); and in patients receiving amphotericin B, as compared with those receiving paromomycin, nephrotoxicity (4% vs. 0), fevers (57 vs. 3%), rigors (24% vs. 0), and vomiting (10 vs. <1%).  Paromomycin was shown to be noninferior to amphotericin B for the treatment of visceral leishmaniasis in India.  (ClinicalTrials.gov no., NCT00216346.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyn_4O1tWAAbVg90H21EOLACvtfcHk0lh8YjJGvrMTiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmslKjsr4%253D&md5=1ffd9122dd3b8d8fbe17ed41471f3fb7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa066536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa066536%26sid%3Dliteratum%253Aachs%26aulast%3DSundar%26aufirst%3DS.%26aulast%3DJha%26aufirst%3DT.%2BK.%26aulast%3DThakur%26aufirst%3DC.%2BP.%26aulast%3DSinha%26aufirst%3DP.%2BK.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3DInjectable%2520Paromomycin%2520for%2520Visceral%2520Leishmaniasis%2520in%2520India%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2571%26epage%3D2581%26doi%3D10.1056%2FNEJMoa066536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span>Drugs for Neglected
Diseases initiative
(DND <i>i</i>) Portfolio. <a href="https://www.dndi.org/diseases-projects/leishmaniasis/leish-portfolio/" class="extLink">https://www.dndi.org/diseases-projects/leishmaniasis/leish-portfolio/</a> (accessed April 23, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs+for+Neglected%0ADiseases+initiative%0A%28DND+i%29+Portfolio.+https%3A%2F%2Fwww.dndi.org%2Fdiseases-projects%2Fleishmaniasis%2Fleish-portfolio%2F+%28accessed+April+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3Di%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbaniak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflaumer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 12 is a Drug Target for Visceral Leishmaniasis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>560</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0356-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fs41586-018-0356-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=30046105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=560&publication_year=2018&pages=192-197&author=S.+Wyllieauthor=M.+Thomasauthor=S.+Pattersonauthor=S.+Crouchauthor=M.+De+Ryckerauthor=R.+Loweauthor=S.+Greshamauthor=M.+D.+Urbaniakauthor=T.+D.+Ottoauthor=L.+Stojanovskiauthor=F.+R.+C.+Simeonsauthor=S.+Manthriauthor=L.+M.+MacLeanauthor=F.+Zuccottoauthor=N.+Homeyerauthor=H.+Pflaumerauthor=M.+Boescheauthor=L.+Sastryauthor=P.+Connollyauthor=S.+Albrechtauthor=M.+Berrimanauthor=G.+Drewesauthor=D.+W.+Grayauthor=S.+Ghidelli-Disseauthor=S.+Dixonauthor=J.+M.+Fiandorauthor=P.+G.+Wyattauthor=M.+A.+J.+Fergusonauthor=A.+H.+Fairlambauthor=T.+J.+Milesauthor=K.+D.+Readauthor=I.+H.+Gilbert&title=Cyclin-Dependent+Kinase+12+is+a+Drug+Target+for+Visceral+Leishmaniasis&doi=10.1038%2Fs41586-018-0356-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis</span></div><div class="casAuthors">Wyllie, Susan; Thomas, Michael; Patterson, Stephen; Crouch, Sabrinia; De Rycker, Manu; Lowe, Rhiannon; Gresham, Stephanie; Urbaniak, Michael D.; Otto, Thomas D.; Stojanovski, Laste; Simeons, Frederick R. C.; Manthri, Sujatha; MacLean, Lorna M.; Zuccotto, Fabio; Homeyer, Nadine; Pflaumer, Hannah; Boesche, Markus; Sastry, Lalitha; Connolly, Paul; Albrecht, Sebastian; Berriman, Matt; Drewes, Gerard; Gray, David W.; Ghidelli-Disse, Sonja; Dixon, Susan; Fiandor, Jose M.; Wyatt, Paul G.; Ferguson, Michael A. J.; Fairlamb, Alan H.; Miles, Timothy J.; Read, Kevin D.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">560</span>
        (<span class="NLM_cas:issue">7717</span>),
    <span class="NLM_cas:pages">192-197</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world.  There is an urgent need for the development of new, effective treatments for this disease.  Here we describe the development of an anti-leishmanial drug-like chem. series based on a pyrazolopyrimidine scaffold.  The leading compd. from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochem., pharmacokinetic and toxicol. properties for further development, and has been declared a preclin. candidate.  Detailed mode-of-action studies indicate that compds. from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWvpd9EzGFxLVg90H21EOLACvtfcHk0lh8YjJGvrMTiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt77I&md5=bea43a232049ade6ed9abea3e0510221</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0356-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0356-z%26sid%3Dliteratum%253Aachs%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DCrouch%26aufirst%3DS.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DLowe%26aufirst%3DR.%26aulast%3DGresham%26aufirst%3DS.%26aulast%3DUrbaniak%26aufirst%3DM.%2BD.%26aulast%3DOtto%26aufirst%3DT.%2BD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMacLean%26aufirst%3DL.%2BM.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DHomeyer%26aufirst%3DN.%26aulast%3DPflaumer%26aufirst%3DH.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DSastry%26aufirst%3DL.%26aulast%3DConnolly%26aufirst%3DP.%26aulast%3DAlbrecht%26aufirst%3DS.%26aulast%3DBerriman%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DDixon%26aufirst%3DS.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DCyclin-Dependent%2520Kinase%252012%2520is%2520a%2520Drug%2520Target%2520for%2520Visceral%2520Leishmaniasis%26jtitle%3DNature%26date%3D2018%26volume%3D560%26spage%3D192%26epage%3D197%26doi%3D10.1038%2Fs41586-018-0356-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueren-Calabuig, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebrian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeacock, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczynska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata-Cantero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nühs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viayna Gaza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical Candidate for the Treatment of Visceral Leishmaniasis that Acts Through Proteasome Inhibition</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">9318</span>– <span class="NLM_lpage">9323</span>, <span class="refDoi"> DOI: 10.1073/pnas.1820175116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1073%2Fpnas.1820175116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=30962368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFGlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=9318-9323&author=S.+Wyllieauthor=S.+Brandauthor=M.+Thomasauthor=M.+De+Ryckerauthor=C.+Chungauthor=I.+Penaauthor=R.+P.+Binghamauthor=J.+A.+Bueren-Calabuigauthor=J.+Cantizaniauthor=D.+Cebrianauthor=P.+D.+Craggsauthor=L.+Fergusonauthor=P.+Goswamiauthor=J.+Hobrathauthor=J.+Howeauthor=L.+Jeacockauthor=E.-J.+Koauthor=J.+Korczynskaauthor=L.+MacLeanauthor=S.+Manthriauthor=M.+S.+Martinezauthor=L.+Mata-Canteroauthor=S.+Monizauthor=A.+N%C3%BChsauthor=M.+Osuna-Cabelloauthor=E.+Pintoauthor=J.+Rileyauthor=S.+Robinsonauthor=P.+Rowlandauthor=F.+R.+C.+Simeonsauthor=Y.+Shishikuraauthor=D.+Spinksauthor=L.+Stojanovskiauthor=J.+Thomasauthor=S.+Thompsonauthor=E.+Viayna+Gazaauthor=R.+J.+Wallauthor=F.+Zuccottoauthor=D.+Hornauthor=M.+A.+J.+Fergusonauthor=A.+H.+Fairlambauthor=J.+M.+Fiandorauthor=J.+Martinauthor=D.+W.+Grayauthor=T.+J.+Milesauthor=I.+H.+Gilbertauthor=K.+D.+Readauthor=M.+Marcoauthor=P.+G.+Wyatt&title=Preclinical+Candidate+for+the+Treatment+of+Visceral+Leishmaniasis+that+Acts+Through+Proteasome+Inhibition&doi=10.1073%2Fpnas.1820175116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition</span></div><div class="casAuthors">Wyllie, Susan; Brand, Stephen; Thomas, Michael; De Rycker, Manu; Chung, Chun-wa; Pena, Imanol; Bingham, Ryan P.; Bueren-Calabuig, Juan A.; Cantizani, Juan; Cebrian, David; Craggs, Peter D.; Ferguson, Liam; Goswami, Panchali; Hobrath, Judith; Howe, Jonathan; Jeacock, Laura; Ko, Eun-Jung; Korczynska, Justyna; MacLean, Lorna; Manthri, Sujatha; Martinez, Maria S.; Mata-Cantero, Lydia; Moniz, Sonia; NA1/4hs, Andrea; Osuna-Cabello, Maria; Pinto, Erika; Riley, Jennifer; Robinson, Sharon; Rowland, Paul; Simeons, Frederick R. C.; Shishikura, Yoko; Spinks, Daniel; Stojanovski, Laste; Thomas, John; Thompson, Stephen; Gaza, Elisabet Viayna; Wall, Richard J.; Zuccotto, Fabio; Horn, David; Ferguson, Michael A. J.; Fairlamb, Alan H.; Fiandor, Jose M.; Martin, Julio; Gray, David W.; Miles, Timothy J.; Gilbert, Ian H.; Read, Kevin D.; Marco, Maria; Wyatt, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9318-9323</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and Leishmania infantum, is one of the major parasitic diseases worldwide.  There is an urgent need for new drugs to treat VL, because current therapies are unfit for purpose in a resource-poor setting.  Here, we describe the development of a preclin. drug candidate, GSK3494245/DDD01305143/compd. 8, with potential to treat this neglected tropical disease.  The compd. series was discovered by repurposing hits from a screen against the related parasite Trypanosoma cruzi.  Subsequent optimization of the chem. series resulted in the development of a potent cidal compd. with activity against a range of clin. relevant L. donovani and L. infantum isolates.  Compd. 8 demonstrates promising pharmacokinetic properties and impressive in vivo efficacy in our mouse model of infection comparable with those of the current oral antileishmanial miltefosine.  Detailed mode of action studies confirm that this compd. acts principally by inhibition of the chymotrypsin-like activity catalyzed by the β5 subunit of the L. donovani proteasome.  High-resoln. cryo-EM structures of apo and compd. 8-bound Leishmania tarentolae 20S proteasome reveal a previously undiscovered inhibitor site that lies between the β4 and β5 proteasome subunits.  This induced pocket exploits β4 residues that are divergent between humans and kinetoplastid parasites and is consistent with all of our exptl. and mutagenesis data.  As a result of these comprehensive studies and due to a favorable developability and safety profile, compd. 8 is being advanced toward human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLTLZPb2MCLVg90H21EOLACvtfcHk0ljFGsuYQer9Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFGlsb0%253D&md5=799defb4ef812d64ffe230c78aff3511</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1820175116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1820175116%26sid%3Dliteratum%253Aachs%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.%26aulast%3DPena%26aufirst%3DI.%26aulast%3DBingham%26aufirst%3DR.%2BP.%26aulast%3DBueren-Calabuig%26aufirst%3DJ.%2BA.%26aulast%3DCantizani%26aufirst%3DJ.%26aulast%3DCebrian%26aufirst%3DD.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DFerguson%26aufirst%3DL.%26aulast%3DGoswami%26aufirst%3DP.%26aulast%3DHobrath%26aufirst%3DJ.%26aulast%3DHowe%26aufirst%3DJ.%26aulast%3DJeacock%26aufirst%3DL.%26aulast%3DKo%26aufirst%3DE.-J.%26aulast%3DKorczynska%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DMata-Cantero%26aufirst%3DL.%26aulast%3DMoniz%26aufirst%3DS.%26aulast%3DN%25C3%25BChs%26aufirst%3DA.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DE.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DViayna%2BGaza%26aufirst%3DE.%26aulast%3DWall%26aufirst%3DR.%2BJ.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DPreclinical%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Visceral%2520Leishmaniasis%2520that%2520Acts%2520Through%2520Proteasome%2520Inhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D9318%26epage%3D9323%26doi%3D10.1073%2Fpnas.1820175116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathison, C. J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myburgh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, H. X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span> <span> </span><span class="NLM_article-title">Proteasome Inhibition for Treatment of Leishmaniasis, Chagas Disease and Sleeping Sickness</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nature19339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fnature19339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=27501246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=229-233&author=S.+Khareauthor=A.+S.+Nagleauthor=A.+Biggartauthor=Y.+H.+Laiauthor=F.+Liangauthor=L.+C.+Davisauthor=S.+W.+Barnesauthor=C.+J.+N.+Mathisonauthor=E.+Myburghauthor=M.-Y.+Gaoauthor=J.+R.+Gillespieauthor=X.+Liuauthor=J.+L.+Tanauthor=M.+Stinsonauthor=I.+C.+Riveraauthor=J.+Ballardauthor=V.+Yehauthor=T.+Groesslauthor=G.+Federeauthor=H.+X.+Y.+Kohauthor=J.+D.+Venableauthor=B.+Bursulayaauthor=M.+Shapiroauthor=P.+K.+Mishraauthor=G.+Spraggonauthor=A.+Brockauthor=J.+C.+Mottramauthor=F.+S.+Bucknerauthor=S.+P.+S.+Raoauthor=B.+G.+Wenauthor=J.+R.+Walkerauthor=T.+Tuntlandauthor=V.+Molteniauthor=R.+J.+Glynneauthor=F.+Supek&title=Proteasome+Inhibition+for+Treatment+of+Leishmaniasis%2C+Chagas+Disease+and+Sleeping+Sickness&doi=10.1038%2Fnature19339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness</span></div><div class="casAuthors">Khare, Shilpi; Nagle, Advait S.; Biggart, Agnes; Lai, Yin H.; Liang, Fang; Davis, Lauren C.; Barnes, S. Whitney; Mathison, Casey J. N.; Myburgh, Elmarie; Gao, Mu-Yun; Gillespie, J. Robert; Liu, Xianzhong; Tan, Jocelyn L.; Stinson, Monique; Rivera, Ianne C.; Ballard, Jaime; Yeh, Vince; Groessl, Todd; Federe, Glenn; Koh, Hazel X. Y.; Venable, John D.; Bursulaya, Badry; Shapiro, Michael; Mishra, Pranab K.; Spraggon, Glen; Brock, Ansgar; Mottram, Jeremy C.; Buckner, Frederick S.; Rao, Srinivasa P. S.; Wen, Ben G.; Walker, John R.; Tuntland, Tove; Molteni, Valentina; Glynne, Richard J.; Supek, Frantisek</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths annually.  The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp., resp.  These parasites have similar biol. and genomic sequence, suggesting that all three diseases could be cured with drugs that modulate the activity of a conserved parasite target.  However, no such mol. targets or broad spectrum drugs have been identified to date.  Here we describe a selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection.  GNF6702 inhibits the kinetoplastid proteasome through a non-competitive mechanism, does not inhibit the mammalian proteasome or growth of mammalian cells, and is well-tolerated in mice.  Our data provide genetic and chem. validation of the parasite proteasome as a promising therapeutic target for treatment of kinetoplastid infections, and underscore the possibility of developing a single class of drugs for these neglected diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PXMn1-tj_7Vg90H21EOLACvtfcHk0ljFGsuYQer9Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL&md5=a05e7ce0f6b912b3003c5b3f42a005bb</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnature19339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19339%26sid%3Dliteratum%253Aachs%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DNagle%26aufirst%3DA.%2BS.%26aulast%3DBiggart%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DMathison%26aufirst%3DC.%2BJ.%2BN.%26aulast%3DMyburgh%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DGillespie%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DJ.%2BL.%26aulast%3DStinson%26aufirst%3DM.%26aulast%3DRivera%26aufirst%3DI.%2BC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DYeh%26aufirst%3DV.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DFedere%26aufirst%3DG.%26aulast%3DKoh%26aufirst%3DH.%2BX.%2BY.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DP.%2BK.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBrock%26aufirst%3DA.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DWen%26aufirst%3DB.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DSupek%26aufirst%3DF.%26atitle%3DProteasome%2520Inhibition%2520for%2520Treatment%2520of%2520Leishmaniasis%252C%2520Chagas%2520Disease%2520and%2520Sleeping%2520Sickness%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D229%26epage%3D233%26doi%3D10.1038%2Fnature19339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallyburton, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frearson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span> <span> </span><span class="NLM_article-title">Comparison of a High-Throughput High Content Intracellular <i>Leishmania donovani</i> Assay with an Axenic Amastigote Assay</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2913</span>– <span class="NLM_lpage">2922</span>, <span class="refDoi"> DOI: 10.1128/AAC.02398-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1128%2FAAC.02398-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=23571538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVartrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2913-2922&author=M.+De%0ARyckerauthor=I.+Hallyburtonauthor=J.+Thomasauthor=L.+Campbellauthor=S.+Wyllieauthor=D.+Joshiauthor=S.+Cameronauthor=I.+H.+Gilbertauthor=P.+G.+Wyattauthor=J.+A.+Frearsonauthor=A.+H.+Fairlambauthor=D.+W.+Gray&title=Comparison+of+a+High-Throughput+High+Content+Intracellular+Leishmania+donovani+Assay+with+an+Axenic+Amastigote+Assay&doi=10.1128%2FAAC.02398-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay</span></div><div class="casAuthors">De Rycker, Manu; Hallyburton, Irene; Thomas, John; Campbell, Lorna; Wyllie, Susan; Joshi, Dhananjay; Cameron, Scott; Gilbert, Ian H.; Wyatt, Paul G.; Frearson, Julie A.; Fairlamb, Alan H.; Gray, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2913-2922</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Visceral leishmaniasis is a neglected tropical disease with significant health impact.  The current treatments are poor, and there is an urgent need to develop new drugs.  Primary screening assays used for drug discovery campaigns have typically used free-living forms of the Leishmania parasite to allow for high-throughput screening.  Such screens do not necessarily reflect the physiol. situation, as the disease-causing stage of the parasite resides inside human host cells.  Assessing the drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods.  We describe here a 384-well microscopy-based intramacrophage Leishmania donovani assay and compare it to an axenic amastigote system.  A panel of eight ref. compds. was tested in both systems, as well as a human counterscreen cell line, and our findings show that for most clin. used compds. both axenic and intramacrophage assays report very similar results.  A set of 15,659 diverse compds. was also screened using both systems.  This resulted in the identification of seven new antileishmanial compds. and revealed a high false-pos. rate for the axenic assay.  We conclude that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of axenic assay, and we discuss how modifications to the axenic assay may render it more suitable for hit-discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXnzJTYkYtJrVg90H21EOLACvtfcHk0lgCXcFZ8YrNyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVartrvL&md5=9d7d79eea02abc10f3a5c26fac47de27</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FAAC.02398-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02398-12%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DHallyburton%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DL.%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DFrearson%26aufirst%3DJ.%2BA.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DGray%26aufirst%3DD.%2BW.%26atitle%3DComparison%2520of%2520a%2520High-Throughput%2520High%2520Content%2520Intracellular%2520Leishmania%2520donovani%2520Assay%2520with%2520an%2520Axenic%2520Amastigote%2520Assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D2913%26epage%3D2922%26doi%3D10.1128%2FAAC.02398-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Don, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioset, J.-R.</span></span> <span> </span><span class="NLM_article-title">Screening Strategies to Identify New Chemical Diversity for Drug Development to Treat Kinetoplastid Infections</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1017/S003118201300142X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1017%2FS003118201300142X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=23985066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A280%3ADC%252BC3sbjtFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=140-146&author=R.+Donauthor=J.-R.+Ioset&title=Screening+Strategies+to+Identify+New+Chemical+Diversity+for+Drug+Development+to+Treat+Kinetoplastid+Infections&doi=10.1017%2FS003118201300142X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections</span></div><div class="casAuthors">Don Rob; Ioset Jean-Robert</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Drugs for Neglected Diseases initiative (DNDi) has defined and implemented an early discovery strategy over the last few years, in fitting with its virtual R&D business model.  This strategy relies on a medium- to high-throughput phenotypic assay platform to expedite the screening of compound libraries accessed through its collaborations with partners from the pharmaceutical industry.  We review the pragmatic approaches used to select compound libraries for screening against kinetoplastids, taking into account screening capacity.  The advantages, limitations and current achievements in identifying new quality series for further development into preclinical candidates are critically discussed, together with attractive new approaches currently under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8FURC2GtUulm8bhe6roZYfW6udTcc2eaM1kx9rNyG-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbjtFGmsA%253D%253D&md5=ae473acad2714a482e5acc926b8fe85f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1017%2FS003118201300142X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS003118201300142X%26sid%3Dliteratum%253Aachs%26aulast%3DDon%26aufirst%3DR.%26aulast%3DIoset%26aufirst%3DJ.-R.%26atitle%3DScreening%2520Strategies%2520to%2520Identify%2520New%2520Chemical%2520Diversity%2520for%2520Drug%2520Development%2520to%2520Treat%2520Kinetoplastid%2520Infections%26jtitle%3DParasitology%26date%3D2014%26volume%3D141%26spage%3D140%26epage%3D146%26doi%3D10.1017%2FS003118201300142X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peña, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilar Manzano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Padilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardera, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colmenarejo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roquero, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios-Anton, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherstnev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julio Martin, J.</span></span> <span> </span><span class="NLM_article-title">New Compound Sets Identified from High Throughput Phenotypic Screening against Three Kinetoplastid Parasites: an Open Resource</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">8771</span> <span class="refDoi"> DOI: 10.1038/srep08771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fsrep08771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=25740547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKhur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=I.+Pe%C3%B1aauthor=M.+Pilar+Manzanoauthor=J.+Cantizaniauthor=A.+Kesslerauthor=J.+Alonso-Padillaauthor=A.+I.+Barderaauthor=E.+Alvarezauthor=G.+Colmenarejoauthor=I.+Cotilloauthor=I.+Roqueroauthor=F.+de+Dios-Antonauthor=V.+Barrosoauthor=A.+Rodriguezauthor=D.+W.+Grayauthor=M.+Navarroauthor=V.+Kumarauthor=A.+Sherstnevauthor=D.+H.+Drewryauthor=J.+R.+Brownauthor=J.+M.+Fiandorauthor=J.+Julio+Martin&title=New+Compound+Sets+Identified+from+High+Throughput+Phenotypic+Screening+against+Three+Kinetoplastid+Parasites%3A+an+Open+Resource&doi=10.1038%2Fsrep08771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource</span></div><div class="casAuthors">Pena, Imanol; Pilar Manzano, M.; Cantizani, Juan; Kessler, Albane; Alonso-Padilla, Julio; Bardera, Ana I.; Alvarez, Emilio; Colmenarejo, Gonzalo; Cotillo, Ignacio; Roquero, Irene; de Dios-Anton, Francisco; Barroso, Vanessa; Rodriguez, Ana; Gray, David W.; Navarro, Miguel; Kumar, Vinod; Sherstnev, Alexander; Drewry, David H.; Brown, James R.; Fiandor, Jose M.; Martin, J. Julio</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8771</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Using whole-cell phenotypic assays, the GlaxoSmithKline high-throughput screening (HTS) diversity set of 1.8 million compds. was screened against the three kinetoplastids most relevant to human disease, i.e.  Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.  Secondary confirmatory and orthogonal intracellular anti-parasiticidal assays were conducted, and the potential for non-specific cytotoxicity detd.  Hit compds. were chem. clustered and triaged for desirable physicochem. properties.  The hypothetical biol. target space covered by these diversity sets was investigated through bioinformatics methodologies.  Consequently, three anti-kinetoplastid chem. boxes of ∼200 compds. each were assembled.  Functional analyses of these compds. suggest a wide array of potential modes of action against kinetoplastid kinases, proteases and cytochromes as well as potential host-pathogen targets.  This is the first published parallel high throughput screening of a pharma compd. collection against kinetoplastids.  The compd. sets are provided as an open resource for future lead discovery programs, and to address important research questions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAQjKOCN5nErVg90H21EOLACvtfcHk0lhhu106YOQ-3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKhur7M&md5=c28afb0ae168147ee70d1f9cc905d272</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsrep08771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep08771%26sid%3Dliteratum%253Aachs%26aulast%3DPe%25C3%25B1a%26aufirst%3DI.%26aulast%3DPilar%2BManzano%26aufirst%3DM.%26aulast%3DCantizani%26aufirst%3DJ.%26aulast%3DKessler%26aufirst%3DA.%26aulast%3DAlonso-Padilla%26aufirst%3DJ.%26aulast%3DBardera%26aufirst%3DA.%2BI.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DColmenarejo%26aufirst%3DG.%26aulast%3DCotillo%26aufirst%3DI.%26aulast%3DRoquero%26aufirst%3DI.%26aulast%3Dde%2BDios-Anton%26aufirst%3DF.%26aulast%3DBarroso%26aufirst%3DV.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSherstnev%26aufirst%3DA.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DJulio%2BMartin%26aufirst%3DJ.%26atitle%3DNew%2520Compound%2520Sets%2520Identified%2520from%2520High%2520Throughput%2520Phenotypic%2520Screening%2520against%2520Three%2520Kinetoplastid%2520Parasites%253A%2520an%2520Open%2520Resource%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fsrep08771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting Physical in Drug Discovery II: the Impact of Chromatographic Hydrophobicity Measurements and Aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&author=R.+J.+Youngauthor=D.+V.+S.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+Physical+in+Drug+Discovery+II%3A+the+Impact+of+Chromatographic+Hydrophobicity+Measurements+and+Aromaticity&doi=10.1016%2Fj.drudis.2011.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0lhhu106YOQ-3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520Physical%2520in%2520Drug%2520Discovery%2520II%253A%2520the%2520Impact%2520of%2520Chromatographic%2520Hydrophobicity%2520Measurements%2520and%2520Aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajakane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Pedraglio, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleghorn, L. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Siles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada-Campos, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Gomez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span> <span> </span><span class="NLM_article-title">Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1202</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=1180-1202&author=M.+G.+Thomasauthor=M.+De+Ryckerauthor=M.+Ajakaneauthor=S.+Albrechtauthor=A.+I.+Alvarez-Pedraglioauthor=M.+Boescheauthor=S.+Brandauthor=L.+Campbellauthor=J.+Cantizani-Perezauthor=L.+A.+T.+Cleghornauthor=R.+C.+B.+Copleyauthor=S.+D.+Crouchauthor=A.+Dauganauthor=G.+Drewesauthor=S.+Ferrerauthor=S.+Ghidelli-Disseauthor=S.+Gonzalezauthor=S.+L.+Greshamauthor=A.+P.+Hillauthor=S.+J.+Hindleyauthor=R.+M.+Loweauthor=C.+J.+MacKenzieauthor=L.+MacLeanauthor=S.+Manthriauthor=F.+Martinauthor=J.+Miguel-Silesauthor=V.+L.+Nguyenauthor=S.+Norvalauthor=M.+Osuna-Cabelloauthor=A.+Woodlandauthor=S.+Pattersonauthor=I.+Penaauthor=M.+T.+Quesada-Camposauthor=I.+H.+Reidauthor=C.+Revillauthor=J.+Rileyauthor=J.+R.+Ruiz-Gomezauthor=Y.+Shishikuraauthor=F.+R.+C.+Simeonsauthor=A.+Smithauthor=V.+C.+Smithauthor=D.+Spinksauthor=L.+Stojanovskiauthor=J.+Thomasauthor=S.+Thompsonauthor=T.+Underwoodauthor=D.+W.+Grayauthor=J.+M.+Fiandorauthor=I.+H.+Gilbertauthor=P.+G.+Wyattauthor=K.+D.+Readauthor=T.+J.+Miles&title=Identification+of+GSK3186899%2FDDD853651+as+a+Preclinical+Development+Candidate+for+the+Treatment+of+Visceral+Leishmaniasis&doi=10.1021%2Facs.jmedchem.8b01218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01218%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%2BG.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DAjakane%26aufirst%3DM.%26aulast%3DAlbrecht%26aufirst%3DS.%26aulast%3DAlvarez-Pedraglio%26aufirst%3DA.%2BI.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DL.%26aulast%3DCantizani-Perez%26aufirst%3DJ.%26aulast%3DCleghorn%26aufirst%3DL.%2BA.%2BT.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DCrouch%26aufirst%3DS.%2BD.%26aulast%3DDaugan%26aufirst%3DA.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DGonzalez%26aufirst%3DS.%26aulast%3DGresham%26aufirst%3DS.%2BL.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DHindley%26aufirst%3DS.%2BJ.%26aulast%3DLowe%26aufirst%3DR.%2BM.%26aulast%3DMacKenzie%26aufirst%3DC.%2BJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DMiguel-Siles%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DV.%2BL.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DWoodland%26aufirst%3DA.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DPena%26aufirst%3DI.%26aulast%3DQuesada-Campos%26aufirst%3DM.%2BT.%26aulast%3DReid%26aufirst%3DI.%2BH.%26aulast%3DRevill%26aufirst%3DC.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DRuiz-Gomez%26aufirst%3DJ.%2BR.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DV.%2BC.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DUnderwood%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26atitle%3DIdentification%2520of%2520GSK3186899%252FDDD853651%2520as%2520a%2520Preclinical%2520Development%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Visceral%2520Leishmaniasis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D63%26spage%3D1180%26epage%3D1202%26doi%3D10.1021%2Facs.jmedchem.8b01218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melamed, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlow, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embrey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zrada, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillmock, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleif, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabryelski, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassahun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span></span> <span> </span><span class="NLM_article-title">A Potent and Orally Active HIV-1 Integrase Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1016%2Fj.bmcl.2006.11.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=17194584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1392-1398&author=M.+S.+Egbertsonauthor=H.+M.+Moritzauthor=J.+Y.+Melamedauthor=W.+Hanauthor=D.+S.+Perlowauthor=M.+S.+Kuoauthor=M.+Embreyauthor=J.+P.+Vaccaauthor=M.+M.+Zradaauthor=A.+R.+Cortesauthor=A.+Wallaceauthor=Y.+Leonardauthor=D.+J.+Hazudaauthor=M.+D.+Millerauthor=P.+J.+Felockauthor=K.+A.+Stillmockauthor=M.+V.+Witmerauthor=W.+Schleifauthor=L.+J.+Gabryelskiauthor=G.+Moyerauthor=J.+D.+Ellisauthor=L.+Jinauthor=W.+Xuauthor=M.+P.+Braunauthor=K.+Kassahunauthor=N.+N.+Tsouauthor=S.+D.+Young&title=A+Potent+and+Orally+Active+HIV-1+Integrase+Inhibitor&doi=10.1016%2Fj.bmcl.2006.11.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A potent and orally active HIV-1 integrase inhibitor</span></div><div class="casAuthors">Egbertson, Melissa S.; Moritz, H. Marie; Melamed, Jeffrey Y.; Han, Wei; Perlow, Debra S.; Kuo, Michelle S.; Embrey, Mark; Vacca, Joseph P.; Zrada, Matthew M.; Cortes, Amanda R.; Wallace, Audrey; Leonard, Yvonne; Hazuda, Daria J.; Miller, Michael D.; Felock, Peter J.; Stillmock, Kara A.; Witmer, Marc V.; Schleif, William; Gabryelski, Lori J.; Moyer, Gregory; Ellis, Joan D.; Jin, Lixia; Xu, Wei; Braun, Matthew P.; Kassahun, Kellem; Tsou, Nancy N.; Young, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1392-1398</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A 1,6-naphthyridine inhibitor of HIV-1 integrase has been discovered with excellent inhibitory activity in cells, good pharmacokinetics, and an excellent ability to inhibit virus with mutant enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVTId1m0YgC7Vg90H21EOLACvtfcHk0lhCqHwMBLStyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjt7s%253D&md5=5b718b54eae1ddfc33430472a0c3169c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.080%26sid%3Dliteratum%253Aachs%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26aulast%3DMoritz%26aufirst%3DH.%2BM.%26aulast%3DMelamed%26aufirst%3DJ.%2BY.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DPerlow%26aufirst%3DD.%2BS.%26aulast%3DKuo%26aufirst%3DM.%2BS.%26aulast%3DEmbrey%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DZrada%26aufirst%3DM.%2BM.%26aulast%3DCortes%26aufirst%3DA.%2BR.%26aulast%3DWallace%26aufirst%3DA.%26aulast%3DLeonard%26aufirst%3DY.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DFelock%26aufirst%3DP.%2BJ.%26aulast%3DStillmock%26aufirst%3DK.%2BA.%26aulast%3DWitmer%26aufirst%3DM.%2BV.%26aulast%3DSchleif%26aufirst%3DW.%26aulast%3DGabryelski%26aufirst%3DL.%2BJ.%26aulast%3DMoyer%26aufirst%3DG.%26aulast%3DEllis%26aufirst%3DJ.%2BD.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DBraun%26aufirst%3DM.%2BP.%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26atitle%3DA%2520Potent%2520and%2520Orally%2520Active%2520HIV-1%2520Integrase%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1392%26epage%3D1398%26doi%3D10.1016%2Fj.bmcl.2006.11.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tephly, T. R.</span></span> <span> </span><span class="NLM_article-title">UPD-Glucuronosyltransferases</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.2174/1389200003339171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.2174%2F1389200003339171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=11465080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlOrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=143-161&author=C.+D.+Kingauthor=G.+R.+Riosauthor=M.+D.+Greenauthor=T.+R.+Tephly&title=UPD-Glucuronosyltransferases&doi=10.2174%2F1389200003339171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">UDP-Glucuronosyltransferases</span></div><div class="casAuthors">King, C. D.; Rios, G. R.; Green, M. D.; Tephly, T. R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-161</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review, with 97 refs.  Glucuronidation represents a major pathway which enhances the elimination of many lipophilic xenobiotics and endobiotics to more water-sol. compds.  The UDP-glucuronosyltransferase (UGT) family catalyzes the glucuronidation of the glycosyl group of a nucleotide sugar to an acceptor compd. (aglycon) at a nucleophilic functional group of oxygen (e.g., hydroxyl or carboxylic acid groups), nitrogen (e.g., amines), sulfur (e.g., thiols), and carbon, with the formation of a β-D-glucuronide product.  At this time, over 35 different UGT gene products have been described from several different species.  UGTs have been divided into two distinct subfamilies based on sequence identities, UGT1 and UGT2.  The UGT1 gene subfamily consists of a no. of UGTs that result from alternate splicing of multiple first exons and share common exons 2-5.  The substrate specificities of the various isoforms have been examd. in cultured cell expts., and include bilirubin, amines, and planar and bulky phenol.  The UGT2 gene family is different in that the UGT2 mRNAs are transcribed from individual genes.  The UGT2 subfamily consists of numerous enzymes which catalyze the glucuronidation of a diverse chem. base including steroids, bile acids, and opioids.  Until recently, the liver has been the major focus for studying the metab. of xenobiotics and endobiotics.  Several groups have identified extrahepatic tissues that express UGT isoforms including the kidney, gastrointestinal tract and brain.  This review discusses the two UGT gene families, substrate specificities, and the recent discoveries of UGTs in extrahepatic tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBOsINL0g5V7Vg90H21EOLACvtfcHk0lhCqHwMBLStyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlOrs70%253D&md5=49f69c7783523498ed31887f3b9d0a55</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1389200003339171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200003339171%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DRios%26aufirst%3DG.%2BR.%26aulast%3DGreen%26aufirst%3DM.%2BD.%26aulast%3DTephly%26aufirst%3DT.%2BR.%26atitle%3DUPD-Glucuronosyltransferases%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2000%26volume%3D1%26spage%3D143%26epage%3D161%26doi%3D10.2174%2F1389200003339171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deSchoolmeester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayers, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhardt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selmi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swales, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittamore, P. R.</span></span> <span> </span><span class="NLM_article-title">Novel Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor with Reduced Acyl Glucuronide Liability: The Discovery of 4-[4-(2-Adamantylcarbamoyl)-5-<i>tert</i>-butyl-pyrazol-1-yl]benzoic Acid (AZD8329)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10136</span>– <span class="NLM_lpage">10147</span>, <span class="refDoi"> DOI: 10.1021/jm301252n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301252n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10136-10147&author=J.+S.+Scottauthor=J.+deSchoolmeesterauthor=E.+Kilgourauthor=R.+M.+Mayersauthor=M.+J.+Packerauthor=D.+Hargreavesauthor=S.+Gerhardtauthor=D.+J.+Oggauthor=A.+Reesauthor=N.+Selmiauthor=A.+Stockerauthor=J.+G.+Swalesauthor=P.+R.+Whittamore&title=Novel+Acidic+11%CE%B2-Hydroxysteroid+Dehydrogenase+Type+1+%2811%CE%B2-HSD1%29+Inhibitor+with+Reduced+Acyl+Glucuronide+Liability%3A+The+Discovery+of+4-%5B4-%282-Adamantylcarbamoyl%29-5-tert-butyl-pyrazol-1-yl%5Dbenzoic+Acid+%28AZD8329%29&doi=10.1021%2Fjm301252n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor with Reduced Acyl Glucuronide Liability: The Discovery of 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic Acid (AZD8329)</span></div><div class="casAuthors">Scott, James S.; deSchoolmeester, Joanne; Kilgour, Elaine; Mayers, Rachel M.; Packer, Martin J.; Hargreaves, David; Gerhardt, Stefan; Ogg, Derek J.; Rees, Amanda; Selmi, Nidhal; Stocker, Andrew; Swales, John G.; Whittamore, Paul R. O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10136-10147</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of 11β-HSD1 is viewed as a potential target for the treatment of obesity and other elements of the metabolic syndrome.  We report here the optimization of a carboxylic acid class of inhibitors from AZD4017 (I) to the development candidate AZD8329 (II).  A structural change from pyridine to pyrazole together with structural optimization led to an improved tech. profile in terms of both soly. and pharmacokinetics.  The extent of acyl glucuronidation was reduced through structural optimization of both the carboxylic acid and amide substituents, coupled with a redn. in lipophilicity leading to an overall increase in metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKFfab5QO3Q7Vg90H21EOLACvtfcHk0liJM8WGn8iRNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChsrbF&md5=c48d951089cae3c4ad95c938ecaaf8e5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm301252n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301252n%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DdeSchoolmeester%26aufirst%3DJ.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DMayers%26aufirst%3DR.%2BM.%26aulast%3DPacker%26aufirst%3DM.%2BJ.%26aulast%3DHargreaves%26aufirst%3DD.%26aulast%3DGerhardt%26aufirst%3DS.%26aulast%3DOgg%26aufirst%3DD.%2BJ.%26aulast%3DRees%26aufirst%3DA.%26aulast%3DSelmi%26aufirst%3DN.%26aulast%3DStocker%26aufirst%3DA.%26aulast%3DSwales%26aufirst%3DJ.%2BG.%26aulast%3DWhittamore%26aufirst%3DP.%2BR.%26atitle%3DNovel%2520Acidic%252011%25CE%25B2-Hydroxysteroid%2520Dehydrogenase%2520Type%25201%2520%252811%25CE%25B2-HSD1%2529%2520Inhibitor%2520with%2520Reduced%2520Acyl%2520Glucuronide%2520Liability%253A%2520The%2520Discovery%2520of%25204-%255B4-%25282-Adamantylcarbamoyl%2529-5-tert-butyl-pyrazol-1-yl%255Dbenzoic%2520Acid%2520%2528AZD8329%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10136%26epage%3D10147%26doi%3D10.1021%2Fjm301252n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Croxtall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Raltegravir</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.2165/00003495-200969080-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.2165%2F00003495-200969080-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=19496631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2iur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1059-1075&author=J.+D.+Croxtallauthor=S.+J.+Keam&title=Raltegravir&doi=10.2165%2F00003495-200969080-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Raltegravir: A review of its use in the management of HIV infection in treatment-experienced patients</span></div><div class="casAuthors">Croxtall, Jamie D.; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1059-1075</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Raltegravir (Isentress), an integrase inhibitor, inhibits the insertion of HIV-1 complementary DNA into the host genome.  It is indicated in combination with other antiretroviral therapy (ART) agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple ART agents.  It is the first of a new class of ART agents to be approved that, as a result of a different mechanism of action to other ART agents, has good activity against multidrug-resistant HIV-1 strains.  In clin. trials in treatment-experienced patients with HIV-1 infection and evidence of viral replication, the addn. of oral raltegravir to an optimized background therapy (OBT) regimen improved virol. and immunol. responses at 16 and 48 wk to a greater extent than placebo plus OBT.  Raltegravir therapy was generally well tolerated, with a similar incidence of mild to moderate adverse events in the treatment and placebo arms.  The introduction of integrase inhibitors extends the options available for managing treatment-experienced patients with multiple-drug-resistant HIV-1 infection.  Results to date suggest that the combination of raltegravir and OBT will be a valuable treatment option for this difficult-to-treat patient group.  Pharmacol. Properties Raltegravir is a selective inhibitor of integrase, an HIV-1-specific enzyme that is responsible for the insertion of viral complimentary DNA into the host genome.  In in vitro studies, the 95% inhibitory concn. (IC95) of raltegravir in human T-lymphoid cells infected with a lab. strain of HIV-1 was 31 nmol/L and ranged from 6 to 50 nmol/L in human peripheral blood mono-nuclear cells, infected with clin. isolates of HIV-1, including strains resistant to other classes of ART.  Specific mutations within the HIV-1 integrase gene (predominantly at Q148, N155 or Y143) are correlated with virol. resistance to raltegravir.  Patients with higher baseline levels of HIV-1 RNA and less active OBT regimens are at the highest risk of integrase mutations arising during treatment.  Oral raltegravir is rapidly absorbed, with a mean max. plasma concn. reached at a median time of ≈1 h.  The mean plasma concn. of raltegravir at the end of a 12-h dose administration interval after a 400 mg dose exceeded the IC95 against HIV-1 in vitro.  Raltegravir is metabolized in humans through uridine diphosphate-glucuronosyltransferase-mediated glucuronidation in the liver, and is eliminated in faeces and urine.  The mean elimination half-life of raltegravir is 7-12 h.  Raltegravir does not significantly affect the activity of the cytochrome P 450 system and therefore is not expected to interact with other ART agents that are substrates for these enzymes.  Therapeutic Efficacy In the two phase III BENCHMRK trials (n = 699), orally administered raltegravir 400 mg twice daily plus OBT improved both virol. and immunol. outcomes in treatment-experienced patients with HIV-1 infection, evidence of viral replication and HIV-1 strains resistant to multiple ART agents.  At 16 wk in the individual trials and at 48 wk in the combined anal., raltegravir plus OBT reduced HIV-1 RNA levels to <400 copies/mL (primary endpoint) and <50 copies/mL in a significantly greater no. of patients and significantly increased CD4+ cell counts from baseline when compared with placebo plus OBT.  Moreover, prespecified subgroup analyses indicated that in the BENCHMRK trials, the greater efficacy of raltegravir plus OBT compared with placebo plus OBT was maintained in patients with baseline characteristics that typically predict a poor response to ART therapy, for example, higher HIV-1 RNA levels, lower CD4+ cell counts and less active OBT regimens.  Tolerability Raltegravir was generally well tolerated when used in combination with OBT regimens in treatment-experienced patients with HIV-1 infection in trials of up to 48 wk' duration.  The majority of adverse events were mild to moderate in severity, and of similar incidence in the raltegravir plus OBT and placebo plus OBT treatment arms; treatment-related discontinuations were uncommon.  The most common drug-related adverse events reported were diarrhoea, headache, nausea and fatigue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyz5MAsFmghLVg90H21EOLACvtfcHk0liJM8WGn8iRNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2iur%252FO&md5=31aa629ea39025c767bed33e1e2550f5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2165%2F00003495-200969080-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200969080-00007%26sid%3Dliteratum%253Aachs%26aulast%3DCroxtall%26aufirst%3DJ.%2BD.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DRaltegravir%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1059%26epage%3D1075%26doi%3D10.2165%2F00003495-200969080-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embrey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guare, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillmock, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassahun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleif, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span></span> <span> </span><span class="NLM_article-title">A Naphthyridine Carboxamide Provides Evidence for Discordant Resistance Between Mechanistically Identical Inhibitors of HIV-1 Integrase</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">11233</span>– <span class="NLM_lpage">11238</span>, <span class="refDoi"> DOI: 10.1073/pnas.0402357101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1073%2Fpnas.0402357101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=15277684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVKgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=11233-11238&author=D.+J.+Hazudaauthor=N.+J.+Anthonyauthor=R.+P.+Gomezauthor=S.+M.+Jollyauthor=J.+S.+Waiauthor=L.+Zhuangauthor=T.+E.+Fisherauthor=M.+Embreyauthor=J.+P.+Guareauthor=M.+S.+Egbertsonauthor=J.+P.+Vaccaauthor=J.+R.+Huffauthor=P.+J.+Felockauthor=M.+V.+Witmerauthor=K.+A.+Stillmockauthor=R.+Danovichauthor=J.+Groblerauthor=M.+D.+Millerauthor=A.+S.+Espesethauthor=L.+Jinauthor=I.+W.+Chenauthor=J.+H.+Linauthor=K.+Kassahunauthor=J.+D.+Ellisauthor=B.+K.+Wongauthor=W.+Xuauthor=P.+G.+Pearsonauthor=W.+A.+Schleifauthor=R.+Corteseauthor=E.+Eminiauthor=V.+Summaauthor=M.+K.+Hollowayauthor=S.+D.+Young&title=A+Naphthyridine+Carboxamide+Provides+Evidence+for+Discordant+Resistance+Between+Mechanistically+Identical+Inhibitors+of+HIV-1+Integrase&doi=10.1073%2Fpnas.0402357101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase</span></div><div class="casAuthors">Hazuda, Daria J.; Anthony, Neville J.; Gomez, Robert P.; Jolly, Samson M.; Wai, John S.; Zhuang, Linghang; Fisher, Thorsten E.; Embrey, Mark; Guare, James P., Jr.; Egbertson, Melissa S.; Vacca, Joseph P.; Huff, Joel R.; Felock, Peter J.; Witmer, Marc V.; Stillmock, Kara A.; Danovich, Robert; Grobler, Jay; Miller, Michael D.; Espeseth, Amy S.; Jin, Lixia; Chen, I-Wu; Lin, Jiunn H.; Kassahun, Kelem; Ellis, Joan D.; Wong, Bradley K.; Xu, Wei; Pearson, Paul G.; Schleif, William A.; Cortese, Riccardo; Emini, Emilio; Summa, Vincenzo; Holloway, M. Katharine; Young, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11233-11238</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The increasing incidence of resistance to current HIV-1 therapy underscores the need to develop antiretroviral agents with new mechanisms of action.  Integrase, one of three viral enzymes essential for HIV-1 replication, presents an important yet unexploited opportunity for drug development.  The authors describe here the identification and characterization of L-870,810, a small-mol. inhibitor of HIV-1 integrase with potent antiviral activity in cell culture and good pharmacokinetic properties.  L-870,810 is an inhibitor with an 8-hydroxy-(1,6)-naphthyridine-7-carboxamide pharmacophore.  The compd. inhibits HIV-1 integrase-mediated strand transfer, and its antiviral activity in vitro is a direct consequence of this ascribed effect on integration.  L-870,810 is mechanistically identical to previously described inhibitors from the diketo acid series; however, viruses selected for resistance to L-870,810 contain mutations (integrase residues 72, 121, and 125) that uniquely confer resistance to the naphthyridine.  Conversely, mutations assocd. with resistance to the diketo acid do not engender naphthyridine resistance.  Importantly, the mutations assocd. with resistance to each of these inhibitors map to distinct regions within the integrase active site.  Therefore, the authors propose a model of the two inhibitors that is consistent with this observation and suggests specific interactions with discrete binding sites for each ligand.  These studies provide a structural basis and rationale for developing integrase inhibitors with the potential for unique and nonoverlapping resistance profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpHqKKxVFjLVg90H21EOLACvtfcHk0lgHZfvuQ0NBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVKgtrY%253D&md5=a94bedb2c16c751c5a9298708504fa4d</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0402357101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0402357101%26sid%3Dliteratum%253Aachs%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DAnthony%26aufirst%3DN.%2BJ.%26aulast%3DGomez%26aufirst%3DR.%2BP.%26aulast%3DJolly%26aufirst%3DS.%2BM.%26aulast%3DWai%26aufirst%3DJ.%2BS.%26aulast%3DZhuang%26aufirst%3DL.%26aulast%3DFisher%26aufirst%3DT.%2BE.%26aulast%3DEmbrey%26aufirst%3DM.%26aulast%3DGuare%26aufirst%3DJ.%2BP.%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DFelock%26aufirst%3DP.%2BJ.%26aulast%3DWitmer%26aufirst%3DM.%2BV.%26aulast%3DStillmock%26aufirst%3DK.%2BA.%26aulast%3DDanovich%26aufirst%3DR.%26aulast%3DGrobler%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DEspeseth%26aufirst%3DA.%2BS.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DI.%2BW.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DJ.%2BD.%26aulast%3DWong%26aufirst%3DB.%2BK.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DSchleif%26aufirst%3DW.%2BA.%26aulast%3DCortese%26aufirst%3DR.%26aulast%3DEmini%26aufirst%3DE.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26atitle%3DA%2520Naphthyridine%2520Carboxamide%2520Provides%2520Evidence%2520for%2520Discordant%2520Resistance%2520Between%2520Mechanistically%2520Identical%2520Inhibitors%2520of%2520HIV-1%2520Integrase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D11233%26epage%3D11238%26doi%3D10.1073%2Fpnas.0402357101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Little, S.</span>; <span class="NLM_string-name">Drusano, G.</span>; <span class="NLM_string-name">Schooley, R.</span></span> In  <i>Antiviral Effect of L-000870810, a Novel HIV-1 Integrase Inhibitor, in HIV-1 Infected Patients</i>, 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Abstract 161, Feb 22–25, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=S.+Little&author=G.+Drusano&author=R.+Schooley&title=Antiviral+Effect+of+L-000870810%2C+a+Novel+HIV-1+Integrase+Inhibitor%2C+in+HIV-1+Infected+Patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLittle%26aufirst%3DS.%26jtitle%3DAntiviral%2520Effect%2520of%2520L-000870810%252C%2520a%2520Novel%2520HIV-1%2520Integrase%2520Inhibitor%252C%2520in%2520HIV-1%2520Infected%2520Patients%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing Safety-Related Drug Attrition: The Use of in Vitro Pharmacological Profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+Safety-Related+Drug+Attrition%3A+The+Use+of+in+Vitro+Pharmacological+Profiling&doi=10.1038%2Fnrd3845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0lgHZfvuQ0NBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520Safety-Related%2520Drug%2520Attrition%253A%2520The%2520Use%2520of%2520in%2520Vitro%2520Pharmacological%2520Profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wall, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span> <span> </span><span class="NLM_article-title">Antitrypanosomal 8-Hydroxy-Naphthyridines are Chelators of Divalent Transition Metals</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>, <span class="NLM_elocation-id">e00235-18</span> <span class="refDoi"> DOI: 10.1128/AAC.00235-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1128%2FAAC.00235-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=29844044" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&author=R.+J.+Wallauthor=S.+Monizauthor=M.+G.+Thomasauthor=S.+Norvalauthor=E.+J.+Koauthor=M.+Marcoauthor=T.+J.+Milesauthor=I.+H.+Gilbertauthor=D.+Hornauthor=A.+H.+Fairlambauthor=S.+Wyllie&title=Antitrypanosomal+8-Hydroxy-Naphthyridines+are+Chelators+of+Divalent+Transition+Metals&doi=10.1128%2FAAC.00235-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.00235-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00235-18%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DR.%2BJ.%26aulast%3DMoniz%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%2BG.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DWyllie%26aufirst%3DS.%26atitle%3DAntitrypanosomal%25208-Hydroxy-Naphthyridines%2520are%2520Chelators%2520of%2520Divalent%2520Transition%2520Metals%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26doi%3D10.1128%2FAAC.00235-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johns, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garvey, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span> <span> </span><span class="NLM_article-title">The Use of Oxadiazole and Triazole Substituted Naphthyridines as HIV-1 Integrase Inhibitors. Part 1: Establishing the Pharmacophore</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1802</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1016%2Fj.bmcl.2009.01.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=19217781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1802-1806&author=B.+A.+Johnsauthor=J.+G.+Weatherheadauthor=S.+H.+Allenauthor=J.+B.+Thompsonauthor=E.+P.+Garveyauthor=S.+A.+Fosterauthor=J.+L.+Jeffreyauthor=W.+H.+Miller&title=The+Use+of+Oxadiazole+and+Triazole+Substituted+Naphthyridines+as+HIV-1+Integrase+Inhibitors.+Part+1%3A+Establishing+the+Pharmacophore&doi=10.1016%2Fj.bmcl.2009.01.090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore</span></div><div class="casAuthors">Johns, Brian A.; Weatherhead, Jason G.; Allen, Scott H.; Thompson, James B.; Garvey, Edward P.; Foster, Scott A.; Jeffrey, Jerry L.; Miller, Wayne H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1802-1806</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of HIV-1 integrase inhibitors contg. a novel metal binding motif consisting of the 8-hydroxy-1,6-naphthyridine core and either an oxadiazole or triazole has been identified.  The design of the key structural components was based on a two-metal coordination pharmacophore.  This report presents initial structure-activity data that shows the new chelation architecture delivers potent inhibition in both enzymic and antiviral assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu2rzx6WTsI7Vg90H21EOLACvtfcHk0lgrddrI-QTPYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltb0%253D&md5=78e7d1b81f1a889c901bb08678b932a7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.090%26sid%3Dliteratum%253Aachs%26aulast%3DJohns%26aufirst%3DB.%2BA.%26aulast%3DWeatherhead%26aufirst%3DJ.%2BG.%26aulast%3DAllen%26aufirst%3DS.%2BH.%26aulast%3DThompson%26aufirst%3DJ.%2BB.%26aulast%3DGarvey%26aufirst%3DE.%2BP.%26aulast%3DFoster%26aufirst%3DS.%2BA.%26aulast%3DJeffrey%26aufirst%3DJ.%2BL.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26atitle%3DThe%2520Use%2520of%2520Oxadiazole%2520and%2520Triazole%2520Substituted%2520Naphthyridines%2520as%2520HIV-1%2520Integrase%2520Inhibitors.%2520Part%25201%253A%2520Establishing%2520the%2520Pharmacophore%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1802%26epage%3D1806%26doi%3D10.1016%2Fj.bmcl.2009.01.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crescenzi, B.</span>; <span class="NLM_string-name">Gardelli, C.</span>; <span class="NLM_string-name">Muraglia, E.</span>; <span class="NLM_string-name">Nizi, E.</span>; <span class="NLM_string-name">Orvieto, F.</span>; <span class="NLM_string-name">Pace, P.</span>; <span class="NLM_string-name">Pescatore, G.</span>; <span class="NLM_string-name">Petrocchi, A.</span>; <span class="NLM_string-name">Poma, M.</span>; <span class="NLM_string-name">Rowley, M.</span>; <span class="NLM_string-name">Scarpelli, R.</span>; <span class="NLM_string-name">Summa, V.</span></span> <span> </span><span class="NLM_article-title">N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integrase</span>. <span class="NLM_patent">WO2003035077</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=B.+Crescenzi&author=C.+Gardelli&author=E.+Muraglia&author=E.+Nizi&author=F.+Orvieto&author=P.+Pace&author=G.+Pescatore&author=A.+Petrocchi&author=M.+Poma&author=M.+Rowley&author=R.+Scarpelli&author=V.+Summa&title=N-Substituted+Hydroxypyrimidinone+Carboxamide+Inhibitors+of+HIV+Integrase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrescenzi%26aufirst%3DB.%26atitle%3DN-Substituted%2520Hydroxypyrimidinone%2520Carboxamide%2520Inhibitors%2520of%2520HIV%2520Integrase%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazemi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y.-Q.</span></span> <span> </span><span class="NLM_article-title">Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9492</span>– <span class="NLM_lpage">9509</span>, <span class="refDoi"> DOI: 10.1021/jm300667v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300667v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOltrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9492-9509&author=L.-F.+Zengauthor=Y.+Wangauthor=R.+Kazemiauthor=S.+Xuauthor=Z.-L.+Xuauthor=T.+W.+Sanchezauthor=L.-M.+Yangauthor=B.+Debnathauthor=S.+Oddeauthor=H.+Xieauthor=Y.-T.+Zhengauthor=J.+Dingauthor=N.+Neamatiauthor=Y.-Q.+Long&title=Repositioning+HIV-1+Integrase+Inhibitors+for+Cancer+Therapeutics%3A+1%2C6-Naphthyridine-7-carboxamide+as+a+Promising+Scaffold+with+Drug-like+Properties&doi=10.1021%2Fjm300667v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties</span></div><div class="casAuthors">Zeng, Li-Fan; Wang, Yong; Kazemi, Roza; Xu, Shili; Xu, Zhong-Liang; Sanchez, Tino W.; Yang, Liu-Meng; Debnath, Bikash; Odde, Srinivas; Xie, Hua; Zheng, Yong-Tang; Ding, Jian; Neamati, Nouri; Long, Ya-Qiu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9492-9509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among a large no. of HIV-1 integrase (IN) inhibitors, the 8-hydroxy-[1,6]naphthyridines (i.e., L-870,810) were one of the promising class of antiretroviral drugs developed by Merck Labs.  In spite of its remarkable potency and efficacy, unfortunately upon completion of phase I clin. studies, development of L-870,810 was halted.  Because of its desirable pharmacol. and pharmaceutical properties we were intrigued to design novel analogs of L-870,810 with goals to (1) improve upon limitations of naphthyridine-7-carboxamides as antiviral agents and (2) to reposition their use as innovative cytotoxic agents for cancer therapeutics.  Herein, we report on the design and synthesis of a series of 1,6-naphthyridine-7-carboxamides with various substitutions at the 5- and 8-positions.  All the new 5-substituted-8-hydroxy-[1,6]naphthyridines were potent IN inhibitors and the 5-substituted-8-amino-[1,6]naphthyridines, e.g. I [R = OH, NHCH2CH2OH, NHBn, etc.], were significantly cytotoxic.  Further optimization of the 5,8-disubstituted-[1,6]naphthyridines with structural variation on 7-carboxamide delivered novel compds. with significant cytotoxicity in a panel of cancer cell lines and effective inhibition against select oncogenic kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwQgFkPHff-LVg90H21EOLACvtfcHk0lgrddrI-QTPYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOltrvN&md5=1dfedb7d079e37cdd5244253e351e2df</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm300667v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300667v%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.-F.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKazemi%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DZ.-L.%26aulast%3DSanchez%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DL.-M.%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DOdde%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DY.-T.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DNeamati%26aufirst%3DN.%26aulast%3DLong%26aufirst%3DY.-Q.%26atitle%3DRepositioning%2520HIV-1%2520Integrase%2520Inhibitors%2520for%2520Cancer%2520Therapeutics%253A%25201%252C6-Naphthyridine-7-carboxamide%2520as%2520a%2520Promising%2520Scaffold%2520with%2520Drug-like%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9492%26epage%3D9509%26doi%3D10.1021%2Fjm300667v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viayna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayawardhana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epemolu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, T. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of 5-Amino1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7284</span>– <span class="NLM_lpage">7299</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyhtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7284-7299&author=S.+Brandauthor=E.+J.+Koauthor=E.+Viaynaauthor=S.+Thompsonauthor=D.+Spinksauthor=M.+Thomasauthor=L.+Sandbergauthor=A.+F.+Franciscoauthor=S.+Jayawardhanaauthor=V.+C.+Smithauthor=C.+Jansenauthor=M.+De+Ryckerauthor=J.+Thomasauthor=L.+MacLeanauthor=M.+Osuna-Cabelloauthor=J.+Rileyauthor=P.+Scullionauthor=L.+Stojanovskiauthor=F.+R.+C.+Simeonsauthor=O.+Epemoluauthor=Y.+Shishikuraauthor=S.+D.+Crouchauthor=T.+S.+Bakshiauthor=C.+J.+Nixonauthor=I.+H.+Reidauthor=A.+P.+Hillauthor=T.+Z.+Underwoodauthor=S.+J.+Hindleyauthor=S.+A.+Robinsonauthor=J.+M.+Kellyauthor=J.+M.+Fiandorauthor=P.+G.+Wyattauthor=M.+Marcoauthor=T.+J.+Milesauthor=K.+D.+Readauthor=I.+H.+Gilbert&title=Discovery+and+Optimization+of+5-Amino1%2C2%2C3-triazole-4-carboxamide+Series+against+Trypanosoma+cruzi&doi=10.1021%2Facs.jmedchem.7b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi</span></div><div class="casAuthors">Brand, Stephen; Ko, Eun Jung; Viayna, Elisabet; Thompson, Stephen; Spinks, Daniel; Thomas, Michael; Sandberg, Lars; Francisco, Amanda F.; Jayawardhana, Shiromani; Smith, Victoria C.; Jansen, Chimed; De Rycker, Manu; Thomas, John; MacLean, Lorna; Osuna-Cabello, Maria; Riley, Jennifer; Scullion, Paul; Stojanovski, Laste; Simeons, Frederick R. C.; Epemolu, Ola; Shishikura, Yoko; Crouch, Sabrinia D.; Bakshi, Tania S.; Nixon, Christopher J.; Reid, Iain H.; Hill, Alan P.; Underwood, Tim Z.; Hindley, Sean J.; Robinson, Sharon A.; Kelly, John M.; Fiandor, Jose M.; Wyatt, Paul G.; Marco, Maria; Miles, Timothy J.; Read, Kevin D.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7284-7299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-related deaths in endemic regions of Latin America.  There is an urgent need for new safer treatments because current std. therapeutic options, benznidazole and nifurtimox, have significant side effects and are only effective in the acute phase of the infection with limited efficacy in the chronic phase.  Phenotypic high content screening against the intracellular parasite in infected VERO cells was used to identify a novel hit series of 5-amino-1,2,3-triazole-4-carboxamides (ATC).  Optimization of the ATC series gave improvements in potency, aq. soly., and metabolic stability, which combined to give significant improvements in oral exposure.  Mitigation of a potential Ames and hERG liability ultimately led to two promising compds., one of which demonstrated significant suppression of parasite burden in a mouse model of Chagas' disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojbFlfMdTr17Vg90H21EOLACvtfcHk0li13BRpR5N--g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyhtr7P&md5=0e8c6127795fa38fe500bbc3832cf9c4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00463%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DViayna%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DSandberg%26aufirst%3DL.%26aulast%3DFrancisco%26aufirst%3DA.%2BF.%26aulast%3DJayawardhana%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DV.%2BC.%26aulast%3DJansen%26aufirst%3DC.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DScullion%26aufirst%3DP.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DEpemolu%26aufirst%3DO.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DCrouch%26aufirst%3DS.%2BD.%26aulast%3DBakshi%26aufirst%3DT.%2BS.%26aulast%3DNixon%26aufirst%3DC.%2BJ.%26aulast%3DReid%26aufirst%3DI.%2BH.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DUnderwood%26aufirst%3DT.%2BZ.%26aulast%3DHindley%26aufirst%3DS.%2BJ.%26aulast%3DRobinson%26aufirst%3DS.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%25205-Amino1%252C2%252C3-triazole-4-carboxamide%2520Series%2520against%2520Trypanosoma%2520cruzi%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7284%26epage%3D7299%26doi%3D10.1021%2Facs.jmedchem.7b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iratxe  Barbolla</span>, <span class="hlFld-ContribAuthor ">Leidi  Hernández-Suárez</span>, <span class="hlFld-ContribAuthor ">Viviana  Quevedo-Tumailli</span>, <span class="hlFld-ContribAuthor ">Deyani  Nocedo-Mena</span>, <span class="hlFld-ContribAuthor ">Sonia  Arrasate</span>, <span class="hlFld-ContribAuthor ">María Auxiliadora  Dea-Ayuela</span>, <span class="hlFld-ContribAuthor ">Humberto  González-Díaz</span>, <span class="hlFld-ContribAuthor ">Nuria  Sotomayor</span>, <span class="hlFld-ContribAuthor ">Esther  Lete</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-mediated synthesis and biological evaluation of C-10b substituted Dihydropyrrolo[1,2-b]isoquinolines as antileishmanial agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113458. <a href="https://doi.org/10.1016/j.ejmech.2021.113458" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113458</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113458%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPalladium-mediated%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BC-10b%252Bsubstituted%252BDihydropyrrolo%25255B1%25252C2-b%25255Disoquinolines%252Bas%252Bantileishmanial%252Bagents%26aulast%3DBarbolla%26aufirst%3DIratxe%26date%3D2021%26volume%3D220%26spage%3D113458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming-Shu  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Gong</span>, <span class="hlFld-ContribAuthor ">Zhi-Cheng  Yu</span>, <span class="hlFld-ContribAuthor ">Yan-Guang  Tian</span>, <span class="hlFld-ContribAuthor ">Lin-Sheng  Zhuo</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Neng-Fang  She</span>. </span><span class="cited-content_cbyCitation_article-title">Grignard Reagent Utilization Enables a Practical and Scalable Construction of 3-Substituted 5-Chloro-1,6-naphthyridin-4-one Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (23)
                                     , 5667. <a href="https://doi.org/10.3390/molecules25235667" title="DOI URL">https://doi.org/10.3390/molecules25235667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25235667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25235667%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DGrignard%252BReagent%252BUtilization%252BEnables%252Ba%252BPractical%252Band%252BScalable%252BConstruction%252Bof%252B3-Substituted%252B5-Chloro-1%25252C6-naphthyridin-4-one%252BDerivatives%26aulast%3DWang%26aufirst%3DMing-Shu%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D23%26spage%3D5667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chrom Log <i>D</i><sub>7.4</sub><i>vs</i> intramacrophage potency (Ld InMac pEC<sub>50</sub>) for all compounds presented. The green line represents Chrom Log <i>D</i><sub>7.4</sub> = 3; the black line represents Ld InMac pEC<sub>50</sub> = 5.8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Highlighting the acceptor–donor–acceptor motifs of triazole analogue <b>1</b>, amide analogue <b>7</b>, and Raltegravir <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. PK profile of <b>26</b>, showing levels of parent, glucuronide adduct, major hydroxylated metabolite, and other minor metabolites. Data are based on two replicates, with error bars representing the range of the data from the two runs. Blood/water (30 μL, 1:2) were collected following 50 mg/kg ip administration to Balb C mice at prescribed time points; 90 μL of acetonitrile (ACN) was then added to each sample and the samples were centrifuged for 5 min at 7000 rpm; 90 μL of supernatant was removed and added to 50 μL of Milli-Q water before ultrahigh-performance liquid chromatography–quadrupole time-of-flight (UPLC Q-TOF) analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,4-dioxane/acetic acid, 140–200 °C, 22–38%; (b) NBS, dichloromethane (DCM), 2 h, 84%; (c) acetohydrazide, 1,4-dioxane/acetic acid, 200 °C, 30 min, 45%; (d) relevant amine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), <i>N</i>-methyl-2-pyrrolidone (NMP), 180 °C, 1–18 h, 25–50%; (e) TsCl, NEt<sub>3</sub>, DCM, 40 °C, 3 h, 83%; (f) i. for <b>12</b>: pyrrolidin-2-one, Cs<sub>2</sub>CO<sub>3</sub>, Pd(OAc)<sub>2</sub>, Xantphos, 1,4-dioxane, 65 °C. For <b>13</b>: 1,2-thiazinane 1,1-dioxide, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, 1,4-dioxane, 65 °C. ii. NaOMe, dimethylformamide (DMF), 50 °C. iii. Acetohydrazide, 1,4-dioxane/acetic acid, 180 °C, 2 h, 7–16% over three steps; (g) BnBr, PPH<sub>3</sub>, diisopropyl azodicarboxylate (DIAD), tetrahydrofuran (THF), 0 °C, 18 h, 15%; (h) phenylboronic acid, K<sub>3</sub>PO<sub>4</sub>, Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, DMF/water, 130 °C, then acetohydrazide, 1,4-dioxane/acetic acid, 200 °C, 45 min, 3% over two steps (<b>14</b>); (i) i. relevant boronic acid, K<sub>3</sub>PO<sub>4</sub>, tetrakis, 1,4-dioxane/water, 120 °C, 1.5 h. ii. Acetohydrazide, 1,4-dioxane/acetic acid, 180 °C, 18 h, 22% (<b>15</b>)/24% (<b>16</b>) over two steps.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) i. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), DIPEA, hydroxybenzotriazole (HOBt), acethydrazide, DCM, 0 °C, 18 h. ii. PPh<sub>3</sub>, CCl<sub>4</sub>, NEt<sub>3</sub>, MeCN, 60 °C, 2 h, 53%. (b) i. Phenylboronic acid, Na<sub>2</sub>CO<sub>3</sub>, tetrakis, 1,4-dioxane/water, 120 °C, 18 h. ii. Trimethylchlorosilane, NaI, MeCN, reflux, 18 h, 44% over two steps; (c) i. oxalyl chloride, DCM, RT then 3-ethoxy-3-oxo-propanoic acid, BuLi, −78 °C, 1 h. ii. DMF·dimethylacetamide (DMA), DMF, 100 °C, 1 h. iii. MeNH<sub>2</sub>, ether/EtOH, RT, 1 h. iv. 1 M NaOH, MeOH, RT, 2 h, 69% over four steps; (d) DIPEA, T3P, DMF, 2 h, 8%; (e) lithium diisopropylamide (LDA), <i>tert</i>-butyl acetate, THF, −78 °C, 2 h, quant. (f) i. ABSA, NEt<sub>3</sub>, MeCN, 0 °C, 18 h. ii. PBu<sub>3</sub>, THF, RT, 15 min. iii. DBU, MeI, MeCN, RT, 18 h, 32% over three steps. (g) i. Trifluoroacetyl (TFA), DCM, RT, 18 h. ii. EDCI, HOBt, DIPEA, DCM, 16 h, 88% over two steps. (h) i. MeNH–OH, Na<sub>2</sub>CO<sub>3</sub>, water/EtOH, 28 h, 80 °C. ii. Diethyl acetylenedicarboxylate, EtOH, RT, 1 h, 61% over two steps. (i) <i>p</i>-Xylene, reflux, 2 days, 41%; (j) toluene, reflux, 18 h, 46%.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/medium/jm0c00705_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00705/20200929/images/large/jm0c00705_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00705&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) i. EtOH, reflux, 18 h, 65%; (b) NBS, DCM, room temperature (RT), 2 h, 93%; (c) TsCl, NEt<sub>3</sub>, DCM, 40 °C, 2 days, 49%; (d) i. 1,2-thiazinane 1,1-dioxide, Cs<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, 1,4-dioxane, 65 °C, 24 h. ii. NaOMe, DMF, 50 °C, 24 h. iii. 4-Fluorobenzylamine, T3P, DIPEA, DMF, RT, 18 h, 11% over three steps; (e) relevant amine, EtOH, 100 °C, 18 h, 45–86%; (f) (2-methoxyphenyl)boronic acid, K<sub>3</sub>PO<sub>4</sub>, Pd(dppf)Cl<sub>2</sub>·DCM, 1,4-dioxane/water, 140 °C, 1 h, 30% (<b>26</b>)/38% (<b>33</b>); (g) relevant amine, DIPEA, NMP, 150–180 °C, 5 h, 17% (<b>31</b>)/33% (<b>32</b>); (h) i. (2-methoxyphenyl)boronic acid, tetrakis, Na<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/water, 60 °C, 18 h. ii. NaOMe, MeOH, 50 °C, 15 min. iii. LiOH, water, 60 °C, 18 h, 58% over three steps; (i) trans-4-methoxycyclohexanamine, DIPEA, T3P, 50 °C, 18 h, 56%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i66">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 23 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>World
Health Organization (WHO) List of Neglected Tropical Diseases</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>. <a href="http://www.who.int/neglected_diseases/diseases/en/" class="extLink">http://www.who.int/neglected_diseases/diseases/en/</a> (accessed April 23, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+World%0AHealth+Organization+%28WHO%29+List+of+Neglected+Tropical+Diseases%3B+World+Health+Organization%3A+Geneva%2C+2018.+http%3A%2F%2Fwww.who.int%2Fneglected_diseases%2Fdiseases%2Fen%2F+%28accessed+April+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWorld%250AHealth%2520Organization%2520%2528WHO%2529%2520List%2520of%2520Neglected%2520Tropical%2520Diseases%26pub%3DWorld%2520Health%2520Organization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrie, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Anti-trypanosomatid Drug Discovery: an Ongoing Challenge and a Continuing Need</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/nrmicro.2016.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fnrmicro.2016.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=28239154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=217-231&author=M.+C.+Fieldauthor=D.+Hornauthor=A.+H.+Fairlambauthor=M.+A.+J.+Fergusonauthor=D.+W.+Grayauthor=K.+D.+Readauthor=M.+De+Ryckerauthor=L.+S.+Torrieauthor=P.+G.+Wyattauthor=S.+Wyllieauthor=I.+H.+Gilbert&title=Anti-trypanosomatid+Drug+Discovery%3A+an+Ongoing+Challenge+and+a+Continuing+Need&doi=10.1038%2Fnrmicro.2016.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need</span></div><div class="casAuthors">Field, Mark C.; Horn, David; Fairlamb, Alan H.; Ferguson, Michael A. J.; Gray, David W.; Read, Kevin D.; De Rycker, Manu; Torrie, Leah S.; Wyatt, Paul G.; Wyllie, Susan; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-231</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases.  These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal.  Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them.  In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled.  In addn., we consider the important challenges to drug discovery strategies and the new technologies that can address them.  The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIBpRGL7YaP7Vg90H21EOLACvtfcHk0lg27a88YW9L5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D&md5=1585d954d6eb695196a6c8921a84e300</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro.2016.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro.2016.193%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BC.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DTorrie%26aufirst%3DL.%2BS.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DAnti-trypanosomatid%2520Drug%2520Discovery%253A%2520an%2520Ongoing%2520Challenge%2520and%2520a%2520Continuing%2520Need%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2017%26volume%3D15%26spage%3D217%26epage%3D231%26doi%3D10.1038%2Fnrmicro.2016.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span> <i>World
Health Organization (WHO) Leishmaniasis Fact Sheet</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>. <a href="https://www.who.int/news-room/fact-sheets/detail/leishmaniasis" class="extLink">https://www.who.int/news-room/fact-sheets/detail/leishmaniasis</a> (accessed April 23, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+World%0AHealth+Organization+%28WHO%29+Leishmaniasis+Fact+Sheet%3B+World+Health+Organization%3A+Geneva%2C+2019.+https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fleishmaniasis+%28accessed+April+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWorld%250AHealth%2520Organization%2520%2528WHO%2529%2520Leishmaniasis%2520Fact%2520Sheet%26pub%3DWorld%2520Health%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olliaro, P. L.</span></span> <span> </span><span class="NLM_article-title">Miltefosine in the treatment of leishmaniasis: Clinical Evidence for Informed Clinical Risk Management</span>. <i>Ther. Clin. Risk Manage.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">740</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=18472998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGrtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=733-740&author=S.+Sundarauthor=P.+L.+Olliaro&title=Miltefosine+in+the+treatment+of+leishmaniasis%3A+Clinical+Evidence+for+Informed+Clinical+Risk+Management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management</span></div><div class="casAuthors">Sundar, Shyam; Olliaro, Piero L.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutics and Clinical Risk Management</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">733-740</span>CODEN:
                <span class="NLM_cas:coden">TCRMA6</span>;
        ISSN:<span class="NLM_cas:issn">1176-6336</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press (NZ) Ltd.</span>)
        </div><div class="casAbstract">A review.  Visceral leishmaniasis (VL) is a life-threatening disease.  Traditional treatment with pentavalent antimony injections has become ineffective in the area with the world's highest prevalence of disease (North Bihar, India) and is becoming less effective elsewhere as well.  A replacement is needed, best if it can be given to more patients outside the hospital.  Miltefosine is the first oral drug registered for VL.  Given daily under medical supervision for 4 wk, it cures 94% of patients (both children and adults) and is reasonably safe.  Miltefosine has great potential for improving access to treatment and overall control of VL and will be crit. in the VL elimination campaign in the Indian subcontinent, but must be safeguarded or will be lost if misused.  Its main limitations are adherence (and hence potential for selection of drug resistant parasites) and teratogenicity (pregnancy must be avoided during treatment and the following two months).  This calls for responsible deployment, setting in place mechanisms to protect female patients in child-bearing age, monitoring effects and optimizing adherence in real-life conditions through directly obsd. therapy.  One option to protect the useful life-span of miltefosine consists in shortening treatment duration by combining it with another drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPDC_6xNNyc7Vg90H21EOLACvtfcHk0lg27a88YW9L5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGrtLzK&md5=9a845dabc6ff85abb881cbb77e7aaa0d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSundar%26aufirst%3DS.%26aulast%3DOlliaro%26aufirst%3DP.%2BL.%26atitle%3DMiltefosine%2520in%2520the%2520treatment%2520of%2520leishmaniasis%253A%2520Clinical%2520Evidence%2520for%2520Informed%2520Clinical%2520Risk%2520Management%26jtitle%3DTher.%2520Clin.%2520Risk%2520Manage.%26date%3D2007%26volume%3D3%26spage%3D733%26epage%3D740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span> <span> </span><span class="NLM_article-title">Injectable Paromomycin for Visceral Leishmaniasis in India</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">2571</span>– <span class="NLM_lpage">2581</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa066536</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1056%2FNEJMoa066536" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=17582067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmslKjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2571-2581&author=S.+Sundarauthor=T.+K.+Jhaauthor=C.+P.+Thakurauthor=P.+K.+Sinhaauthor=S.+K.+Bhattacharya&title=Injectable+Paromomycin+for+Visceral+Leishmaniasis+in+India&doi=10.1056%2FNEJMoa066536"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Injectable paromomycin for visceral leishmaniasis in India</span></div><div class="casAuthors">Sundar, Shyam; Jha, T. K.; Thakur, Chandreshwar P.; Sinha, Prabhat K.; Bhattacharya, Sujit K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2571-2581</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in South Asia, Africa, and Brazil.  Safe, effective, and affordable new therapies are needed.  We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present std. of care in Bihar, India.  In 4 treatment centers for visceral leishmaniasis, 667 patients between 5 and 55 years of age who were neg. for the human immunodeficiency virus and had parasitol. confirmed visceral leishmaniasis were randomly assigned in a 3:1 ratio to receive paromomycin (502 patients) at a dose of 11 mg per kg of body wt. i.m. daily for 21 days or amphotericin B (165 patients) at a dose of 1 mg per kg i.v. every other day for 30 days.  Final cure was assessed 6 mo after the end of treatment; safety assessments included daily clin. evaluations and weekly lab. and audiometric evaluations.  Noninferiority testing was used to compare 6-mo cure rates, with a chosen margin of noninferiority of 10 percentage points.  Paromomycin was shown to be noninferior to amphotericin B (final cure rate, 94.6% vs. 98.8%; difference, 4.2 percentage points; upper bound of the 97.5% confidence interval, 6.9).  Mortality rates in the 2 groups were < 1%.  Adverse events, which were more common among patients receiving paromomycin than among those receiving amphotericin B (6% vs. 2%), included transient elevation of aspartate aminotransferase levels (>3 times the upper limit of the normal range); transient reversible ototoxicity (2% vs. 0); and injection-site pain (55% vs. 0); and in patients receiving amphotericin B, as compared with those receiving paromomycin, nephrotoxicity (4% vs. 0), fevers (57 vs. 3%), rigors (24% vs. 0), and vomiting (10 vs. <1%).  Paromomycin was shown to be noninferior to amphotericin B for the treatment of visceral leishmaniasis in India.  (ClinicalTrials.gov no., NCT00216346.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyn_4O1tWAAbVg90H21EOLACvtfcHk0lg27a88YW9L5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmslKjsr4%253D&md5=1ffd9122dd3b8d8fbe17ed41471f3fb7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa066536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa066536%26sid%3Dliteratum%253Aachs%26aulast%3DSundar%26aufirst%3DS.%26aulast%3DJha%26aufirst%3DT.%2BK.%26aulast%3DThakur%26aufirst%3DC.%2BP.%26aulast%3DSinha%26aufirst%3DP.%2BK.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26atitle%3DInjectable%2520Paromomycin%2520for%2520Visceral%2520Leishmaniasis%2520in%2520India%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2571%26epage%3D2581%26doi%3D10.1056%2FNEJMoa066536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span>Drugs for Neglected
Diseases initiative
(DND <i>i</i>) Portfolio. <a href="https://www.dndi.org/diseases-projects/leishmaniasis/leish-portfolio/" class="extLink">https://www.dndi.org/diseases-projects/leishmaniasis/leish-portfolio/</a> (accessed April 23, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs+for+Neglected%0ADiseases+initiative%0A%28DND+i%29+Portfolio.+https%3A%2F%2Fwww.dndi.org%2Fdiseases-projects%2Fleishmaniasis%2Fleish-portfolio%2F+%28accessed+April+23%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3Di%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbaniak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflaumer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 12 is a Drug Target for Visceral Leishmaniasis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>560</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0356-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fs41586-018-0356-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=30046105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=560&publication_year=2018&pages=192-197&author=S.+Wyllieauthor=M.+Thomasauthor=S.+Pattersonauthor=S.+Crouchauthor=M.+De+Ryckerauthor=R.+Loweauthor=S.+Greshamauthor=M.+D.+Urbaniakauthor=T.+D.+Ottoauthor=L.+Stojanovskiauthor=F.+R.+C.+Simeonsauthor=S.+Manthriauthor=L.+M.+MacLeanauthor=F.+Zuccottoauthor=N.+Homeyerauthor=H.+Pflaumerauthor=M.+Boescheauthor=L.+Sastryauthor=P.+Connollyauthor=S.+Albrechtauthor=M.+Berrimanauthor=G.+Drewesauthor=D.+W.+Grayauthor=S.+Ghidelli-Disseauthor=S.+Dixonauthor=J.+M.+Fiandorauthor=P.+G.+Wyattauthor=M.+A.+J.+Fergusonauthor=A.+H.+Fairlambauthor=T.+J.+Milesauthor=K.+D.+Readauthor=I.+H.+Gilbert&title=Cyclin-Dependent+Kinase+12+is+a+Drug+Target+for+Visceral+Leishmaniasis&doi=10.1038%2Fs41586-018-0356-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis</span></div><div class="casAuthors">Wyllie, Susan; Thomas, Michael; Patterson, Stephen; Crouch, Sabrinia; De Rycker, Manu; Lowe, Rhiannon; Gresham, Stephanie; Urbaniak, Michael D.; Otto, Thomas D.; Stojanovski, Laste; Simeons, Frederick R. C.; Manthri, Sujatha; MacLean, Lorna M.; Zuccotto, Fabio; Homeyer, Nadine; Pflaumer, Hannah; Boesche, Markus; Sastry, Lalitha; Connolly, Paul; Albrecht, Sebastian; Berriman, Matt; Drewes, Gerard; Gray, David W.; Ghidelli-Disse, Sonja; Dixon, Susan; Fiandor, Jose M.; Wyatt, Paul G.; Ferguson, Michael A. J.; Fairlamb, Alan H.; Miles, Timothy J.; Read, Kevin D.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">560</span>
        (<span class="NLM_cas:issue">7717</span>),
    <span class="NLM_cas:pages">192-197</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world.  There is an urgent need for the development of new, effective treatments for this disease.  Here we describe the development of an anti-leishmanial drug-like chem. series based on a pyrazolopyrimidine scaffold.  The leading compd. from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochem., pharmacokinetic and toxicol. properties for further development, and has been declared a preclin. candidate.  Detailed mode-of-action studies indicate that compds. from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWvpd9EzGFxLVg90H21EOLACvtfcHk0liSmsGofMDPdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt77I&md5=bea43a232049ade6ed9abea3e0510221</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0356-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0356-z%26sid%3Dliteratum%253Aachs%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DCrouch%26aufirst%3DS.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DLowe%26aufirst%3DR.%26aulast%3DGresham%26aufirst%3DS.%26aulast%3DUrbaniak%26aufirst%3DM.%2BD.%26aulast%3DOtto%26aufirst%3DT.%2BD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMacLean%26aufirst%3DL.%2BM.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DHomeyer%26aufirst%3DN.%26aulast%3DPflaumer%26aufirst%3DH.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DSastry%26aufirst%3DL.%26aulast%3DConnolly%26aufirst%3DP.%26aulast%3DAlbrecht%26aufirst%3DS.%26aulast%3DBerriman%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DDixon%26aufirst%3DS.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DCyclin-Dependent%2520Kinase%252012%2520is%2520a%2520Drug%2520Target%2520for%2520Visceral%2520Leishmaniasis%26jtitle%3DNature%26date%3D2018%26volume%3D560%26spage%3D192%26epage%3D197%26doi%3D10.1038%2Fs41586-018-0356-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bueren-Calabuig, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebrian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craggs, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobrath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeacock, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korczynska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata-Cantero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nühs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viayna Gaza, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Preclinical Candidate for the Treatment of Visceral Leishmaniasis that Acts Through Proteasome Inhibition</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">9318</span>– <span class="NLM_lpage">9323</span>, <span class="refDoi"> DOI: 10.1073/pnas.1820175116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1073%2Fpnas.1820175116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=30962368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFGlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=9318-9323&author=S.+Wyllieauthor=S.+Brandauthor=M.+Thomasauthor=M.+De+Ryckerauthor=C.+Chungauthor=I.+Penaauthor=R.+P.+Binghamauthor=J.+A.+Bueren-Calabuigauthor=J.+Cantizaniauthor=D.+Cebrianauthor=P.+D.+Craggsauthor=L.+Fergusonauthor=P.+Goswamiauthor=J.+Hobrathauthor=J.+Howeauthor=L.+Jeacockauthor=E.-J.+Koauthor=J.+Korczynskaauthor=L.+MacLeanauthor=S.+Manthriauthor=M.+S.+Martinezauthor=L.+Mata-Canteroauthor=S.+Monizauthor=A.+N%C3%BChsauthor=M.+Osuna-Cabelloauthor=E.+Pintoauthor=J.+Rileyauthor=S.+Robinsonauthor=P.+Rowlandauthor=F.+R.+C.+Simeonsauthor=Y.+Shishikuraauthor=D.+Spinksauthor=L.+Stojanovskiauthor=J.+Thomasauthor=S.+Thompsonauthor=E.+Viayna+Gazaauthor=R.+J.+Wallauthor=F.+Zuccottoauthor=D.+Hornauthor=M.+A.+J.+Fergusonauthor=A.+H.+Fairlambauthor=J.+M.+Fiandorauthor=J.+Martinauthor=D.+W.+Grayauthor=T.+J.+Milesauthor=I.+H.+Gilbertauthor=K.+D.+Readauthor=M.+Marcoauthor=P.+G.+Wyatt&title=Preclinical+Candidate+for+the+Treatment+of+Visceral+Leishmaniasis+that+Acts+Through+Proteasome+Inhibition&doi=10.1073%2Fpnas.1820175116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition</span></div><div class="casAuthors">Wyllie, Susan; Brand, Stephen; Thomas, Michael; De Rycker, Manu; Chung, Chun-wa; Pena, Imanol; Bingham, Ryan P.; Bueren-Calabuig, Juan A.; Cantizani, Juan; Cebrian, David; Craggs, Peter D.; Ferguson, Liam; Goswami, Panchali; Hobrath, Judith; Howe, Jonathan; Jeacock, Laura; Ko, Eun-Jung; Korczynska, Justyna; MacLean, Lorna; Manthri, Sujatha; Martinez, Maria S.; Mata-Cantero, Lydia; Moniz, Sonia; NA1/4hs, Andrea; Osuna-Cabello, Maria; Pinto, Erika; Riley, Jennifer; Robinson, Sharon; Rowland, Paul; Simeons, Frederick R. C.; Shishikura, Yoko; Spinks, Daniel; Stojanovski, Laste; Thomas, John; Thompson, Stephen; Gaza, Elisabet Viayna; Wall, Richard J.; Zuccotto, Fabio; Horn, David; Ferguson, Michael A. J.; Fairlamb, Alan H.; Fiandor, Jose M.; Martin, Julio; Gray, David W.; Miles, Timothy J.; Gilbert, Ian H.; Read, Kevin D.; Marco, Maria; Wyatt, Paul G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9318-9323</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and Leishmania infantum, is one of the major parasitic diseases worldwide.  There is an urgent need for new drugs to treat VL, because current therapies are unfit for purpose in a resource-poor setting.  Here, we describe the development of a preclin. drug candidate, GSK3494245/DDD01305143/compd. 8, with potential to treat this neglected tropical disease.  The compd. series was discovered by repurposing hits from a screen against the related parasite Trypanosoma cruzi.  Subsequent optimization of the chem. series resulted in the development of a potent cidal compd. with activity against a range of clin. relevant L. donovani and L. infantum isolates.  Compd. 8 demonstrates promising pharmacokinetic properties and impressive in vivo efficacy in our mouse model of infection comparable with those of the current oral antileishmanial miltefosine.  Detailed mode of action studies confirm that this compd. acts principally by inhibition of the chymotrypsin-like activity catalyzed by the β5 subunit of the L. donovani proteasome.  High-resoln. cryo-EM structures of apo and compd. 8-bound Leishmania tarentolae 20S proteasome reveal a previously undiscovered inhibitor site that lies between the β4 and β5 proteasome subunits.  This induced pocket exploits β4 residues that are divergent between humans and kinetoplastid parasites and is consistent with all of our exptl. and mutagenesis data.  As a result of these comprehensive studies and due to a favorable developability and safety profile, compd. 8 is being advanced toward human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLTLZPb2MCLVg90H21EOLACvtfcHk0liSmsGofMDPdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFGlsb0%253D&md5=799defb4ef812d64ffe230c78aff3511</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1820175116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1820175116%26sid%3Dliteratum%253Aachs%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.%26aulast%3DPena%26aufirst%3DI.%26aulast%3DBingham%26aufirst%3DR.%2BP.%26aulast%3DBueren-Calabuig%26aufirst%3DJ.%2BA.%26aulast%3DCantizani%26aufirst%3DJ.%26aulast%3DCebrian%26aufirst%3DD.%26aulast%3DCraggs%26aufirst%3DP.%2BD.%26aulast%3DFerguson%26aufirst%3DL.%26aulast%3DGoswami%26aufirst%3DP.%26aulast%3DHobrath%26aufirst%3DJ.%26aulast%3DHowe%26aufirst%3DJ.%26aulast%3DJeacock%26aufirst%3DL.%26aulast%3DKo%26aufirst%3DE.-J.%26aulast%3DKorczynska%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DM.%2BS.%26aulast%3DMata-Cantero%26aufirst%3DL.%26aulast%3DMoniz%26aufirst%3DS.%26aulast%3DN%25C3%25BChs%26aufirst%3DA.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DPinto%26aufirst%3DE.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DRobinson%26aufirst%3DS.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DViayna%2BGaza%26aufirst%3DE.%26aulast%3DWall%26aufirst%3DR.%2BJ.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DPreclinical%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Visceral%2520Leishmaniasis%2520that%2520Acts%2520Through%2520Proteasome%2520Inhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D9318%26epage%3D9323%26doi%3D10.1073%2Fpnas.1820175116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathison, C. J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myburgh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, H. X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span> <span> </span><span class="NLM_article-title">Proteasome Inhibition for Treatment of Leishmaniasis, Chagas Disease and Sleeping Sickness</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nature19339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fnature19339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=27501246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=229-233&author=S.+Khareauthor=A.+S.+Nagleauthor=A.+Biggartauthor=Y.+H.+Laiauthor=F.+Liangauthor=L.+C.+Davisauthor=S.+W.+Barnesauthor=C.+J.+N.+Mathisonauthor=E.+Myburghauthor=M.-Y.+Gaoauthor=J.+R.+Gillespieauthor=X.+Liuauthor=J.+L.+Tanauthor=M.+Stinsonauthor=I.+C.+Riveraauthor=J.+Ballardauthor=V.+Yehauthor=T.+Groesslauthor=G.+Federeauthor=H.+X.+Y.+Kohauthor=J.+D.+Venableauthor=B.+Bursulayaauthor=M.+Shapiroauthor=P.+K.+Mishraauthor=G.+Spraggonauthor=A.+Brockauthor=J.+C.+Mottramauthor=F.+S.+Bucknerauthor=S.+P.+S.+Raoauthor=B.+G.+Wenauthor=J.+R.+Walkerauthor=T.+Tuntlandauthor=V.+Molteniauthor=R.+J.+Glynneauthor=F.+Supek&title=Proteasome+Inhibition+for+Treatment+of+Leishmaniasis%2C+Chagas+Disease+and+Sleeping+Sickness&doi=10.1038%2Fnature19339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness</span></div><div class="casAuthors">Khare, Shilpi; Nagle, Advait S.; Biggart, Agnes; Lai, Yin H.; Liang, Fang; Davis, Lauren C.; Barnes, S. Whitney; Mathison, Casey J. N.; Myburgh, Elmarie; Gao, Mu-Yun; Gillespie, J. Robert; Liu, Xianzhong; Tan, Jocelyn L.; Stinson, Monique; Rivera, Ianne C.; Ballard, Jaime; Yeh, Vince; Groessl, Todd; Federe, Glenn; Koh, Hazel X. Y.; Venable, John D.; Bursulaya, Badry; Shapiro, Michael; Mishra, Pranab K.; Spraggon, Glen; Brock, Ansgar; Mottram, Jeremy C.; Buckner, Frederick S.; Rao, Srinivasa P. S.; Wen, Ben G.; Walker, John R.; Tuntland, Tove; Molteni, Valentina; Glynne, Richard J.; Supek, Frantisek</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths annually.  The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp., resp.  These parasites have similar biol. and genomic sequence, suggesting that all three diseases could be cured with drugs that modulate the activity of a conserved parasite target.  However, no such mol. targets or broad spectrum drugs have been identified to date.  Here we describe a selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection.  GNF6702 inhibits the kinetoplastid proteasome through a non-competitive mechanism, does not inhibit the mammalian proteasome or growth of mammalian cells, and is well-tolerated in mice.  Our data provide genetic and chem. validation of the parasite proteasome as a promising therapeutic target for treatment of kinetoplastid infections, and underscore the possibility of developing a single class of drugs for these neglected diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PXMn1-tj_7Vg90H21EOLACvtfcHk0lh1w49kWsjZRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL&md5=a05e7ce0f6b912b3003c5b3f42a005bb</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnature19339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19339%26sid%3Dliteratum%253Aachs%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DNagle%26aufirst%3DA.%2BS.%26aulast%3DBiggart%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DMathison%26aufirst%3DC.%2BJ.%2BN.%26aulast%3DMyburgh%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DGillespie%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DJ.%2BL.%26aulast%3DStinson%26aufirst%3DM.%26aulast%3DRivera%26aufirst%3DI.%2BC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DYeh%26aufirst%3DV.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DFedere%26aufirst%3DG.%26aulast%3DKoh%26aufirst%3DH.%2BX.%2BY.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DP.%2BK.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBrock%26aufirst%3DA.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DWen%26aufirst%3DB.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DSupek%26aufirst%3DF.%26atitle%3DProteasome%2520Inhibition%2520for%2520Treatment%2520of%2520Leishmaniasis%252C%2520Chagas%2520Disease%2520and%2520Sleeping%2520Sickness%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D229%26epage%3D233%26doi%3D10.1038%2Fnature19339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallyburton, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frearson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span> <span> </span><span class="NLM_article-title">Comparison of a High-Throughput High Content Intracellular <i>Leishmania donovani</i> Assay with an Axenic Amastigote Assay</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2913</span>– <span class="NLM_lpage">2922</span>, <span class="refDoi"> DOI: 10.1128/AAC.02398-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1128%2FAAC.02398-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=23571538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVartrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=2913-2922&author=M.+De%0ARyckerauthor=I.+Hallyburtonauthor=J.+Thomasauthor=L.+Campbellauthor=S.+Wyllieauthor=D.+Joshiauthor=S.+Cameronauthor=I.+H.+Gilbertauthor=P.+G.+Wyattauthor=J.+A.+Frearsonauthor=A.+H.+Fairlambauthor=D.+W.+Gray&title=Comparison+of+a+High-Throughput+High+Content+Intracellular+Leishmania+donovani+Assay+with+an+Axenic+Amastigote+Assay&doi=10.1128%2FAAC.02398-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay</span></div><div class="casAuthors">De Rycker, Manu; Hallyburton, Irene; Thomas, John; Campbell, Lorna; Wyllie, Susan; Joshi, Dhananjay; Cameron, Scott; Gilbert, Ian H.; Wyatt, Paul G.; Frearson, Julie A.; Fairlamb, Alan H.; Gray, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2913-2922</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Visceral leishmaniasis is a neglected tropical disease with significant health impact.  The current treatments are poor, and there is an urgent need to develop new drugs.  Primary screening assays used for drug discovery campaigns have typically used free-living forms of the Leishmania parasite to allow for high-throughput screening.  Such screens do not necessarily reflect the physiol. situation, as the disease-causing stage of the parasite resides inside human host cells.  Assessing the drug sensitivity of intracellular parasites on scale has recently become feasible with the advent of high-content screening methods.  We describe here a 384-well microscopy-based intramacrophage Leishmania donovani assay and compare it to an axenic amastigote system.  A panel of eight ref. compds. was tested in both systems, as well as a human counterscreen cell line, and our findings show that for most clin. used compds. both axenic and intramacrophage assays report very similar results.  A set of 15,659 diverse compds. was also screened using both systems.  This resulted in the identification of seven new antileishmanial compds. and revealed a high false-pos. rate for the axenic assay.  We conclude that the intramacrophage assay is more suited as a primary hit-discovery platform than the current form of axenic assay, and we discuss how modifications to the axenic assay may render it more suitable for hit-discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXnzJTYkYtJrVg90H21EOLACvtfcHk0lglwwgUx3DQWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVartrvL&md5=9d7d79eea02abc10f3a5c26fac47de27</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1128%2FAAC.02398-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02398-12%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DHallyburton%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DL.%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DFrearson%26aufirst%3DJ.%2BA.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DGray%26aufirst%3DD.%2BW.%26atitle%3DComparison%2520of%2520a%2520High-Throughput%2520High%2520Content%2520Intracellular%2520Leishmania%2520donovani%2520Assay%2520with%2520an%2520Axenic%2520Amastigote%2520Assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D2913%26epage%3D2922%26doi%3D10.1128%2FAAC.02398-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Don, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioset, J.-R.</span></span> <span> </span><span class="NLM_article-title">Screening Strategies to Identify New Chemical Diversity for Drug Development to Treat Kinetoplastid Infections</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1017/S003118201300142X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1017%2FS003118201300142X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=23985066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A280%3ADC%252BC3sbjtFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2014&pages=140-146&author=R.+Donauthor=J.-R.+Ioset&title=Screening+Strategies+to+Identify+New+Chemical+Diversity+for+Drug+Development+to+Treat+Kinetoplastid+Infections&doi=10.1017%2FS003118201300142X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections</span></div><div class="casAuthors">Don Rob; Ioset Jean-Robert</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Drugs for Neglected Diseases initiative (DNDi) has defined and implemented an early discovery strategy over the last few years, in fitting with its virtual R&D business model.  This strategy relies on a medium- to high-throughput phenotypic assay platform to expedite the screening of compound libraries accessed through its collaborations with partners from the pharmaceutical industry.  We review the pragmatic approaches used to select compound libraries for screening against kinetoplastids, taking into account screening capacity.  The advantages, limitations and current achievements in identifying new quality series for further development into preclinical candidates are critically discussed, together with attractive new approaches currently under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8FURC2GtUulm8bhe6roZYfW6udTcc2eYaHSeJK6Fyebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbjtFGmsA%253D%253D&md5=ae473acad2714a482e5acc926b8fe85f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1017%2FS003118201300142X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS003118201300142X%26sid%3Dliteratum%253Aachs%26aulast%3DDon%26aufirst%3DR.%26aulast%3DIoset%26aufirst%3DJ.-R.%26atitle%3DScreening%2520Strategies%2520to%2520Identify%2520New%2520Chemical%2520Diversity%2520for%2520Drug%2520Development%2520to%2520Treat%2520Kinetoplastid%2520Infections%26jtitle%3DParasitology%26date%3D2014%26volume%3D141%26spage%3D140%26epage%3D146%26doi%3D10.1017%2FS003118201300142X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peña, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilar Manzano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Padilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardera, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colmenarejo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roquero, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios-Anton, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherstnev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julio Martin, J.</span></span> <span> </span><span class="NLM_article-title">New Compound Sets Identified from High Throughput Phenotypic Screening against Three Kinetoplastid Parasites: an Open Resource</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">8771</span> <span class="refDoi"> DOI: 10.1038/srep08771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fsrep08771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=25740547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKhur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=I.+Pe%C3%B1aauthor=M.+Pilar+Manzanoauthor=J.+Cantizaniauthor=A.+Kesslerauthor=J.+Alonso-Padillaauthor=A.+I.+Barderaauthor=E.+Alvarezauthor=G.+Colmenarejoauthor=I.+Cotilloauthor=I.+Roqueroauthor=F.+de+Dios-Antonauthor=V.+Barrosoauthor=A.+Rodriguezauthor=D.+W.+Grayauthor=M.+Navarroauthor=V.+Kumarauthor=A.+Sherstnevauthor=D.+H.+Drewryauthor=J.+R.+Brownauthor=J.+M.+Fiandorauthor=J.+Julio+Martin&title=New+Compound+Sets+Identified+from+High+Throughput+Phenotypic+Screening+against+Three+Kinetoplastid+Parasites%3A+an+Open+Resource&doi=10.1038%2Fsrep08771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">New Compound Sets Identified from High Throughput Phenotypic Screening Against Three Kinetoplastid Parasites: An Open Resource</span></div><div class="casAuthors">Pena, Imanol; Pilar Manzano, M.; Cantizani, Juan; Kessler, Albane; Alonso-Padilla, Julio; Bardera, Ana I.; Alvarez, Emilio; Colmenarejo, Gonzalo; Cotillo, Ignacio; Roquero, Irene; de Dios-Anton, Francisco; Barroso, Vanessa; Rodriguez, Ana; Gray, David W.; Navarro, Miguel; Kumar, Vinod; Sherstnev, Alexander; Drewry, David H.; Brown, James R.; Fiandor, Jose M.; Martin, J. Julio</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8771</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Using whole-cell phenotypic assays, the GlaxoSmithKline high-throughput screening (HTS) diversity set of 1.8 million compds. was screened against the three kinetoplastids most relevant to human disease, i.e.  Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.  Secondary confirmatory and orthogonal intracellular anti-parasiticidal assays were conducted, and the potential for non-specific cytotoxicity detd.  Hit compds. were chem. clustered and triaged for desirable physicochem. properties.  The hypothetical biol. target space covered by these diversity sets was investigated through bioinformatics methodologies.  Consequently, three anti-kinetoplastid chem. boxes of ∼200 compds. each were assembled.  Functional analyses of these compds. suggest a wide array of potential modes of action against kinetoplastid kinases, proteases and cytochromes as well as potential host-pathogen targets.  This is the first published parallel high throughput screening of a pharma compd. collection against kinetoplastids.  The compd. sets are provided as an open resource for future lead discovery programs, and to address important research questions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAQjKOCN5nErVg90H21EOLACvtfcHk0lglwwgUx3DQWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKhur7M&md5=c28afb0ae168147ee70d1f9cc905d272</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsrep08771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep08771%26sid%3Dliteratum%253Aachs%26aulast%3DPe%25C3%25B1a%26aufirst%3DI.%26aulast%3DPilar%2BManzano%26aufirst%3DM.%26aulast%3DCantizani%26aufirst%3DJ.%26aulast%3DKessler%26aufirst%3DA.%26aulast%3DAlonso-Padilla%26aufirst%3DJ.%26aulast%3DBardera%26aufirst%3DA.%2BI.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DColmenarejo%26aufirst%3DG.%26aulast%3DCotillo%26aufirst%3DI.%26aulast%3DRoquero%26aufirst%3DI.%26aulast%3Dde%2BDios-Anton%26aufirst%3DF.%26aulast%3DBarroso%26aufirst%3DV.%26aulast%3DRodriguez%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DNavarro%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSherstnev%26aufirst%3DA.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DJulio%2BMartin%26aufirst%3DJ.%26atitle%3DNew%2520Compound%2520Sets%2520Identified%2520from%2520High%2520Throughput%2520Phenotypic%2520Screening%2520against%2520Three%2520Kinetoplastid%2520Parasites%253A%2520an%2520Open%2520Resource%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fsrep08771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting Physical in Drug Discovery II: the Impact of Chromatographic Hydrophobicity Measurements and Aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&author=R.+J.+Youngauthor=D.+V.+S.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+Physical+in+Drug+Discovery+II%3A+the+Impact+of+Chromatographic+Hydrophobicity+Measurements+and+Aromaticity&doi=10.1016%2Fj.drudis.2011.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0lhqePX_gIqt1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520Physical%2520in%2520Drug%2520Discovery%2520II%253A%2520the%2520Impact%2520of%2520Chromatographic%2520Hydrophobicity%2520Measurements%2520and%2520Aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajakane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez-Pedraglio, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleghorn, L. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Siles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada-Campos, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Gomez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span> <span> </span><span class="NLM_article-title">Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1202</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=1180-1202&author=M.+G.+Thomasauthor=M.+De+Ryckerauthor=M.+Ajakaneauthor=S.+Albrechtauthor=A.+I.+Alvarez-Pedraglioauthor=M.+Boescheauthor=S.+Brandauthor=L.+Campbellauthor=J.+Cantizani-Perezauthor=L.+A.+T.+Cleghornauthor=R.+C.+B.+Copleyauthor=S.+D.+Crouchauthor=A.+Dauganauthor=G.+Drewesauthor=S.+Ferrerauthor=S.+Ghidelli-Disseauthor=S.+Gonzalezauthor=S.+L.+Greshamauthor=A.+P.+Hillauthor=S.+J.+Hindleyauthor=R.+M.+Loweauthor=C.+J.+MacKenzieauthor=L.+MacLeanauthor=S.+Manthriauthor=F.+Martinauthor=J.+Miguel-Silesauthor=V.+L.+Nguyenauthor=S.+Norvalauthor=M.+Osuna-Cabelloauthor=A.+Woodlandauthor=S.+Pattersonauthor=I.+Penaauthor=M.+T.+Quesada-Camposauthor=I.+H.+Reidauthor=C.+Revillauthor=J.+Rileyauthor=J.+R.+Ruiz-Gomezauthor=Y.+Shishikuraauthor=F.+R.+C.+Simeonsauthor=A.+Smithauthor=V.+C.+Smithauthor=D.+Spinksauthor=L.+Stojanovskiauthor=J.+Thomasauthor=S.+Thompsonauthor=T.+Underwoodauthor=D.+W.+Grayauthor=J.+M.+Fiandorauthor=I.+H.+Gilbertauthor=P.+G.+Wyattauthor=K.+D.+Readauthor=T.+J.+Miles&title=Identification+of+GSK3186899%2FDDD853651+as+a+Preclinical+Development+Candidate+for+the+Treatment+of+Visceral+Leishmaniasis&doi=10.1021%2Facs.jmedchem.8b01218"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01218%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%2BG.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DAjakane%26aufirst%3DM.%26aulast%3DAlbrecht%26aufirst%3DS.%26aulast%3DAlvarez-Pedraglio%26aufirst%3DA.%2BI.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DL.%26aulast%3DCantizani-Perez%26aufirst%3DJ.%26aulast%3DCleghorn%26aufirst%3DL.%2BA.%2BT.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DCrouch%26aufirst%3DS.%2BD.%26aulast%3DDaugan%26aufirst%3DA.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DGonzalez%26aufirst%3DS.%26aulast%3DGresham%26aufirst%3DS.%2BL.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DHindley%26aufirst%3DS.%2BJ.%26aulast%3DLowe%26aufirst%3DR.%2BM.%26aulast%3DMacKenzie%26aufirst%3DC.%2BJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DMiguel-Siles%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DV.%2BL.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DWoodland%26aufirst%3DA.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DPena%26aufirst%3DI.%26aulast%3DQuesada-Campos%26aufirst%3DM.%2BT.%26aulast%3DReid%26aufirst%3DI.%2BH.%26aulast%3DRevill%26aufirst%3DC.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DRuiz-Gomez%26aufirst%3DJ.%2BR.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DV.%2BC.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DUnderwood%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26atitle%3DIdentification%2520of%2520GSK3186899%252FDDD853651%2520as%2520a%2520Preclinical%2520Development%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Visceral%2520Leishmaniasis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D63%26spage%3D1180%26epage%3D1202%26doi%3D10.1021%2Facs.jmedchem.8b01218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melamed, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlow, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embrey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zrada, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillmock, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleif, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabryelski, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassahun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span></span> <span> </span><span class="NLM_article-title">A Potent and Orally Active HIV-1 Integrase Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.11.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1016%2Fj.bmcl.2006.11.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=17194584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1392-1398&author=M.+S.+Egbertsonauthor=H.+M.+Moritzauthor=J.+Y.+Melamedauthor=W.+Hanauthor=D.+S.+Perlowauthor=M.+S.+Kuoauthor=M.+Embreyauthor=J.+P.+Vaccaauthor=M.+M.+Zradaauthor=A.+R.+Cortesauthor=A.+Wallaceauthor=Y.+Leonardauthor=D.+J.+Hazudaauthor=M.+D.+Millerauthor=P.+J.+Felockauthor=K.+A.+Stillmockauthor=M.+V.+Witmerauthor=W.+Schleifauthor=L.+J.+Gabryelskiauthor=G.+Moyerauthor=J.+D.+Ellisauthor=L.+Jinauthor=W.+Xuauthor=M.+P.+Braunauthor=K.+Kassahunauthor=N.+N.+Tsouauthor=S.+D.+Young&title=A+Potent+and+Orally+Active+HIV-1+Integrase+Inhibitor&doi=10.1016%2Fj.bmcl.2006.11.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A potent and orally active HIV-1 integrase inhibitor</span></div><div class="casAuthors">Egbertson, Melissa S.; Moritz, H. Marie; Melamed, Jeffrey Y.; Han, Wei; Perlow, Debra S.; Kuo, Michelle S.; Embrey, Mark; Vacca, Joseph P.; Zrada, Matthew M.; Cortes, Amanda R.; Wallace, Audrey; Leonard, Yvonne; Hazuda, Daria J.; Miller, Michael D.; Felock, Peter J.; Stillmock, Kara A.; Witmer, Marc V.; Schleif, William; Gabryelski, Lori J.; Moyer, Gregory; Ellis, Joan D.; Jin, Lixia; Xu, Wei; Braun, Matthew P.; Kassahun, Kellem; Tsou, Nancy N.; Young, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1392-1398</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A 1,6-naphthyridine inhibitor of HIV-1 integrase has been discovered with excellent inhibitory activity in cells, good pharmacokinetics, and an excellent ability to inhibit virus with mutant enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVTId1m0YgC7Vg90H21EOLACvtfcHk0lijNXo0VjUPRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjt7s%253D&md5=5b718b54eae1ddfc33430472a0c3169c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.11.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.11.080%26sid%3Dliteratum%253Aachs%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26aulast%3DMoritz%26aufirst%3DH.%2BM.%26aulast%3DMelamed%26aufirst%3DJ.%2BY.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DPerlow%26aufirst%3DD.%2BS.%26aulast%3DKuo%26aufirst%3DM.%2BS.%26aulast%3DEmbrey%26aufirst%3DM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DZrada%26aufirst%3DM.%2BM.%26aulast%3DCortes%26aufirst%3DA.%2BR.%26aulast%3DWallace%26aufirst%3DA.%26aulast%3DLeonard%26aufirst%3DY.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DFelock%26aufirst%3DP.%2BJ.%26aulast%3DStillmock%26aufirst%3DK.%2BA.%26aulast%3DWitmer%26aufirst%3DM.%2BV.%26aulast%3DSchleif%26aufirst%3DW.%26aulast%3DGabryelski%26aufirst%3DL.%2BJ.%26aulast%3DMoyer%26aufirst%3DG.%26aulast%3DEllis%26aufirst%3DJ.%2BD.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DBraun%26aufirst%3DM.%2BP.%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26atitle%3DA%2520Potent%2520and%2520Orally%2520Active%2520HIV-1%2520Integrase%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1392%26epage%3D1398%26doi%3D10.1016%2Fj.bmcl.2006.11.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tephly, T. R.</span></span> <span> </span><span class="NLM_article-title">UPD-Glucuronosyltransferases</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.2174/1389200003339171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.2174%2F1389200003339171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=11465080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlOrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=143-161&author=C.+D.+Kingauthor=G.+R.+Riosauthor=M.+D.+Greenauthor=T.+R.+Tephly&title=UPD-Glucuronosyltransferases&doi=10.2174%2F1389200003339171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">UDP-Glucuronosyltransferases</span></div><div class="casAuthors">King, C. D.; Rios, G. R.; Green, M. D.; Tephly, T. R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-161</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review, with 97 refs.  Glucuronidation represents a major pathway which enhances the elimination of many lipophilic xenobiotics and endobiotics to more water-sol. compds.  The UDP-glucuronosyltransferase (UGT) family catalyzes the glucuronidation of the glycosyl group of a nucleotide sugar to an acceptor compd. (aglycon) at a nucleophilic functional group of oxygen (e.g., hydroxyl or carboxylic acid groups), nitrogen (e.g., amines), sulfur (e.g., thiols), and carbon, with the formation of a β-D-glucuronide product.  At this time, over 35 different UGT gene products have been described from several different species.  UGTs have been divided into two distinct subfamilies based on sequence identities, UGT1 and UGT2.  The UGT1 gene subfamily consists of a no. of UGTs that result from alternate splicing of multiple first exons and share common exons 2-5.  The substrate specificities of the various isoforms have been examd. in cultured cell expts., and include bilirubin, amines, and planar and bulky phenol.  The UGT2 gene family is different in that the UGT2 mRNAs are transcribed from individual genes.  The UGT2 subfamily consists of numerous enzymes which catalyze the glucuronidation of a diverse chem. base including steroids, bile acids, and opioids.  Until recently, the liver has been the major focus for studying the metab. of xenobiotics and endobiotics.  Several groups have identified extrahepatic tissues that express UGT isoforms including the kidney, gastrointestinal tract and brain.  This review discusses the two UGT gene families, substrate specificities, and the recent discoveries of UGTs in extrahepatic tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBOsINL0g5V7Vg90H21EOLACvtfcHk0lijNXo0VjUPRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlOrs70%253D&md5=49f69c7783523498ed31887f3b9d0a55</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F1389200003339171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200003339171%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DRios%26aufirst%3DG.%2BR.%26aulast%3DGreen%26aufirst%3DM.%2BD.%26aulast%3DTephly%26aufirst%3DT.%2BR.%26atitle%3DUPD-Glucuronosyltransferases%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2000%26volume%3D1%26spage%3D143%26epage%3D161%26doi%3D10.2174%2F1389200003339171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deSchoolmeester, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilgour, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayers, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhardt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selmi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swales, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittamore, P. R.</span></span> <span> </span><span class="NLM_article-title">Novel Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor with Reduced Acyl Glucuronide Liability: The Discovery of 4-[4-(2-Adamantylcarbamoyl)-5-<i>tert</i>-butyl-pyrazol-1-yl]benzoic Acid (AZD8329)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10136</span>– <span class="NLM_lpage">10147</span>, <span class="refDoi"> DOI: 10.1021/jm301252n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301252n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10136-10147&author=J.+S.+Scottauthor=J.+deSchoolmeesterauthor=E.+Kilgourauthor=R.+M.+Mayersauthor=M.+J.+Packerauthor=D.+Hargreavesauthor=S.+Gerhardtauthor=D.+J.+Oggauthor=A.+Reesauthor=N.+Selmiauthor=A.+Stockerauthor=J.+G.+Swalesauthor=P.+R.+Whittamore&title=Novel+Acidic+11%CE%B2-Hydroxysteroid+Dehydrogenase+Type+1+%2811%CE%B2-HSD1%29+Inhibitor+with+Reduced+Acyl+Glucuronide+Liability%3A+The+Discovery+of+4-%5B4-%282-Adamantylcarbamoyl%29-5-tert-butyl-pyrazol-1-yl%5Dbenzoic+Acid+%28AZD8329%29&doi=10.1021%2Fjm301252n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor with Reduced Acyl Glucuronide Liability: The Discovery of 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic Acid (AZD8329)</span></div><div class="casAuthors">Scott, James S.; deSchoolmeester, Joanne; Kilgour, Elaine; Mayers, Rachel M.; Packer, Martin J.; Hargreaves, David; Gerhardt, Stefan; Ogg, Derek J.; Rees, Amanda; Selmi, Nidhal; Stocker, Andrew; Swales, John G.; Whittamore, Paul R. O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10136-10147</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of 11β-HSD1 is viewed as a potential target for the treatment of obesity and other elements of the metabolic syndrome.  We report here the optimization of a carboxylic acid class of inhibitors from AZD4017 (I) to the development candidate AZD8329 (II).  A structural change from pyridine to pyrazole together with structural optimization led to an improved tech. profile in terms of both soly. and pharmacokinetics.  The extent of acyl glucuronidation was reduced through structural optimization of both the carboxylic acid and amide substituents, coupled with a redn. in lipophilicity leading to an overall increase in metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKFfab5QO3Q7Vg90H21EOLACvtfcHk0lijNXo0VjUPRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChsrbF&md5=c48d951089cae3c4ad95c938ecaaf8e5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm301252n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301252n%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DdeSchoolmeester%26aufirst%3DJ.%26aulast%3DKilgour%26aufirst%3DE.%26aulast%3DMayers%26aufirst%3DR.%2BM.%26aulast%3DPacker%26aufirst%3DM.%2BJ.%26aulast%3DHargreaves%26aufirst%3DD.%26aulast%3DGerhardt%26aufirst%3DS.%26aulast%3DOgg%26aufirst%3DD.%2BJ.%26aulast%3DRees%26aufirst%3DA.%26aulast%3DSelmi%26aufirst%3DN.%26aulast%3DStocker%26aufirst%3DA.%26aulast%3DSwales%26aufirst%3DJ.%2BG.%26aulast%3DWhittamore%26aufirst%3DP.%2BR.%26atitle%3DNovel%2520Acidic%252011%25CE%25B2-Hydroxysteroid%2520Dehydrogenase%2520Type%25201%2520%252811%25CE%25B2-HSD1%2529%2520Inhibitor%2520with%2520Reduced%2520Acyl%2520Glucuronide%2520Liability%253A%2520The%2520Discovery%2520of%25204-%255B4-%25282-Adamantylcarbamoyl%2529-5-tert-butyl-pyrazol-1-yl%255Dbenzoic%2520Acid%2520%2528AZD8329%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10136%26epage%3D10147%26doi%3D10.1021%2Fjm301252n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Croxtall, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Raltegravir</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1075</span>, <span class="refDoi"> DOI: 10.2165/00003495-200969080-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.2165%2F00003495-200969080-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=19496631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2iur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1059-1075&author=J.+D.+Croxtallauthor=S.+J.+Keam&title=Raltegravir&doi=10.2165%2F00003495-200969080-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Raltegravir: A review of its use in the management of HIV infection in treatment-experienced patients</span></div><div class="casAuthors">Croxtall, Jamie D.; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1059-1075</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Raltegravir (Isentress), an integrase inhibitor, inhibits the insertion of HIV-1 complementary DNA into the host genome.  It is indicated in combination with other antiretroviral therapy (ART) agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple ART agents.  It is the first of a new class of ART agents to be approved that, as a result of a different mechanism of action to other ART agents, has good activity against multidrug-resistant HIV-1 strains.  In clin. trials in treatment-experienced patients with HIV-1 infection and evidence of viral replication, the addn. of oral raltegravir to an optimized background therapy (OBT) regimen improved virol. and immunol. responses at 16 and 48 wk to a greater extent than placebo plus OBT.  Raltegravir therapy was generally well tolerated, with a similar incidence of mild to moderate adverse events in the treatment and placebo arms.  The introduction of integrase inhibitors extends the options available for managing treatment-experienced patients with multiple-drug-resistant HIV-1 infection.  Results to date suggest that the combination of raltegravir and OBT will be a valuable treatment option for this difficult-to-treat patient group.  Pharmacol. Properties Raltegravir is a selective inhibitor of integrase, an HIV-1-specific enzyme that is responsible for the insertion of viral complimentary DNA into the host genome.  In in vitro studies, the 95% inhibitory concn. (IC95) of raltegravir in human T-lymphoid cells infected with a lab. strain of HIV-1 was 31 nmol/L and ranged from 6 to 50 nmol/L in human peripheral blood mono-nuclear cells, infected with clin. isolates of HIV-1, including strains resistant to other classes of ART.  Specific mutations within the HIV-1 integrase gene (predominantly at Q148, N155 or Y143) are correlated with virol. resistance to raltegravir.  Patients with higher baseline levels of HIV-1 RNA and less active OBT regimens are at the highest risk of integrase mutations arising during treatment.  Oral raltegravir is rapidly absorbed, with a mean max. plasma concn. reached at a median time of ≈1 h.  The mean plasma concn. of raltegravir at the end of a 12-h dose administration interval after a 400 mg dose exceeded the IC95 against HIV-1 in vitro.  Raltegravir is metabolized in humans through uridine diphosphate-glucuronosyltransferase-mediated glucuronidation in the liver, and is eliminated in faeces and urine.  The mean elimination half-life of raltegravir is 7-12 h.  Raltegravir does not significantly affect the activity of the cytochrome P 450 system and therefore is not expected to interact with other ART agents that are substrates for these enzymes.  Therapeutic Efficacy In the two phase III BENCHMRK trials (n = 699), orally administered raltegravir 400 mg twice daily plus OBT improved both virol. and immunol. outcomes in treatment-experienced patients with HIV-1 infection, evidence of viral replication and HIV-1 strains resistant to multiple ART agents.  At 16 wk in the individual trials and at 48 wk in the combined anal., raltegravir plus OBT reduced HIV-1 RNA levels to <400 copies/mL (primary endpoint) and <50 copies/mL in a significantly greater no. of patients and significantly increased CD4+ cell counts from baseline when compared with placebo plus OBT.  Moreover, prespecified subgroup analyses indicated that in the BENCHMRK trials, the greater efficacy of raltegravir plus OBT compared with placebo plus OBT was maintained in patients with baseline characteristics that typically predict a poor response to ART therapy, for example, higher HIV-1 RNA levels, lower CD4+ cell counts and less active OBT regimens.  Tolerability Raltegravir was generally well tolerated when used in combination with OBT regimens in treatment-experienced patients with HIV-1 infection in trials of up to 48 wk' duration.  The majority of adverse events were mild to moderate in severity, and of similar incidence in the raltegravir plus OBT and placebo plus OBT treatment arms; treatment-related discontinuations were uncommon.  The most common drug-related adverse events reported were diarrhoea, headache, nausea and fatigue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyz5MAsFmghLVg90H21EOLACvtfcHk0livmowg-J91rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2iur%252FO&md5=31aa629ea39025c767bed33e1e2550f5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2165%2F00003495-200969080-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200969080-00007%26sid%3Dliteratum%253Aachs%26aulast%3DCroxtall%26aufirst%3DJ.%2BD.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DRaltegravir%26jtitle%3DDrugs%26date%3D2009%26volume%3D69%26spage%3D1059%26epage%3D1075%26doi%3D10.2165%2F00003495-200969080-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anthony, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolly, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embrey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guare, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egbertson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huff, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felock, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stillmock, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danovich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grobler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassahun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleif, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S. D.</span></span> <span> </span><span class="NLM_article-title">A Naphthyridine Carboxamide Provides Evidence for Discordant Resistance Between Mechanistically Identical Inhibitors of HIV-1 Integrase</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">11233</span>– <span class="NLM_lpage">11238</span>, <span class="refDoi"> DOI: 10.1073/pnas.0402357101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1073%2Fpnas.0402357101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=15277684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVKgtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=11233-11238&author=D.+J.+Hazudaauthor=N.+J.+Anthonyauthor=R.+P.+Gomezauthor=S.+M.+Jollyauthor=J.+S.+Waiauthor=L.+Zhuangauthor=T.+E.+Fisherauthor=M.+Embreyauthor=J.+P.+Guareauthor=M.+S.+Egbertsonauthor=J.+P.+Vaccaauthor=J.+R.+Huffauthor=P.+J.+Felockauthor=M.+V.+Witmerauthor=K.+A.+Stillmockauthor=R.+Danovichauthor=J.+Groblerauthor=M.+D.+Millerauthor=A.+S.+Espesethauthor=L.+Jinauthor=I.+W.+Chenauthor=J.+H.+Linauthor=K.+Kassahunauthor=J.+D.+Ellisauthor=B.+K.+Wongauthor=W.+Xuauthor=P.+G.+Pearsonauthor=W.+A.+Schleifauthor=R.+Corteseauthor=E.+Eminiauthor=V.+Summaauthor=M.+K.+Hollowayauthor=S.+D.+Young&title=A+Naphthyridine+Carboxamide+Provides+Evidence+for+Discordant+Resistance+Between+Mechanistically+Identical+Inhibitors+of+HIV-1+Integrase&doi=10.1073%2Fpnas.0402357101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase</span></div><div class="casAuthors">Hazuda, Daria J.; Anthony, Neville J.; Gomez, Robert P.; Jolly, Samson M.; Wai, John S.; Zhuang, Linghang; Fisher, Thorsten E.; Embrey, Mark; Guare, James P., Jr.; Egbertson, Melissa S.; Vacca, Joseph P.; Huff, Joel R.; Felock, Peter J.; Witmer, Marc V.; Stillmock, Kara A.; Danovich, Robert; Grobler, Jay; Miller, Michael D.; Espeseth, Amy S.; Jin, Lixia; Chen, I-Wu; Lin, Jiunn H.; Kassahun, Kelem; Ellis, Joan D.; Wong, Bradley K.; Xu, Wei; Pearson, Paul G.; Schleif, William A.; Cortese, Riccardo; Emini, Emilio; Summa, Vincenzo; Holloway, M. Katharine; Young, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">11233-11238</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The increasing incidence of resistance to current HIV-1 therapy underscores the need to develop antiretroviral agents with new mechanisms of action.  Integrase, one of three viral enzymes essential for HIV-1 replication, presents an important yet unexploited opportunity for drug development.  The authors describe here the identification and characterization of L-870,810, a small-mol. inhibitor of HIV-1 integrase with potent antiviral activity in cell culture and good pharmacokinetic properties.  L-870,810 is an inhibitor with an 8-hydroxy-(1,6)-naphthyridine-7-carboxamide pharmacophore.  The compd. inhibits HIV-1 integrase-mediated strand transfer, and its antiviral activity in vitro is a direct consequence of this ascribed effect on integration.  L-870,810 is mechanistically identical to previously described inhibitors from the diketo acid series; however, viruses selected for resistance to L-870,810 contain mutations (integrase residues 72, 121, and 125) that uniquely confer resistance to the naphthyridine.  Conversely, mutations assocd. with resistance to the diketo acid do not engender naphthyridine resistance.  Importantly, the mutations assocd. with resistance to each of these inhibitors map to distinct regions within the integrase active site.  Therefore, the authors propose a model of the two inhibitors that is consistent with this observation and suggests specific interactions with discrete binding sites for each ligand.  These studies provide a structural basis and rationale for developing integrase inhibitors with the potential for unique and nonoverlapping resistance profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRpHqKKxVFjLVg90H21EOLACvtfcHk0livmowg-J91rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVKgtrY%253D&md5=a94bedb2c16c751c5a9298708504fa4d</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0402357101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0402357101%26sid%3Dliteratum%253Aachs%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DAnthony%26aufirst%3DN.%2BJ.%26aulast%3DGomez%26aufirst%3DR.%2BP.%26aulast%3DJolly%26aufirst%3DS.%2BM.%26aulast%3DWai%26aufirst%3DJ.%2BS.%26aulast%3DZhuang%26aufirst%3DL.%26aulast%3DFisher%26aufirst%3DT.%2BE.%26aulast%3DEmbrey%26aufirst%3DM.%26aulast%3DGuare%26aufirst%3DJ.%2BP.%26aulast%3DEgbertson%26aufirst%3DM.%2BS.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DFelock%26aufirst%3DP.%2BJ.%26aulast%3DWitmer%26aufirst%3DM.%2BV.%26aulast%3DStillmock%26aufirst%3DK.%2BA.%26aulast%3DDanovich%26aufirst%3DR.%26aulast%3DGrobler%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DM.%2BD.%26aulast%3DEspeseth%26aufirst%3DA.%2BS.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DI.%2BW.%26aulast%3DLin%26aufirst%3DJ.%2BH.%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DJ.%2BD.%26aulast%3DWong%26aufirst%3DB.%2BK.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DSchleif%26aufirst%3DW.%2BA.%26aulast%3DCortese%26aufirst%3DR.%26aulast%3DEmini%26aufirst%3DE.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26atitle%3DA%2520Naphthyridine%2520Carboxamide%2520Provides%2520Evidence%2520for%2520Discordant%2520Resistance%2520Between%2520Mechanistically%2520Identical%2520Inhibitors%2520of%2520HIV-1%2520Integrase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D11233%26epage%3D11238%26doi%3D10.1073%2Fpnas.0402357101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Little, S.</span>; <span class="NLM_string-name">Drusano, G.</span>; <span class="NLM_string-name">Schooley, R.</span></span> In  <i>Antiviral Effect of L-000870810, a Novel HIV-1 Integrase Inhibitor, in HIV-1 Infected Patients</i>, 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Abstract 161, Feb 22–25, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=S.+Little&author=G.+Drusano&author=R.+Schooley&title=Antiviral+Effect+of+L-000870810%2C+a+Novel+HIV-1+Integrase+Inhibitor%2C+in+HIV-1+Infected+Patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLittle%26aufirst%3DS.%26jtitle%3DAntiviral%2520Effect%2520of%2520L-000870810%252C%2520a%2520Novel%2520HIV-1%2520Integrase%2520Inhibitor%252C%2520in%2520HIV-1%2520Infected%2520Patients%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing Safety-Related Drug Attrition: The Use of in Vitro Pharmacological Profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+Safety-Related+Drug+Attrition%3A+The+Use+of+in+Vitro+Pharmacological+Profiling&doi=10.1038%2Fnrd3845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0lgOzXtwjRyTTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520Safety-Related%2520Drug%2520Attrition%253A%2520The%2520Use%2520of%2520in%2520Vitro%2520Pharmacological%2520Profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wall, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span> <span> </span><span class="NLM_article-title">Antitrypanosomal 8-Hydroxy-Naphthyridines are Chelators of Divalent Transition Metals</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>, <span class="NLM_elocation-id">e00235-18</span> <span class="refDoi"> DOI: 10.1128/AAC.00235-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1128%2FAAC.00235-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=29844044" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&author=R.+J.+Wallauthor=S.+Monizauthor=M.+G.+Thomasauthor=S.+Norvalauthor=E.+J.+Koauthor=M.+Marcoauthor=T.+J.+Milesauthor=I.+H.+Gilbertauthor=D.+Hornauthor=A.+H.+Fairlambauthor=S.+Wyllie&title=Antitrypanosomal+8-Hydroxy-Naphthyridines+are+Chelators+of+Divalent+Transition+Metals&doi=10.1128%2FAAC.00235-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.00235-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00235-18%26sid%3Dliteratum%253Aachs%26aulast%3DWall%26aufirst%3DR.%2BJ.%26aulast%3DMoniz%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%2BG.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DWyllie%26aufirst%3DS.%26atitle%3DAntitrypanosomal%25208-Hydroxy-Naphthyridines%2520are%2520Chelators%2520of%2520Divalent%2520Transition%2520Metals%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26doi%3D10.1128%2FAAC.00235-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johns, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garvey, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span> <span> </span><span class="NLM_article-title">The Use of Oxadiazole and Triazole Substituted Naphthyridines as HIV-1 Integrase Inhibitors. Part 1: Establishing the Pharmacophore</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1802</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=10.1016%2Fj.bmcl.2009.01.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=19217781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1802-1806&author=B.+A.+Johnsauthor=J.+G.+Weatherheadauthor=S.+H.+Allenauthor=J.+B.+Thompsonauthor=E.+P.+Garveyauthor=S.+A.+Fosterauthor=J.+L.+Jeffreyauthor=W.+H.+Miller&title=The+Use+of+Oxadiazole+and+Triazole+Substituted+Naphthyridines+as+HIV-1+Integrase+Inhibitors.+Part+1%3A+Establishing+the+Pharmacophore&doi=10.1016%2Fj.bmcl.2009.01.090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore</span></div><div class="casAuthors">Johns, Brian A.; Weatherhead, Jason G.; Allen, Scott H.; Thompson, James B.; Garvey, Edward P.; Foster, Scott A.; Jeffrey, Jerry L.; Miller, Wayne H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1802-1806</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of HIV-1 integrase inhibitors contg. a novel metal binding motif consisting of the 8-hydroxy-1,6-naphthyridine core and either an oxadiazole or triazole has been identified.  The design of the key structural components was based on a two-metal coordination pharmacophore.  This report presents initial structure-activity data that shows the new chelation architecture delivers potent inhibition in both enzymic and antiviral assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu2rzx6WTsI7Vg90H21EOLACvtfcHk0lgOzXtwjRyTTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltb0%253D&md5=78e7d1b81f1a889c901bb08678b932a7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.090%26sid%3Dliteratum%253Aachs%26aulast%3DJohns%26aufirst%3DB.%2BA.%26aulast%3DWeatherhead%26aufirst%3DJ.%2BG.%26aulast%3DAllen%26aufirst%3DS.%2BH.%26aulast%3DThompson%26aufirst%3DJ.%2BB.%26aulast%3DGarvey%26aufirst%3DE.%2BP.%26aulast%3DFoster%26aufirst%3DS.%2BA.%26aulast%3DJeffrey%26aufirst%3DJ.%2BL.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26atitle%3DThe%2520Use%2520of%2520Oxadiazole%2520and%2520Triazole%2520Substituted%2520Naphthyridines%2520as%2520HIV-1%2520Integrase%2520Inhibitors.%2520Part%25201%253A%2520Establishing%2520the%2520Pharmacophore%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1802%26epage%3D1806%26doi%3D10.1016%2Fj.bmcl.2009.01.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crescenzi, B.</span>; <span class="NLM_string-name">Gardelli, C.</span>; <span class="NLM_string-name">Muraglia, E.</span>; <span class="NLM_string-name">Nizi, E.</span>; <span class="NLM_string-name">Orvieto, F.</span>; <span class="NLM_string-name">Pace, P.</span>; <span class="NLM_string-name">Pescatore, G.</span>; <span class="NLM_string-name">Petrocchi, A.</span>; <span class="NLM_string-name">Poma, M.</span>; <span class="NLM_string-name">Rowley, M.</span>; <span class="NLM_string-name">Scarpelli, R.</span>; <span class="NLM_string-name">Summa, V.</span></span> <span> </span><span class="NLM_article-title">N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors of HIV Integrase</span>. <span class="NLM_patent">WO2003035077</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=B.+Crescenzi&author=C.+Gardelli&author=E.+Muraglia&author=E.+Nizi&author=F.+Orvieto&author=P.+Pace&author=G.+Pescatore&author=A.+Petrocchi&author=M.+Poma&author=M.+Rowley&author=R.+Scarpelli&author=V.+Summa&title=N-Substituted+Hydroxypyrimidinone+Carboxamide+Inhibitors+of+HIV+Integrase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrescenzi%26aufirst%3DB.%26atitle%3DN-Substituted%2520Hydroxypyrimidinone%2520Carboxamide%2520Inhibitors%2520of%2520HIV%2520Integrase%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazemi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y.-Q.</span></span> <span> </span><span class="NLM_article-title">Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9492</span>– <span class="NLM_lpage">9509</span>, <span class="refDoi"> DOI: 10.1021/jm300667v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300667v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOltrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9492-9509&author=L.-F.+Zengauthor=Y.+Wangauthor=R.+Kazemiauthor=S.+Xuauthor=Z.-L.+Xuauthor=T.+W.+Sanchezauthor=L.-M.+Yangauthor=B.+Debnathauthor=S.+Oddeauthor=H.+Xieauthor=Y.-T.+Zhengauthor=J.+Dingauthor=N.+Neamatiauthor=Y.-Q.+Long&title=Repositioning+HIV-1+Integrase+Inhibitors+for+Cancer+Therapeutics%3A+1%2C6-Naphthyridine-7-carboxamide+as+a+Promising+Scaffold+with+Drug-like+Properties&doi=10.1021%2Fjm300667v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Repositioning HIV-1 Integrase Inhibitors for Cancer Therapeutics: 1,6-Naphthyridine-7-carboxamide as a Promising Scaffold with Drug-like Properties</span></div><div class="casAuthors">Zeng, Li-Fan; Wang, Yong; Kazemi, Roza; Xu, Shili; Xu, Zhong-Liang; Sanchez, Tino W.; Yang, Liu-Meng; Debnath, Bikash; Odde, Srinivas; Xie, Hua; Zheng, Yong-Tang; Ding, Jian; Neamati, Nouri; Long, Ya-Qiu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9492-9509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among a large no. of HIV-1 integrase (IN) inhibitors, the 8-hydroxy-[1,6]naphthyridines (i.e., L-870,810) were one of the promising class of antiretroviral drugs developed by Merck Labs.  In spite of its remarkable potency and efficacy, unfortunately upon completion of phase I clin. studies, development of L-870,810 was halted.  Because of its desirable pharmacol. and pharmaceutical properties we were intrigued to design novel analogs of L-870,810 with goals to (1) improve upon limitations of naphthyridine-7-carboxamides as antiviral agents and (2) to reposition their use as innovative cytotoxic agents for cancer therapeutics.  Herein, we report on the design and synthesis of a series of 1,6-naphthyridine-7-carboxamides with various substitutions at the 5- and 8-positions.  All the new 5-substituted-8-hydroxy-[1,6]naphthyridines were potent IN inhibitors and the 5-substituted-8-amino-[1,6]naphthyridines, e.g. I [R = OH, NHCH2CH2OH, NHBn, etc.], were significantly cytotoxic.  Further optimization of the 5,8-disubstituted-[1,6]naphthyridines with structural variation on 7-carboxamide delivered novel compds. with significant cytotoxicity in a panel of cancer cell lines and effective inhibition against select oncogenic kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwQgFkPHff-LVg90H21EOLACvtfcHk0lgnGjEbfhtz_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOltrvN&md5=1dfedb7d079e37cdd5244253e351e2df</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm300667v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300667v%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.-F.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKazemi%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DZ.-L.%26aulast%3DSanchez%26aufirst%3DT.%2BW.%26aulast%3DYang%26aufirst%3DL.-M.%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DOdde%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DY.-T.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DNeamati%26aufirst%3DN.%26aulast%3DLong%26aufirst%3DY.-Q.%26atitle%3DRepositioning%2520HIV-1%2520Integrase%2520Inhibitors%2520for%2520Cancer%2520Therapeutics%253A%25201%252C6-Naphthyridine-7-carboxamide%2520as%2520a%2520Promising%2520Scaffold%2520with%2520Drug-like%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9492%26epage%3D9509%26doi%3D10.1021%2Fjm300667v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viayna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayawardhana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epemolu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, T. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of 5-Amino1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7284</span>– <span class="NLM_lpage">7299</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyhtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7284-7299&author=S.+Brandauthor=E.+J.+Koauthor=E.+Viaynaauthor=S.+Thompsonauthor=D.+Spinksauthor=M.+Thomasauthor=L.+Sandbergauthor=A.+F.+Franciscoauthor=S.+Jayawardhanaauthor=V.+C.+Smithauthor=C.+Jansenauthor=M.+De+Ryckerauthor=J.+Thomasauthor=L.+MacLeanauthor=M.+Osuna-Cabelloauthor=J.+Rileyauthor=P.+Scullionauthor=L.+Stojanovskiauthor=F.+R.+C.+Simeonsauthor=O.+Epemoluauthor=Y.+Shishikuraauthor=S.+D.+Crouchauthor=T.+S.+Bakshiauthor=C.+J.+Nixonauthor=I.+H.+Reidauthor=A.+P.+Hillauthor=T.+Z.+Underwoodauthor=S.+J.+Hindleyauthor=S.+A.+Robinsonauthor=J.+M.+Kellyauthor=J.+M.+Fiandorauthor=P.+G.+Wyattauthor=M.+Marcoauthor=T.+J.+Milesauthor=K.+D.+Readauthor=I.+H.+Gilbert&title=Discovery+and+Optimization+of+5-Amino1%2C2%2C3-triazole-4-carboxamide+Series+against+Trypanosoma+cruzi&doi=10.1021%2Facs.jmedchem.7b00463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi</span></div><div class="casAuthors">Brand, Stephen; Ko, Eun Jung; Viayna, Elisabet; Thompson, Stephen; Spinks, Daniel; Thomas, Michael; Sandberg, Lars; Francisco, Amanda F.; Jayawardhana, Shiromani; Smith, Victoria C.; Jansen, Chimed; De Rycker, Manu; Thomas, John; MacLean, Lorna; Osuna-Cabello, Maria; Riley, Jennifer; Scullion, Paul; Stojanovski, Laste; Simeons, Frederick R. C.; Epemolu, Ola; Shishikura, Yoko; Crouch, Sabrinia D.; Bakshi, Tania S.; Nixon, Christopher J.; Reid, Iain H.; Hill, Alan P.; Underwood, Tim Z.; Hindley, Sean J.; Robinson, Sharon A.; Kelly, John M.; Fiandor, Jose M.; Wyatt, Paul G.; Marco, Maria; Miles, Timothy J.; Read, Kevin D.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7284-7299</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chagas' disease, caused by the protozoan parasite Trypanosoma cruzi, is the most common cause of cardiac-related deaths in endemic regions of Latin America.  There is an urgent need for new safer treatments because current std. therapeutic options, benznidazole and nifurtimox, have significant side effects and are only effective in the acute phase of the infection with limited efficacy in the chronic phase.  Phenotypic high content screening against the intracellular parasite in infected VERO cells was used to identify a novel hit series of 5-amino-1,2,3-triazole-4-carboxamides (ATC).  Optimization of the ATC series gave improvements in potency, aq. soly., and metabolic stability, which combined to give significant improvements in oral exposure.  Mitigation of a potential Ames and hERG liability ultimately led to two promising compds., one of which demonstrated significant suppression of parasite burden in a mouse model of Chagas' disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojbFlfMdTr17Vg90H21EOLACvtfcHk0lgnGjEbfhtz_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyhtr7P&md5=0e8c6127795fa38fe500bbc3832cf9c4</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00463%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%2BJ.%26aulast%3DViayna%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DSandberg%26aufirst%3DL.%26aulast%3DFrancisco%26aufirst%3DA.%2BF.%26aulast%3DJayawardhana%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DV.%2BC.%26aulast%3DJansen%26aufirst%3DC.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DScullion%26aufirst%3DP.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DEpemolu%26aufirst%3DO.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DCrouch%26aufirst%3DS.%2BD.%26aulast%3DBakshi%26aufirst%3DT.%2BS.%26aulast%3DNixon%26aufirst%3DC.%2BJ.%26aulast%3DReid%26aufirst%3DI.%2BH.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DUnderwood%26aufirst%3DT.%2BZ.%26aulast%3DHindley%26aufirst%3DS.%2BJ.%26aulast%3DRobinson%26aufirst%3DS.%2BA.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DMarco%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%25205-Amino1%252C2%252C3-triazole-4-carboxamide%2520Series%2520against%2520Trypanosoma%2520cruzi%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7284%26epage%3D7299%26doi%3D10.1021%2Facs.jmedchem.7b00463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i63"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00705">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_41711"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00705?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00705</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental details and HPLC traces for key target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_002.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_001.pdf">jm0c00705_si_001.pdf (1.52 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00705/suppl_file/jm0c00705_si_002.xlsx">jm0c00705_si_002.xlsx (11.64 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00705&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-17%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00705%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00705" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799165b2e953ca6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
